PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22130396-2	2012	Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (peroxisome proliferator-activated receptor-delta [PPAR-delta]-5" adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-delta-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class "Hormone and metabolic modulators."	GW 501516	247-253	peroxisome proliferator activated receptor delta	Homo sapiens	113-161
22130396-2	2012	Among the leading innovations to the rules are that both 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (peroxisome proliferator-activated receptor-delta [PPAR-delta]-5" adenosine monophosphate-activated protein kinase [AMPK] agonist) and GW1516 (PPAR-delta-agonist) are no longer categorized as gene doping substances in the new 2012 prohibited list but as metabolic modulators in the class "Hormone and metabolic modulators."	GW 501516	247-253	peroxisome proliferator activated receptor delta	Homo sapiens	163-173
21896929-9	2011	The latter mimicked the GSIS-amplifying effect of high glucose preexposure and of the PPAR-delta agonist GW501516 in INS-1E cells and isolated rat islets.	GW 501516	105-113	peroxisome proliferator-activated receptor delta	Rattus norvegicus	86-96
23056264-7	2012	Silencing of Angptl4 blocked the effect of GW501516 and bexarotene on LPL activity.	GW 501516	43-51	angiopoietin like 4	Homo sapiens	13-20
23056264-7	2012	Silencing of Angptl4 blocked the effect of GW501516 and bexarotene on LPL activity.	GW 501516	43-51	lipoprotein lipase	Homo sapiens	70-73
22072715-3	2011	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly attenuated Ang II-induced generation of superoxides and suppressed senescence of VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
22072715-3	2011	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly attenuated Ang II-induced generation of superoxides and suppressed senescence of VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
22072715-4	2011	A marked increase in the levels of p53 and p21 induced by Ang II was blunted by the treatment with GW501516.	GW 501516	99-107	tumor protein p53	Homo sapiens	35-38
22072715-4	2011	A marked increase in the levels of p53 and p21 induced by Ang II was blunted by the treatment with GW501516.	GW 501516	99-107	H3 histone pseudogene 16	Homo sapiens	43-46
22072715-7	2011	Finally, administration of GW501516 to apoE-deficient mice treated with Ang II significantly reduced the number of senescent cells in the aorta, where up-regulation of PTEN with reduced levels of phosphorylated Akt and ROS was demonstrated.	GW 501516	27-35	apolipoprotein E	Mus musculus	39-43
22072715-7	2011	Finally, administration of GW501516 to apoE-deficient mice treated with Ang II significantly reduced the number of senescent cells in the aorta, where up-regulation of PTEN with reduced levels of phosphorylated Akt and ROS was demonstrated.	GW 501516	27-35	phosphatase and tensin homolog	Mus musculus	168-172
22072715-7	2011	Finally, administration of GW501516 to apoE-deficient mice treated with Ang II significantly reduced the number of senescent cells in the aorta, where up-regulation of PTEN with reduced levels of phosphorylated Akt and ROS was demonstrated.	GW 501516	27-35	thymoma viral proto-oncogene 1	Mus musculus	211-214
23052247-5	2012	RESULTS: PPARdelta agonist GW501516 upregulated Ski expression in a dose-dependent manner.	GW 501516	27-35	Ski proto-oncogene	Rattus norvegicus	48-51
23056264-4	2012	Expression of Angptl4 was upregulated during myotubes differentiation and by oleic acid, insulin and PPAR delta agonist GW501516.	GW 501516	120-128	angiopoietin like 4	Homo sapiens	14-21
23056264-4	2012	Expression of Angptl4 was upregulated during myotubes differentiation and by oleic acid, insulin and PPAR delta agonist GW501516.	GW 501516	120-128	peroxisome proliferator activated receptor delta	Homo sapiens	101-111
23056264-5	2012	Treatment with GW501516 or Angptl4 overexpression inhibited both lipoprotein lipase (LPL) activity and LPL-dependent uptake of FAs whereas uptake of BSA-bound FAs was not affected by either treatment.	GW 501516	15-23	lipoprotein lipase	Homo sapiens	65-83
23056264-5	2012	Treatment with GW501516 or Angptl4 overexpression inhibited both lipoprotein lipase (LPL) activity and LPL-dependent uptake of FAs whereas uptake of BSA-bound FAs was not affected by either treatment.	GW 501516	15-23	lipoprotein lipase	Homo sapiens	85-88
23056264-5	2012	Treatment with GW501516 or Angptl4 overexpression inhibited both lipoprotein lipase (LPL) activity and LPL-dependent uptake of FAs whereas uptake of BSA-bound FAs was not affected by either treatment.	GW 501516	15-23	lipoprotein lipase	Homo sapiens	103-106
21615395-7	2011	Treatment of myotubes with a selective high-affinity PPARdelta agonist (GW501516) did not change mean PPARD, but enhanced mean PDK4 and ANGPTL4 expression 13- and 16-fold, respectively (P < 0 0001, both).	GW 501516	72-80	peroxisome proliferator activated receptor delta	Homo sapiens	53-62
21615395-7	2011	Treatment of myotubes with a selective high-affinity PPARdelta agonist (GW501516) did not change mean PPARD, but enhanced mean PDK4 and ANGPTL4 expression 13- and 16-fold, respectively (P < 0 0001, both).	GW 501516	72-80	pyruvate dehydrogenase kinase 4	Homo sapiens	127-131
21615395-7	2011	Treatment of myotubes with a selective high-affinity PPARdelta agonist (GW501516) did not change mean PPARD, but enhanced mean PDK4 and ANGPTL4 expression 13- and 16-fold, respectively (P < 0 0001, both).	GW 501516	72-80	angiopoietin like 4	Homo sapiens	136-143
21615395-8	2011	The individual PDK4 and ANGPTL4 expression levels reached upon GW501516 treatment were associated with donors" insulin sensitivity neither (P > 0 2, both).	GW 501516	63-71	pyruvate dehydrogenase kinase 4	Homo sapiens	15-19
21615395-8	2011	The individual PDK4 and ANGPTL4 expression levels reached upon GW501516 treatment were associated with donors" insulin sensitivity neither (P > 0 2, both).	GW 501516	63-71	angiopoietin like 4	Homo sapiens	24-31
21615395-8	2011	The individual PDK4 and ANGPTL4 expression levels reached upon GW501516 treatment were associated with donors" insulin sensitivity neither (P > 0 2, both).	GW 501516	63-71	insulin	Homo sapiens	111-118
21615395-9	2011	However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARdelta responsiveness, were positively associated with donors" insulin sensitivity derived from OGTT (P = 0 0182 and P = 0 0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0 0046 and P = 0 0258, respectively).	GW 501516	9-17	pyruvate dehydrogenase kinase 4	Homo sapiens	46-50
21615395-9	2011	However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARdelta responsiveness, were positively associated with donors" insulin sensitivity derived from OGTT (P = 0 0182 and P = 0 0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0 0046 and P = 0 0258, respectively).	GW 501516	9-17	angiopoietin like 4	Homo sapiens	55-62
21615395-9	2011	However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARdelta responsiveness, were positively associated with donors" insulin sensitivity derived from OGTT (P = 0 0182 and P = 0 0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0 0046 and P = 0 0258, respectively).	GW 501516	9-17	peroxisome proliferator activated receptor delta	Homo sapiens	86-95
21615395-9	2011	However, GW501516-mediated fold increments in PDK4 and ANGPTL4 expression, reflecting PPARdelta responsiveness, were positively associated with donors" insulin sensitivity derived from OGTT (P = 0 0182 and P = 0 0231, respectively) and hyperinsulinemic-euglycemic clamp (P = 0 0046 and P = 0 0258, respectively).	GW 501516	9-17	insulin	Homo sapiens	152-159
21896929-11	2011	High glucose, 4-HNE, and GW501516 also induced luciferase expression in a PPAR-delta-mediated transactivation assay.	GW 501516	25-33	peroxisome proliferator-activated receptor delta	Rattus norvegicus	74-84
21511721-7	2011	Carbaprostacyclin (a stable analogue of PGI(2)) and GW501516 (a PPARdelta selective agonist) significantly accelerated blastocyst hatching but did not increase total cell number of cultured blastocysts.	GW 501516	52-60	peroxisome proliferator activator receptor delta	Mus musculus	64-73
21816786-12	2011	CONCLUSIONS: GW501516 increased the hepatic removal of VLDL particles, which might have resulted from decreased apoC-III concentration.	GW 501516	13-21	apolipoprotein C3	Homo sapiens	112-120
21816786-13	2011	GW501516 increased apoA-II production, resulting in an increased concentration of LpA-I:A-II particles.	GW 501516	0-8	apolipoprotein A2	Homo sapiens	19-26
21816786-3	2011	OBJECTIVE: The aim of the study was to examine the effect of GW501516, a PPAR-delta agonist, on lipoprotein metabolism.	GW 501516	61-69	peroxisome proliferator activated receptor delta	Homo sapiens	73-83
21816786-7	2011	RESULTS: GW501516 decreased plasma triglycerides, fatty acid, apoB-100, and apoB-48 concentrations.	GW 501516	9-17	apolipoprotein B	Homo sapiens	62-70
21816786-7	2011	RESULTS: GW501516 decreased plasma triglycerides, fatty acid, apoB-100, and apoB-48 concentrations.	GW 501516	9-17	apolipoprotein B	Homo sapiens	76-83
21816786-8	2011	GW501516 decreased the concentrations of VLDL-apoB by increasing its fractional catabolism and of apoC-III by decreasing its production rate (P < 0.05).	GW 501516	0-8	apolipoprotein C3	Homo sapiens	98-106
21816786-10	2011	GW501516 increased HDL-cholesterol, apoA-II, and LpA-I:A-II concentrations by increasing apoA-II and LpA-I:A-II production (P < 0.05).	GW 501516	0-8	apolipoprotein A2	Homo sapiens	36-43
21816786-10	2011	GW501516 increased HDL-cholesterol, apoA-II, and LpA-I:A-II concentrations by increasing apoA-II and LpA-I:A-II production (P < 0.05).	GW 501516	0-8	apolipoprotein A2	Homo sapiens	89-96
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	GW 501516	62-70	peroxisome proliferator activator receptor delta	Mus musculus	37-46
21709207-3	2011	Treatment of human EPCs with a selective PPARdelta agonist GW501516 for 24 hours increased the levels of mRNA, protein, and enzymatic activity of GTP cyclohydrolase I (GTPCH I), as well as the production of tetrahydrobiopterin.	GW 501516	59-67	peroxisome proliferator activated receptor delta	Homo sapiens	41-50
21709207-3	2011	Treatment of human EPCs with a selective PPARdelta agonist GW501516 for 24 hours increased the levels of mRNA, protein, and enzymatic activity of GTP cyclohydrolase I (GTPCH I), as well as the production of tetrahydrobiopterin.	GW 501516	59-67	GTP cyclohydrolase 1	Homo sapiens	146-166
21709207-3	2011	Treatment of human EPCs with a selective PPARdelta agonist GW501516 for 24 hours increased the levels of mRNA, protein, and enzymatic activity of GTP cyclohydrolase I (GTPCH I), as well as the production of tetrahydrobiopterin.	GW 501516	59-67	GTP cyclohydrolase 1	Homo sapiens	168-175
21709207-4	2011	The effects of GW501516 were mediated by suppression of PTEN expression, thereby increasing phosphorylation of AKT.	GW 501516	15-23	phosphatase and tensin homolog	Homo sapiens	56-60
21709207-4	2011	The effects of GW501516 were mediated by suppression of PTEN expression, thereby increasing phosphorylation of AKT.	GW 501516	15-23	AKT serine/threonine kinase 1	Homo sapiens	111-114
21709207-5	2011	The AKT signaling also mediated GW501516-induced phosphorylation of endothelial NO synthase.	GW 501516	32-40	AKT serine/threonine kinase 1	Homo sapiens	4-7
21709207-11	2011	GTPCH I-small interfering RNA transfection significantly inhibited in vivo regenerative capacity of EPCs stimulated with GW501516.	GW 501516	121-129	GTP cyclohydrolase 1	Homo sapiens	0-7
21617181-9	2011	Several steps in STAT3 activation require its association with heat shock protein 90 (Hsp90), which was prevented by GW501516 as revealed in immunoprecipitation studies.	GW 501516	117-125	signal transducer and activator of transcription 3	Mus musculus	17-22
22466297-0	2011	GW501516 acts as an efficient PPARalpha activator in the mouse liver.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	30-39
22466297-1	2011	The peroxisome proliferator-activated receptor (PPAR) subtype specificity of GW501516, a well-known PPARdelta-specific agonist, was studied by examining its effects on the expression of endogenous genes in primary hepatocytes and the liver of wild-type and PPARalpha-null mice.	GW 501516	77-85	peroxisome proliferator activated receptor alpha	Mus musculus	4-46
22466297-1	2011	The peroxisome proliferator-activated receptor (PPAR) subtype specificity of GW501516, a well-known PPARdelta-specific agonist, was studied by examining its effects on the expression of endogenous genes in primary hepatocytes and the liver of wild-type and PPARalpha-null mice.	GW 501516	77-85	peroxisome proliferator activated receptor alpha	Mus musculus	48-52
22466297-1	2011	The peroxisome proliferator-activated receptor (PPAR) subtype specificity of GW501516, a well-known PPARdelta-specific agonist, was studied by examining its effects on the expression of endogenous genes in primary hepatocytes and the liver of wild-type and PPARalpha-null mice.	GW 501516	77-85	peroxisome proliferator activator receptor delta	Mus musculus	100-109
22466297-1	2011	The peroxisome proliferator-activated receptor (PPAR) subtype specificity of GW501516, a well-known PPARdelta-specific agonist, was studied by examining its effects on the expression of endogenous genes in primary hepatocytes and the liver of wild-type and PPARalpha-null mice.	GW 501516	77-85	peroxisome proliferator activated receptor alpha	Mus musculus	257-266
22466297-2	2011	GW501516, like the PPARalpha-specific agonist Wy14,643, induced the expression of several PPAR target genes in a dose-dependent manner but this action was mostly absent in the cells and liver of PPARalpha-null mice.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	19-28
22466297-2	2011	GW501516, like the PPARalpha-specific agonist Wy14,643, induced the expression of several PPAR target genes in a dose-dependent manner but this action was mostly absent in the cells and liver of PPARalpha-null mice.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	19-23
22466297-2	2011	GW501516, like the PPARalpha-specific agonist Wy14,643, induced the expression of several PPAR target genes in a dose-dependent manner but this action was mostly absent in the cells and liver of PPARalpha-null mice.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	195-204
22466297-3	2011	Results indicated that GW501516 acts as an efficient PPARalpha activator in the mouse liver.	GW 501516	23-31	peroxisome proliferator activated receptor alpha	Mus musculus	53-62
21617181-9	2011	Several steps in STAT3 activation require its association with heat shock protein 90 (Hsp90), which was prevented by GW501516 as revealed in immunoprecipitation studies.	GW 501516	117-125	heat shock protein, 3	Mus musculus	63-84
21617181-9	2011	Several steps in STAT3 activation require its association with heat shock protein 90 (Hsp90), which was prevented by GW501516 as revealed in immunoprecipitation studies.	GW 501516	117-125	heat shock protein, 3	Mus musculus	86-91
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	GW 501516	62-70	interleukin 6	Mus musculus	86-90
21617181-4	2011	RESULTS: First, we observed that the PPAR-beta/-delta agonist GW501516 prevented both IL-6-dependent reduction in insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes.	GW 501516	62-70	thymoma viral proto-oncogene 1	Mus musculus	133-136
21617181-7	2011	Moreover, GW501516 prevented IL-6-dependent induction of extracellular signal-related kinase (ERK)1/2, a serine-threonine-protein kinase involved in serine STAT3 phosphorylation.	GW 501516	10-18	interleukin 6	Mus musculus	29-33
21617181-7	2011	Moreover, GW501516 prevented IL-6-dependent induction of extracellular signal-related kinase (ERK)1/2, a serine-threonine-protein kinase involved in serine STAT3 phosphorylation.	GW 501516	10-18	mitogen-activated protein kinase 3	Mus musculus	57-101
21617181-7	2011	Moreover, GW501516 prevented IL-6-dependent induction of extracellular signal-related kinase (ERK)1/2, a serine-threonine-protein kinase involved in serine STAT3 phosphorylation.	GW 501516	10-18	signal transducer and activator of transcription 3	Mus musculus	156-161
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	4-12
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	GW 501516	29-37	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	128-138
21511987-0	2011	The role played by the peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome.	GW 501516	105-113	peroxisome proliferator activated receptor delta	Homo sapiens	23-70
21511987-0	2011	The role played by the peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) activator, GW501516, in control of fatty acid metabolism: a new potential therapeutic target for treating metabolic syndrome.	GW 501516	105-113	peroxisome proliferator activated receptor delta	Homo sapiens	78-86
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	GW 501516	29-37	lipin 1	Mus musculus	139-146
21363937-0	2011	The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation.	GW 501516	29-37	peroxisome proliferator activated receptor alpha	Mus musculus	147-156
21363937-3	2011	Exposure to the HFD caused hypertriglyceridemia that was accompanied by reduced hepatic mRNA levels of PPAR-gamma coactivator 1 (PGC-1)-alpha and lipin 1, and these effects were prevented by GW501516 treatment.	GW 501516	191-199	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	129-141
21363937-3	2011	Exposure to the HFD caused hypertriglyceridemia that was accompanied by reduced hepatic mRNA levels of PPAR-gamma coactivator 1 (PGC-1)-alpha and lipin 1, and these effects were prevented by GW501516 treatment.	GW 501516	191-199	lipin 1	Mus musculus	146-153
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	lipin 1	Mus musculus	42-49
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	98-108
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	109-118
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	172-181
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	172-181
21363937-4	2011	GW501516 treatment also increased nuclear lipin 1 protein levels, leading to amplification in the PGC-1alpha-PPARalpha signaling system, as demonstrated by the increase in PPARalpha levels and PPARalpha-DNA binding activity and the increased expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	172-181
21363937-6	2011	Moreover, GW501516 increased the levels of the hepatic endogenous ligand for PPARalpha, 16:0/18:1-phosphatidilcholine and markedly enhanced the expression of the hepatic Vldl receptor.	GW 501516	10-18	peroxisome proliferator activated receptor alpha	Mus musculus	77-86
21363937-6	2011	Moreover, GW501516 increased the levels of the hepatic endogenous ligand for PPARalpha, 16:0/18:1-phosphatidilcholine and markedly enhanced the expression of the hepatic Vldl receptor.	GW 501516	10-18	very low density lipoprotein receptor	Mus musculus	170-183
21363937-7	2011	Interestingly, GW501516 prevented the reduction in AMP-activated protein kinase (AMPK) phosphorylation and the increase in phosphorylated levels of ERK1/2 caused by HFD.	GW 501516	15-23	mitogen-activated protein kinase 3	Mus musculus	148-154
21363937-9	2011	These findings indicate that the hypotriglyceridemic effect of GW501516 in HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-lipin 1-PPARalpha pathway.	GW 501516	63-71	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	170-180
21363937-9	2011	These findings indicate that the hypotriglyceridemic effect of GW501516 in HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-lipin 1-PPARalpha pathway.	GW 501516	63-71	lipin 1	Mus musculus	181-188
21363937-9	2011	These findings indicate that the hypotriglyceridemic effect of GW501516 in HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-lipin 1-PPARalpha pathway.	GW 501516	63-71	peroxisome proliferator activated receptor alpha	Mus musculus	189-198
20221637-7	2011	The PPARbeta/delta agonists GW501516 and PGI(2) caused stimulations of only 1.5-fold in both cell lines.	GW 501516	28-36	peroxisome proliferator activated receptor delta	Homo sapiens	4-12
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	peroxisome proliferator activated receptor delta	Homo sapiens	4-51
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	peroxisome proliferator activated receptor delta	Homo sapiens	59-67
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	tumor necrosis factor	Homo sapiens	101-110
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	RELA proto-oncogene, NF-kB subunit	Homo sapiens	173-176
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	197-201
21146504-0	2011	The peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 prevents TNF-alpha-induced NF-kappaB activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.	GW 501516	83-91	sirtuin 1	Homo sapiens	206-211
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	4-12
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	tumor necrosis factor	Homo sapiens	69-78
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	C-X-C motif chemokine ligand 8	Homo sapiens	128-141
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	C-X-C motif chemokine ligand 8	Homo sapiens	143-147
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	tumor necrosis factor	Homo sapiens	150-159
21146504-3	2011	The PPARbeta/delta agonist GW501516 inhibited the increase caused by TNF-alpha in the mRNA levels of the NF-kappaB target genes interleukin 8 (IL-8), TNF-alpha and thymic stromal lymphopoietin (TSLP).	GW 501516	27-35	thymic stromal lymphopoietin	Homo sapiens	194-198
21146504-4	2011	Likewise, GW501516 prevented the increase in NF-kappaB DNA-binding activity observed in cells exposed to TNF-alpha.	GW 501516	10-18	tumor necrosis factor	Homo sapiens	105-114
21146504-5	2011	The reduction in NF-kappaB activity following GW501516 treatment in cells stimulated with TNF-alpha did not involve either increased IkappaBalpha protein levels or a reduction in the translocation of the p65 subunit of NF-kappaB.	GW 501516	46-54	tumor necrosis factor	Homo sapiens	90-99
21146504-6	2011	In contrast, GW501516 treatment decreased TNF-alpha-induced p65 acetylation.	GW 501516	13-21	tumor necrosis factor	Homo sapiens	42-51
21146504-6	2011	In contrast, GW501516 treatment decreased TNF-alpha-induced p65 acetylation.	GW 501516	13-21	RELA proto-oncogene, NF-kB subunit	Homo sapiens	60-63
21146504-9	2011	GW501516 increased AMPK phosphorylation and the subsequent p300 phosphorylation, leading to a marked reduction in the association between p65 and this transcriptional co-activator.	GW 501516	0-8	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	19-23
21146504-9	2011	GW501516 increased AMPK phosphorylation and the subsequent p300 phosphorylation, leading to a marked reduction in the association between p65 and this transcriptional co-activator.	GW 501516	0-8	E1A binding protein p300	Homo sapiens	59-63
21146504-9	2011	GW501516 increased AMPK phosphorylation and the subsequent p300 phosphorylation, leading to a marked reduction in the association between p65 and this transcriptional co-activator.	GW 501516	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	138-141
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	tumor necrosis factor	Homo sapiens	75-84
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	peroxisome proliferator activated receptor delta	Homo sapiens	139-147
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	178-182
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	sirtuin 1	Homo sapiens	212-217
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	peroxisome proliferator activated receptor delta	Homo sapiens	318-326
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	334-338
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	53-61	sirtuin 1	Homo sapiens	343-348
21070867-9	2011	PPARbeta/delta activation by GW501516 enhanced the physical interaction between PPARbeta/delta and p65, which suggests that this mechanism may also interfere NF-kappaB transactivation capacity in the heart.	GW 501516	29-37	peroxisome proliferator activated receptor delta	Homo sapiens	0-8
21070867-9	2011	PPARbeta/delta activation by GW501516 enhanced the physical interaction between PPARbeta/delta and p65, which suggests that this mechanism may also interfere NF-kappaB transactivation capacity in the heart.	GW 501516	29-37	peroxisome proliferator activated receptor delta	Homo sapiens	80-88
21070867-9	2011	PPARbeta/delta activation by GW501516 enhanced the physical interaction between PPARbeta/delta and p65, which suggests that this mechanism may also interfere NF-kappaB transactivation capacity in the heart.	GW 501516	29-37	RELA proto-oncogene, NF-kB subunit	Homo sapiens	99-102
21070867-10	2011	GW501516-induced PPARbeta/delta activation can attenuate the inflammatory response induced in human cardiac AC16 cells exposed to the saturated fatty acid palmitate and in mice fed a high-fat diet.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	17-25
21297860-6	2011	The transgenic mammary gland also expressed higher levels of PPARdelta and a gene expression profile resembling wild-type mice maintained on a diet containing the PPARdelta agonist, GW501516.	GW 501516	182-190	peroxisome proliferator activator receptor delta	Mus musculus	163-172
21297860-9	2011	GW501516-treated transgenic mice expressed higher levels of fatty acid and phospholipid metabolites than treated wild-type mice, suggesting the involvement of PDK1 in enhancing PPARdelta-driven energy metabolism.	GW 501516	0-8	pyruvate dehydrogenase kinase, isoenzyme 1	Mus musculus	159-163
21297860-9	2011	GW501516-treated transgenic mice expressed higher levels of fatty acid and phospholipid metabolites than treated wild-type mice, suggesting the involvement of PDK1 in enhancing PPARdelta-driven energy metabolism.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	177-186
21300064-7	2011	Treatment of wild-type and ob/ob mice with GW501516 enhanced the increase in plasma GLP-1 level after an oral glucose load and improved glucose tolerance.	GW 501516	43-51	glucagon	Mus musculus	84-89
21352808-2	2011	Activation of PPARdelta by GW501516, a specific agonist of PPARdelta, significantly inhibited the Ang II-induced premature senescence of hVSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
21352808-2	2011	Activation of PPARdelta by GW501516, a specific agonist of PPARdelta, significantly inhibited the Ang II-induced premature senescence of hVSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
21352808-4	2011	Notably, GW501516 up-regulated the expression of antioxidant genes, such as glutathione peroxidase 1, thioredoxin 1, manganese superoxide dismutase and heme oxygenase 1.	GW 501516	9-17	glutathione peroxidase 1	Homo sapiens	76-100
21352808-4	2011	Notably, GW501516 up-regulated the expression of antioxidant genes, such as glutathione peroxidase 1, thioredoxin 1, manganese superoxide dismutase and heme oxygenase 1.	GW 501516	9-17	superoxide dismutase 2	Homo sapiens	117-147
21352808-4	2011	Notably, GW501516 up-regulated the expression of antioxidant genes, such as glutathione peroxidase 1, thioredoxin 1, manganese superoxide dismutase and heme oxygenase 1.	GW 501516	9-17	heme oxygenase 1	Homo sapiens	152-168
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	269-277	C-X-C motif chemokine ligand 8	Homo sapiens	26-30
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	269-277	tumor necrosis factor	Homo sapiens	75-84
21146504-11	2011	Finally, the reduction in IL-8 mRNA levels following GW501516 treatment in TNF-alpha-stimulated cells was abolished in the presence of the PPARbeta/delta antagonist GSK0660, the AMPK inhibitor compound C and the SIRT1 inhibitor sirtinol, indicating that the effects of GW501516 on NF-kappaB activity were dependent on PPARbeta/delta, AMPK and SIRT1, respectively.	GW 501516	269-277	peroxisome proliferator activated receptor delta	Homo sapiens	139-147
21215640-2	2011	Incorporation of structurally constrained oxime-ether based linker in the chemotype of a potent PPARdelta selective agonist GW-501516 was adapted as designing strategy.	GW 501516	124-133	peroxisome proliferator activated receptor delta	Homo sapiens	96-105
21484566-6	2011	PPAR-delta activators increase the capacity for fat oxidation in skeletal muscle.Clinical experience with bezafibrate, which activates PPAR-delta and -alpha, and studies on the PPAR-alpha/delta activator tetradecylthioacetic acid, the PPAR-delta activator GW501516, and combinations of the PPAR-alpha activator fenofibrate with rosiglitazone or pioglitazone have encouraged attempts to develop single molecules that activate two or all three PPARs.	GW 501516	256-264	peroxisome proliferator activated receptor delta	Homo sapiens	0-10
20571903-4	2010	Our results show that GW501516 treatment promoted generation of mitochondrial ATP, as well as expression levels of PGC-1alpha, NRF-1 and mtTFA, decreased basal insulin secretion, but had no effect on glucose-stimulated insulin secretion (GSIS), increased amounts of UCP2 and changed ATP-to-ADP ratio, improved mitochondrial morphology in palmitate-treated beta-cells.	GW 501516	22-30	nuclear respiratory factor 1	Mesocricetus auratus	127-132
21966476-0	2011	GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	12-21
21966476-0	2011	GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice.	GW 501516	0-8	mitogen-activated protein kinase kinase kinase 7	Mus musculus	123-127
21966476-0	2011	GW501516, a PPARdelta agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFkappaB pathway in mice.	GW 501516	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	128-136
21966476-3	2011	Thus, we examined the renoprotective effect of GW501516, a PPARdelta agonist, in a protein-overload mouse nephropathy model and identified its molecular mechanism.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	59-68
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	tumor necrosis factor	Mus musculus	92-109
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	chemokine (C-C motif) ligand 2	Mus musculus	156-161
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	mitogen-activated protein kinase kinase kinase 7	Mus musculus	202-229
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	mitogen-activated protein kinase kinase kinase 7	Mus musculus	231-235
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	237-245
21966476-8	2011	In vitro studies using cultured proximal tubular cells showed that GW501516 attenuated both TNFalpha- and FFA (palmitate)-induced, but not albumin-induced, MCP-1 expression via direct inhibition of the TGF-beta activated kinase 1 (TAK1)-NFkappaB pathway, a common downstream signaling pathway to TNFalpha receptor and toll-like receptor-4.	GW 501516	67-75	tumor necrosis factor	Mus musculus	92-100
21966511-5	2011	The pro-differentiation effect of PPARbeta/delta agonist GW501516 was also abolished when keratinocytes were co-treated with PPARbeta/delta antagonist GSK0660 and similarly in organotypic skin culture incubated with blocking ANGPTL4 monoclonal antibody targeted against the C-terminal fibrinogen-like domain.	GW 501516	57-65	peroxisome proliferator activated receptor delta	Homo sapiens	34-42
21966511-5	2011	The pro-differentiation effect of PPARbeta/delta agonist GW501516 was also abolished when keratinocytes were co-treated with PPARbeta/delta antagonist GSK0660 and similarly in organotypic skin culture incubated with blocking ANGPTL4 monoclonal antibody targeted against the C-terminal fibrinogen-like domain.	GW 501516	57-65	peroxisome proliferator activated receptor delta	Homo sapiens	125-133
21966511-5	2011	The pro-differentiation effect of PPARbeta/delta agonist GW501516 was also abolished when keratinocytes were co-treated with PPARbeta/delta antagonist GSK0660 and similarly in organotypic skin culture incubated with blocking ANGPTL4 monoclonal antibody targeted against the C-terminal fibrinogen-like domain.	GW 501516	57-65	angiopoietin like 4	Homo sapiens	225-232
20571903-4	2010	Our results show that GW501516 treatment promoted generation of mitochondrial ATP, as well as expression levels of PGC-1alpha, NRF-1 and mtTFA, decreased basal insulin secretion, but had no effect on glucose-stimulated insulin secretion (GSIS), increased amounts of UCP2 and changed ATP-to-ADP ratio, improved mitochondrial morphology in palmitate-treated beta-cells.	GW 501516	22-30	insulin	Mesocricetus auratus	160-167
20571903-4	2010	Our results show that GW501516 treatment promoted generation of mitochondrial ATP, as well as expression levels of PGC-1alpha, NRF-1 and mtTFA, decreased basal insulin secretion, but had no effect on glucose-stimulated insulin secretion (GSIS), increased amounts of UCP2 and changed ATP-to-ADP ratio, improved mitochondrial morphology in palmitate-treated beta-cells.	GW 501516	22-30	mitochondrial uncoupling protein 2	Mesocricetus auratus	266-270
20571903-5	2010	GW501516-induced activation of PPARdelta enhanced mitochondrial energy metabolism, but also promoted a concomitant mitochondrial uncoupling and resulted in decreased basal insulin secretion and restricted GSIS; this observation indicated the possible action of a protective mechanism responding to the alleviation of excessive lipid load and basal insulin secretion in lipotoxic beta-cells.	GW 501516	0-8	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	31-40
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	GW 501516	50-58	peroxisome proliferator activator receptor delta	Mus musculus	31-40
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	GW 501516	50-58	interferon gamma	Mus musculus	132-154
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	GW 501516	50-58	interleukin 17A	Mus musculus	159-178
20406305-8	2010	In this study we show that the PPARdelta agonists GW501516 and L165041 ameliorate MOGp35-55-induced EAE in C57BL/6 mice by blocking interferon (IFN)-gamma and interleukin (IL)-17 production by T helper type 1 (Th1) and Th17 cells.	GW 501516	50-58	negative elongation factor complex member C/D, Th1l	Mus musculus	193-213
19946680-0	2010	Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.	GW 501516	75-81	peroxisome proliferator activated receptor delta	Homo sapiens	57-66
20542425-0	2010	Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity.	GW 501516	69-77	peroxisome proliferator activated receptor delta	Homo sapiens	46-54
20542425-2	2010	Herein, we describe an efficient synthesis of a novel isosteric selenium analog of the highly specific PPARbeta/delta ligand 2-methyl-4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazol-5-yl)-methylsulfanyl)phenoxy-acetic acid (GW501516; 1).	GW 501516	229-237	peroxisome proliferator activated receptor delta	Homo sapiens	103-111
20221783-1	2010	Activation of peroxisome proliferator-activated receptor (PPAR) delta by GW501516, a specific PPARdelta ligand, significantly inhibited interleukin (IL)-1beta-induced proliferation and migration of vascular smooth muscle cells (VSMCs).	GW 501516	73-81	peroxisome proliferator activated receptor delta	Homo sapiens	58-62
20221783-1	2010	Activation of peroxisome proliferator-activated receptor (PPAR) delta by GW501516, a specific PPARdelta ligand, significantly inhibited interleukin (IL)-1beta-induced proliferation and migration of vascular smooth muscle cells (VSMCs).	GW 501516	73-81	peroxisome proliferator activated receptor delta	Homo sapiens	94-103
20221783-1	2010	Activation of peroxisome proliferator-activated receptor (PPAR) delta by GW501516, a specific PPARdelta ligand, significantly inhibited interleukin (IL)-1beta-induced proliferation and migration of vascular smooth muscle cells (VSMCs).	GW 501516	73-81	interleukin 1 beta	Homo sapiens	136-158
20221783-2	2010	This effect of GW501516 was dependent on transforming growth factor-beta, and was mediated through the up-regulation of IL-1 receptor antagonist.	GW 501516	15-23	interleukin 1 receptor antagonist	Homo sapiens	120-144
20221783-3	2010	The inhibitory effect of GW501516 on VSMC proliferation was associated with cell cycle arrest at the G1 to S phase transition, which was accompanied by the induction of p21 and p53 along with decreased cyclin-dependent kinase 4 expression.	GW 501516	25-33	cyclin dependent kinase inhibitor 1A	Homo sapiens	169-172
20221783-3	2010	The inhibitory effect of GW501516 on VSMC proliferation was associated with cell cycle arrest at the G1 to S phase transition, which was accompanied by the induction of p21 and p53 along with decreased cyclin-dependent kinase 4 expression.	GW 501516	25-33	tumor protein p53	Homo sapiens	177-180
20221783-3	2010	The inhibitory effect of GW501516 on VSMC proliferation was associated with cell cycle arrest at the G1 to S phase transition, which was accompanied by the induction of p21 and p53 along with decreased cyclin-dependent kinase 4 expression.	GW 501516	25-33	cyclin dependent kinase 4	Homo sapiens	202-227
20221783-4	2010	Inhibition of cell migration by GW501516 was associated with the down-regulation of matrix metalloproteinase (MMP)-2 and MMP-9 in IL-1beta-treated VSMCs.	GW 501516	32-40	matrix metallopeptidase 2	Homo sapiens	84-116
20221783-4	2010	Inhibition of cell migration by GW501516 was associated with the down-regulation of matrix metalloproteinase (MMP)-2 and MMP-9 in IL-1beta-treated VSMCs.	GW 501516	32-40	matrix metallopeptidase 9	Homo sapiens	121-126
20221783-4	2010	Inhibition of cell migration by GW501516 was associated with the down-regulation of matrix metalloproteinase (MMP)-2 and MMP-9 in IL-1beta-treated VSMCs.	GW 501516	32-40	interleukin 1 beta	Homo sapiens	130-138
20221783-5	2010	Inhibition of extracellular signal-regulated kinase significantly reduced the GW501516-mediated inhibition of IL-1beta-stimulated VSMC proliferation.	GW 501516	78-86	interleukin 1 beta	Homo sapiens	110-118
19538467-3	2010	Here, we demonstrate that administration of GW501516, a specific PPARdelta ligand, significantly promoted wound closure in the experimental mouse and had a profound effect on the expression of collagen types I and III, alpha-smooth muscle actin, pSmad3 and TGF-beta1, which play a pivotal role in wound healing processes.	GW 501516	44-52	peroxisome proliferator activator receptor delta	Mus musculus	65-74
19538467-3	2010	Here, we demonstrate that administration of GW501516, a specific PPARdelta ligand, significantly promoted wound closure in the experimental mouse and had a profound effect on the expression of collagen types I and III, alpha-smooth muscle actin, pSmad3 and TGF-beta1, which play a pivotal role in wound healing processes.	GW 501516	44-52	transforming growth factor, beta 1	Mus musculus	257-266
19946680-1	2010	Since January 2009, the list of prohibited substances and methods of doping as established by the World Anti-Doping Agency includes new therapeutics such as the peroxisome-proliferator-activated receptor (PPAR)-delta agonist GW1516, which is categorized as a gene doping substance.	GW 501516	225-231	peroxisome proliferator activated receptor delta	Homo sapiens	161-216
20185762-0	2010	Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	14-63
20185762-4	2010	In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate.	GW 501516	54-62	peroxisome proliferator activator receptor delta	Mus musculus	36-45
20185762-7	2010	In agreement with these changes, GW501516 treatment reversed the increase in DAG and PKCtheta activation caused by palmitate.	GW 501516	33-41	protein kinase C, theta	Mus musculus	85-93
20185762-4	2010	In C2C12 skeletal muscle cells, the PPARdelta agonist GW501516 prevented phosphorylation of insulin receptor substrate-1 at Ser(307) and the inhibition of insulin-stimulated Akt phosphorylation caused by exposure to the saturated fatty acid palmitate.	GW 501516	54-62	insulin receptor substrate 1	Mus musculus	92-120
20185762-9	2010	Consistent with these findings, PPARdelta activation by GW501516 blocked palmitate-induced NF-kappaB DNA-binding activity.	GW 501516	56-64	peroxisome proliferator activator receptor delta	Mus musculus	32-41
20040361-3	2010	After HIT-T15 cells (a beta-cell line) were exposed to high concentrations of palmitate and GW501516 (GW; a selective agonist of PPARdelta), we found that administration of GW increased the expression of PPARdelta mRNA.	GW 501516	92-100	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	129-138
20066433-5	2010	Specific pharmacological activation of PPARbeta using GW0742 or GW501516 in low concentrations inhibits proliferation of human and murine melanoma cells.	GW 501516	64-72	peroxisome proliferator activated receptor delta	Homo sapiens	39-47
19903700-5	2010	METHODS AND RESULTS: En face confocal microscopy of murine aortas demonstrated that the PPARdelta-selective ligand GW501516 induced endothelial haem oxygenase-1 expression.	GW 501516	115-123	peroxisome proliferator activator receptor delta	Mus musculus	88-97
20040361-3	2010	After HIT-T15 cells (a beta-cell line) were exposed to high concentrations of palmitate and GW501516 (GW; a selective agonist of PPARdelta), we found that administration of GW increased the expression of PPARdelta mRNA.	GW 501516	92-100	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	204-213
20040361-3	2010	After HIT-T15 cells (a beta-cell line) were exposed to high concentrations of palmitate and GW501516 (GW; a selective agonist of PPARdelta), we found that administration of GW increased the expression of PPARdelta mRNA.	GW 501516	92-94	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	129-138
20040361-3	2010	After HIT-T15 cells (a beta-cell line) were exposed to high concentrations of palmitate and GW501516 (GW; a selective agonist of PPARdelta), we found that administration of GW increased the expression of PPARdelta mRNA.	GW 501516	92-94	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	204-213
20040361-4	2010	GW-induced activation of PPARdelta up-regulated carnitine palmitoyltransferase 1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), pyruvate dehydrogenase kinase 4 (PDK4), and uncoupling protein 2 (UCP2); alleviated mitochondrial swelling; attenuated apoptosis; and reduced basal insulin secretion induced by increased palmitate in HIT cells.	GW 501516	0-2	peroxisome proliferator-activated receptor delta	Mesocricetus auratus	25-34
20040361-4	2010	GW-induced activation of PPARdelta up-regulated carnitine palmitoyltransferase 1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), pyruvate dehydrogenase kinase 4 (PDK4), and uncoupling protein 2 (UCP2); alleviated mitochondrial swelling; attenuated apoptosis; and reduced basal insulin secretion induced by increased palmitate in HIT cells.	GW 501516	0-2	pyruvate dehydrogenase kinase, isozyme 4	Mesocricetus auratus	131-162
20040361-4	2010	GW-induced activation of PPARdelta up-regulated carnitine palmitoyltransferase 1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), pyruvate dehydrogenase kinase 4 (PDK4), and uncoupling protein 2 (UCP2); alleviated mitochondrial swelling; attenuated apoptosis; and reduced basal insulin secretion induced by increased palmitate in HIT cells.	GW 501516	0-2	pyruvate dehydrogenase kinase, isozyme 4	Mesocricetus auratus	164-168
20040361-4	2010	GW-induced activation of PPARdelta up-regulated carnitine palmitoyltransferase 1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), pyruvate dehydrogenase kinase 4 (PDK4), and uncoupling protein 2 (UCP2); alleviated mitochondrial swelling; attenuated apoptosis; and reduced basal insulin secretion induced by increased palmitate in HIT cells.	GW 501516	0-2	mitochondrial uncoupling protein 2	Mesocricetus auratus	175-195
20040361-4	2010	GW-induced activation of PPARdelta up-regulated carnitine palmitoyltransferase 1 (CPT1), long-chain acyl-CoA dehydrogenase (LCAD), pyruvate dehydrogenase kinase 4 (PDK4), and uncoupling protein 2 (UCP2); alleviated mitochondrial swelling; attenuated apoptosis; and reduced basal insulin secretion induced by increased palmitate in HIT cells.	GW 501516	0-2	mitochondrial uncoupling protein 2	Mesocricetus auratus	197-201
21318167-3	2010	In the present study, we describe a new gastric tumor mouse model that is dependent on the potent and highly selective PPARdelta agonist GW501516 following carcinogen administration.	GW 501516	137-145	peroxisome proliferator activator receptor delta	Mus musculus	119-128
19660859-4	2010	Inhibition of C20 cell proliferation and clonogenicity was observed following treatment with GW0742 or GW501516, two highly specific PPARbeta/delta ligands.	GW 501516	103-111	peroxisome proliferator-activated receptor delta	Rattus norvegicus	133-141
20086318-7	2009	Incubation with 500 nM GW501516 (PPARdelta activator) for 24 h significantly decreased GLUT-4 mRNA in L6 myotubes.	GW 501516	23-31	solute carrier family 2 member 4	Rattus norvegicus	87-93
19744959-5	2009	GW501516, a PPARbeta/delta agonist, was found to stimulate utrophin A mRNA levels in C2C12 muscle cells through an element in the utrophin A promoter.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	12-20
19696401-6	2009	Studies in human platelets showed that PKCalpha, which can mediate platelet activation, was bound and repressed by PPARbeta/delta after platelets were treated with GW501516.	GW 501516	164-172	protein kinase C alpha	Homo sapiens	39-47
19696401-6	2009	Studies in human platelets showed that PKCalpha, which can mediate platelet activation, was bound and repressed by PPARbeta/delta after platelets were treated with GW501516.	GW 501516	164-172	peroxisome proliferator activated receptor delta	Homo sapiens	115-123
19513536-3	2009	The PPARdelta agonist GW501516 exerted similar effects on protein synthesis to IL15.	GW 501516	22-30	peroxisome proliferator activator receptor delta	Mus musculus	4-13
19667161-8	2009	GW501516 (PPARdelta ligand) and WY14643 (PPARalpha ligand) both had an antiproliferative effect of approximately 10%.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	10-19
19667161-12	2009	Treatment with GW501516 and WY14643 resulted in an increase in the VDR expression (2-fold after 120 h).	GW 501516	15-23	vitamin D receptor	Homo sapiens	67-70
19512923-5	2009	A couple of recent studies using the specific PPARdelta agonist GW501516 suggest potent hypolipidaemic actions, presumably caused by enhanced fat oxidation in skeletal muscle.	GW 501516	64-72	peroxisome proliferator activated receptor delta	Homo sapiens	46-55
19435887-3	2009	In this study, we determined the effect of selective PPARdelta agonism with the synthetic ligand, GW501516, on FAO and mitochondrial gene expression in vitro and in vivo.	GW 501516	98-106	peroxisome proliferator activator receptor delta	Mus musculus	53-62
19435887-4	2009	Our results show that activation of PPARdelta by GW501516 led to a robust increase in mRNA levels of key lipid metabolism genes.	GW 501516	49-57	peroxisome proliferator activator receptor delta	Mus musculus	36-45
19461048-6	2009	Administration of a PPARdelta ligand GW501516 to mice also suppressed elastase-induced cell death of aortic VSMCs.	GW 501516	37-45	peroxisome proliferator activator receptor delta	Mus musculus	20-29
19236478-6	2009	By contrast, a PPARbeta/delta activator (GW501516) normalized only the expression of involucrin and filaggrin but not loricrin.	GW 501516	41-49	peroxisome proliferator activator receptor delta	Mus musculus	15-23
19389799-4	2009	Using intravital microscopy in the mouse cremasteric microcirculation, we have shown that activation of PPARbeta/delta by its selective ligand GW501516 inhibits TNF-alpha-induced leukocyte rolling flux, adhesion, and emigration in a dose-dependant manner.	GW 501516	143-151	peroxisome proliferator activator receptor delta	Mus musculus	104-112
19389799-4	2009	Using intravital microscopy in the mouse cremasteric microcirculation, we have shown that activation of PPARbeta/delta by its selective ligand GW501516 inhibits TNF-alpha-induced leukocyte rolling flux, adhesion, and emigration in a dose-dependant manner.	GW 501516	143-151	tumor necrosis factor	Mus musculus	161-170
19389799-5	2009	Moreover, GW501516 reduced the expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin in the cremasteric postcapillary venules.	GW 501516	10-18	intercellular adhesion molecule 1	Mus musculus	72-78
19389799-5	2009	Moreover, GW501516 reduced the expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin in the cremasteric postcapillary venules.	GW 501516	10-18	vascular cell adhesion molecule 1	Mus musculus	80-86
19389799-5	2009	Moreover, GW501516 reduced the expression of adhesion molecules such as ICAM-1, VCAM-1, and E-selectin in the cremasteric postcapillary venules.	GW 501516	10-18	selectin, endothelial cell	Mus musculus	92-102
19389799-6	2009	Similarly, rolling and adhesion of hPMNs under physiological flow on TNF-alpha-activated HUVECs were also inhibited markedly by GW501516.	GW 501516	128-136	tumor necrosis factor	Mus musculus	69-78
19389799-7	2009	These inhibitory responses of GW501516 on activated endothelium were accompanied by a reduction in TNF-alpha-induced endothelial GRO-alpha release and VCAM-1, E-selectin, and ICAM-1 mRNA expression.	GW 501516	30-38	tumor necrosis factor	Mus musculus	99-108
19389799-7	2009	These inhibitory responses of GW501516 on activated endothelium were accompanied by a reduction in TNF-alpha-induced endothelial GRO-alpha release and VCAM-1, E-selectin, and ICAM-1 mRNA expression.	GW 501516	30-38	vascular cell adhesion molecule 1	Mus musculus	151-157
19389799-7	2009	These inhibitory responses of GW501516 on activated endothelium were accompanied by a reduction in TNF-alpha-induced endothelial GRO-alpha release and VCAM-1, E-selectin, and ICAM-1 mRNA expression.	GW 501516	30-38	selectin, endothelial cell	Mus musculus	159-169
19389799-7	2009	These inhibitory responses of GW501516 on activated endothelium were accompanied by a reduction in TNF-alpha-induced endothelial GRO-alpha release and VCAM-1, E-selectin, and ICAM-1 mRNA expression.	GW 501516	30-38	intercellular adhesion molecule 1	Mus musculus	175-181
19483413-7	2009	The amino acid(s) that predominantly influence the potency and selectivity of TIPP-204 are different from that of the well-known PPARdelta-selective agonist GW-501516, which belongs to a different chemical class.	GW 501516	157-166	peroxisome proliferator activated receptor delta	Homo sapiens	129-138
19422681-0	2009	Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.	GW 501516	33-41	peroxisome proliferator-activated receptor delta	Rattus norvegicus	15-24
19422681-7	2009	GW 501516, a specific PPAR-beta agonist, was examined for its capacity to protect from antibody-mediated demyelination and to prevent inflammatory responses induced by IFN-gamma and LPS.	GW 501516	0-9	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-31
19422681-7	2009	GW 501516, a specific PPAR-beta agonist, was examined for its capacity to protect from antibody-mediated demyelination and to prevent inflammatory responses induced by IFN-gamma and LPS.	GW 501516	0-9	interferon gamma	Rattus norvegicus	168-177
19422681-11	2009	RESULTS: GW 501516 decreased the IFN-gamma-induced up-regulation of TNF-alpha and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-beta agonist.	GW 501516	9-18	interferon gamma	Rattus norvegicus	33-42
19422681-11	2009	RESULTS: GW 501516 decreased the IFN-gamma-induced up-regulation of TNF-alpha and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-beta agonist.	GW 501516	9-18	tumor necrosis factor	Rattus norvegicus	68-77
19422681-11	2009	RESULTS: GW 501516 decreased the IFN-gamma-induced up-regulation of TNF-alpha and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-beta agonist.	GW 501516	9-18	nitric oxide synthase 2	Rattus norvegicus	82-86
19422681-11	2009	RESULTS: GW 501516 decreased the IFN-gamma-induced up-regulation of TNF-alpha and iNOS in accord with the proposed anti-inflammatory effects of this PPAR-beta agonist.	GW 501516	9-18	peroxisome proliferator-activated receptor delta	Rattus norvegicus	149-158
18776129-1	2009	We previously demonstrated that a selective agonist of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta), GW501516, stimulated human non-small cell lung carcinoma (NSCLC) growth, partly through inhibition of phosphatase and tensin homolog deleted on chromosome 10 expression.	GW 501516	127-135	peroxisome proliferator activated receptor delta	Homo sapiens	55-108
18776129-1	2009	We previously demonstrated that a selective agonist of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta), GW501516, stimulated human non-small cell lung carcinoma (NSCLC) growth, partly through inhibition of phosphatase and tensin homolog deleted on chromosome 10 expression.	GW 501516	127-135	peroxisome proliferator activated receptor delta	Homo sapiens	110-118
18776129-5	2009	Instead, we found that GW501516 stimulated peroxisome proliferator-activated receptor coactivator gamma (PGC)-1alpha, which activated the phosphatidylinositol 3 kinase (PI3-K)/Akt mitogenic pathway.	GW 501516	23-31	PPARG coactivator 1 alpha	Homo sapiens	54-116
18776129-5	2009	Instead, we found that GW501516 stimulated peroxisome proliferator-activated receptor coactivator gamma (PGC)-1alpha, which activated the phosphatidylinositol 3 kinase (PI3-K)/Akt mitogenic pathway.	GW 501516	23-31	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	138-167
18776129-5	2009	Instead, we found that GW501516 stimulated peroxisome proliferator-activated receptor coactivator gamma (PGC)-1alpha, which activated the phosphatidylinositol 3 kinase (PI3-K)/Akt mitogenic pathway.	GW 501516	23-31	AKT serine/threonine kinase 1	Homo sapiens	176-179
18684227-0	2008	Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium L-glutamate metabolic syndrome mice.	GW 501516	58-66	peroxisome proliferator activator receptor delta	Mus musculus	0-48
19347285-5	2009	We have shown that NSCLC cells express PPARbeta/delta protein and that treatment with a selective PPARbeta/delta agonist, GW501516, stimulated the expression of EP4 and induced NSCLC cell proliferation.	GW 501516	122-130	peroxisome proliferator activated receptor delta	Homo sapiens	39-47
19347285-5	2009	We have shown that NSCLC cells express PPARbeta/delta protein and that treatment with a selective PPARbeta/delta agonist, GW501516, stimulated the expression of EP4 and induced NSCLC cell proliferation.	GW 501516	122-130	peroxisome proliferator activated receptor delta	Homo sapiens	98-106
19347285-5	2009	We have shown that NSCLC cells express PPARbeta/delta protein and that treatment with a selective PPARbeta/delta agonist, GW501516, stimulated the expression of EP4 and induced NSCLC cell proliferation.	GW 501516	122-130	prostaglandin E receptor 4	Homo sapiens	161-164
19266055-0	2009	The PPARdelta ligand GW501516 reduces growth but not apoptosis in mouse inner medullary collecting duct cells.	GW 501516	21-29	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18636547-6	2008	Overexpression of PPARdelta or treatment with the selective PPARdelta ligand, GW501516, also increased beta-catenin binding to TCF/LEF response element and increased its reporter activity.	GW 501516	78-86	peroxisome proliferator activated receptor delta	Homo sapiens	18-27
18636547-6	2008	Overexpression of PPARdelta or treatment with the selective PPARdelta ligand, GW501516, also increased beta-catenin binding to TCF/LEF response element and increased its reporter activity.	GW 501516	78-86	peroxisome proliferator activated receptor delta	Homo sapiens	60-69
18636547-6	2008	Overexpression of PPARdelta or treatment with the selective PPARdelta ligand, GW501516, also increased beta-catenin binding to TCF/LEF response element and increased its reporter activity.	GW 501516	78-86	catenin beta 1	Homo sapiens	103-115
18636547-6	2008	Overexpression of PPARdelta or treatment with the selective PPARdelta ligand, GW501516, also increased beta-catenin binding to TCF/LEF response element and increased its reporter activity.	GW 501516	78-86	hepatocyte nuclear factor 4 alpha	Homo sapiens	127-134
18636547-7	2008	Addition of AA and GW501516 to nuclear extracts induced a comparable degree of beta-catenin binding to TCF/LEF response element.	GW 501516	19-27	catenin beta 1	Homo sapiens	79-91
18636547-7	2008	Addition of AA and GW501516 to nuclear extracts induced a comparable degree of beta-catenin binding to TCF/LEF response element.	GW 501516	19-27	hepatocyte nuclear factor 4 alpha	Homo sapiens	103-110
18687807-5	2008	GW0742 and GW501516 increased expression of known PPARbeta/delta target genes, whereas RA did not; RA increased the expression of known retinoic acid receptor/retinoid X receptor target genes, whereas GW0742 did not affect these genes.	GW 501516	11-19	peroxisome proliferator activated receptor delta	Homo sapiens	50-58
18511850-7	2008	Impaired tube formation and cell proliferation induced by inactivation of COX-1 were rescued by the treatment with iloprost or the selective peroxisome proliferator-activated receptor (PPAR)delta agonist GW501516 but not by the selective PGI(2) receptor agonist cicaprost.	GW 501516	204-212	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	74-79
18701481-5	2008	The synthetic PPARdelta agonist GW501516 augmented these PPARdelta proliferation effects in a dose-dependent manner.	GW 501516	32-40	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
18701481-5	2008	The synthetic PPARdelta agonist GW501516 augmented these PPARdelta proliferation effects in a dose-dependent manner.	GW 501516	32-40	peroxisome proliferator activated receptor delta	Homo sapiens	57-66
18443198-3	2008	RESEARCH DESIGN AND METHODS AND RESULTS: First, we examined whether the PPARbeta/delta agonist GW501516 prevents lipopolysaccharide (LPS)-induced cytokine production in differentiated 3T3-L1 adipocytes.	GW 501516	95-103	peroxisome proliferator-activated receptor delta	Rattus norvegicus	72-80
18443198-4	2008	Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway.	GW 501516	15-23	interleukin 6	Rattus norvegicus	44-48
18443198-4	2008	Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway.	GW 501516	15-23	signal transducer and activator of transcription 3	Rattus norvegicus	125-175
18443198-4	2008	Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway.	GW 501516	15-23	signal transducer and activator of transcription 3	Rattus norvegicus	177-182
18443198-4	2008	Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway.	GW 501516	15-23	suppressor of cytokine signaling 3	Rattus norvegicus	184-218
18443198-4	2008	Treatment with GW501516 blocked LPS-induced IL-6 expression and secretion by adipocytes and the subsequent activation of the signal transducer and activator of transcription 3 (STAT3)-Suppressor of cytokine signaling 3 (SOCS3) pathway.	GW 501516	15-23	suppressor of cytokine signaling 3	Rattus norvegicus	220-225
18443198-9	2008	Interestingly, GW501516 prevented ERK1/2 phosphorylation by LPS.	GW 501516	15-23	mitogen activated protein kinase 3	Rattus norvegicus	34-40
18711014-4	2008	PPAR-delta activation with agonist (GW501516 or L-165041) increased the proliferation of human EPCs and protected them from hypoxia-induced apoptosis.	GW 501516	36-44	peroxisome proliferator activated receptor delta	Homo sapiens	0-10
18390835-7	2008	Conversely, inhibition of PI3K and silencing of p65 by small RNA interference (siRNA) blocked the effect of GW501516 on PTEN expression and on NSCLC cell proliferation.	GW 501516	108-116	phosphatase and tensin homolog	Homo sapiens	120-124
18390835-2	2008	We previously demonstrated that a selective PPARbeta/delta agonist, GW501516, stimulated human non-small cell lung carcinoma (NSCLC) cell growth.	GW 501516	68-76	peroxisome proliferator activated receptor delta	Homo sapiens	44-52
18390835-9	2008	Silencing of IKBalpha enhanced the effect of GW501516 on PTEN protein expression and on cell proliferation.	GW 501516	45-53	phosphatase and tensin homolog	Homo sapiens	57-61
18390835-4	2008	We show that GW501516 decreased phosphate and tensin homolog deleted on chromosome 10 (PTEN), a tumor suppressor known to decrease cell growth and induce apoptosis.	GW 501516	13-21	phosphatase and tensin homolog	Homo sapiens	87-91
18390835-10	2008	It also augmented the GW501516-induced complex formation of PPARbeta/delta and p65 proteins.	GW 501516	22-30	peroxisome proliferator activated receptor delta	Homo sapiens	60-68
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	nuclear factor kappa B subunit 1	Homo sapiens	19-28
18390835-10	2008	It also augmented the GW501516-induced complex formation of PPARbeta/delta and p65 proteins.	GW 501516	22-30	RELA proto-oncogene, NF-kB subunit	Homo sapiens	79-82
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	54-57
18390835-11	2008	Overexpression of PTEN suppressed NSCLC cell growth and eliminated the effect of GW501516 on phosphorylation of Akt.	GW 501516	81-89	phosphatase and tensin homolog	Homo sapiens	18-22
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	99-107
18390835-11	2008	Overexpression of PTEN suppressed NSCLC cell growth and eliminated the effect of GW501516 on phosphorylation of Akt.	GW 501516	81-89	AKT serine/threonine kinase 1	Homo sapiens	112-115
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	AKT serine/threonine kinase 1	Homo sapiens	123-126
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	182-190
18390835-12	2008	Together, our observations suggest that GW501516 induces the proliferation of NSCLC cells by inhibiting the expression of PTEN through activation of PPARbeta/delta, which stimulates PI3K/Akt and NF-kappaB signaling.	GW 501516	40-48	phosphatase and tensin homolog	Homo sapiens	122-126
18390835-6	2008	GW501516 increased NF-kappaB DNA binding activity and p65 protein expression through activation of PPARbeta/delta and PI3K/Akt signals and enhanced the physical interactions between PPARbeta/delta and p65 protein.	GW 501516	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	201-204
18390835-12	2008	Together, our observations suggest that GW501516 induces the proliferation of NSCLC cells by inhibiting the expression of PTEN through activation of PPARbeta/delta, which stimulates PI3K/Akt and NF-kappaB signaling.	GW 501516	40-48	peroxisome proliferator activated receptor delta	Homo sapiens	149-157
18390835-7	2008	Conversely, inhibition of PI3K and silencing of p65 by small RNA interference (siRNA) blocked the effect of GW501516 on PTEN expression and on NSCLC cell proliferation.	GW 501516	108-116	RELA proto-oncogene, NF-kB subunit	Homo sapiens	48-51
18390835-12	2008	Together, our observations suggest that GW501516 induces the proliferation of NSCLC cells by inhibiting the expression of PTEN through activation of PPARbeta/delta, which stimulates PI3K/Akt and NF-kappaB signaling.	GW 501516	40-48	AKT serine/threonine kinase 1	Homo sapiens	187-190
18390835-12	2008	Together, our observations suggest that GW501516 induces the proliferation of NSCLC cells by inhibiting the expression of PTEN through activation of PPARbeta/delta, which stimulates PI3K/Akt and NF-kappaB signaling.	GW 501516	40-48	nuclear factor kappa B subunit 1	Homo sapiens	195-204
18506377-4	2008	Treatment of HepG2 cells with the PPARdelta specific agonist GW501516 increased apoA-II mRNA expression.	GW 501516	61-69	peroxisome proliferator activated receptor delta	Homo sapiens	34-43
18506377-4	2008	Treatment of HepG2 cells with the PPARdelta specific agonist GW501516 increased apoA-II mRNA expression.	GW 501516	61-69	apolipoprotein A2	Homo sapiens	80-87
18506377-5	2008	Likewise, reporter gene assays using a construct containing 2.7 kb of the proximal apoA-II promoter showed increased activity after treatment with GW501516, both in HepG2 and in HuH-7 cells.	GW 501516	147-155	apolipoprotein A2	Homo sapiens	83-90
18155554-1	2008	Replacement of the methyl-thiazole moiety of GW501516 (a PPARdelta selective agonist) with [1,2,4]thiadiazole gave compound 21 which unexpectedly displayed submicromolar potency as a partial agonist at PPARalpha in addition to the high potency at PPARdelta.	GW 501516	45-53	peroxisome proliferator activated receptor delta	Homo sapiens	57-66
18155554-1	2008	Replacement of the methyl-thiazole moiety of GW501516 (a PPARdelta selective agonist) with [1,2,4]thiadiazole gave compound 21 which unexpectedly displayed submicromolar potency as a partial agonist at PPARalpha in addition to the high potency at PPARdelta.	GW 501516	45-53	peroxisome proliferator activated receptor alpha	Homo sapiens	202-211
18155554-1	2008	Replacement of the methyl-thiazole moiety of GW501516 (a PPARdelta selective agonist) with [1,2,4]thiadiazole gave compound 21 which unexpectedly displayed submicromolar potency as a partial agonist at PPARalpha in addition to the high potency at PPARdelta.	GW 501516	45-53	peroxisome proliferator activated receptor delta	Homo sapiens	247-256
18007025-4	2008	The PPARdelta activator GW501516 upregulates TGF-beta1 expression in a dose- and time-dependent manner.	GW 501516	24-32	peroxisome proliferator activator receptor delta	Mus musculus	4-13
18048767-4	2008	METHODS AND RESULTS: In human umbilical vein endothelial cells (HUVECs), the synthetic PPAR-delta ligands GW0742 and GW501516 significantly inhibited tumor necrosis factor (TNF)-alpha-induced expression of vascular cell adhesion molecule-1 and E-selectin (assayed by real-time RT-PCR and Northern blotting), as well as the ensuing endothelial-leukocyte adhesion.	GW 501516	117-125	peroxisome proliferator activated receptor delta	Homo sapiens	87-97
18048767-4	2008	METHODS AND RESULTS: In human umbilical vein endothelial cells (HUVECs), the synthetic PPAR-delta ligands GW0742 and GW501516 significantly inhibited tumor necrosis factor (TNF)-alpha-induced expression of vascular cell adhesion molecule-1 and E-selectin (assayed by real-time RT-PCR and Northern blotting), as well as the ensuing endothelial-leukocyte adhesion.	GW 501516	117-125	tumor necrosis factor	Homo sapiens	150-183
18048767-4	2008	METHODS AND RESULTS: In human umbilical vein endothelial cells (HUVECs), the synthetic PPAR-delta ligands GW0742 and GW501516 significantly inhibited tumor necrosis factor (TNF)-alpha-induced expression of vascular cell adhesion molecule-1 and E-selectin (assayed by real-time RT-PCR and Northern blotting), as well as the ensuing endothelial-leukocyte adhesion.	GW 501516	117-125	vascular cell adhesion molecule 1	Homo sapiens	206-239
18048767-4	2008	METHODS AND RESULTS: In human umbilical vein endothelial cells (HUVECs), the synthetic PPAR-delta ligands GW0742 and GW501516 significantly inhibited tumor necrosis factor (TNF)-alpha-induced expression of vascular cell adhesion molecule-1 and E-selectin (assayed by real-time RT-PCR and Northern blotting), as well as the ensuing endothelial-leukocyte adhesion.	GW 501516	117-125	selectin E	Homo sapiens	244-254
18007025-4	2008	The PPARdelta activator GW501516 upregulates TGF-beta1 expression in a dose- and time-dependent manner.	GW 501516	24-32	transforming growth factor, beta 1	Mus musculus	45-54
18007025-11	2008	Finally, administration of GW501516 to mice upregulated TGF-beta1, whereas the expression of proinflammatory genes including monocyte chemoattractant protein-1 was significantly attenuated in the thoracic aorta.	GW 501516	27-35	transforming growth factor, beta 1	Mus musculus	56-65
18054822-5	2008	Culturing cells in the presence of either GW0742 or GW501516 caused upregulation of the known PPARbeta/delta target gene angiopoietin-like protein 4 (ANGPTL4).	GW 501516	52-60	peroxisome proliferator activated receptor delta	Homo sapiens	94-102
18024853-7	2008	RESULTS: Treatment with GW501516 showed statistically significant reductions in fasting plasma triglycerides (-30%), apolipoprotein B (-26%), LDL cholesterol (-23%), and insulin (-11%), whereas HDL cholesterol was unchanged.	GW 501516	24-32	apolipoprotein B	Homo sapiens	117-133
18024853-7	2008	RESULTS: Treatment with GW501516 showed statistically significant reductions in fasting plasma triglycerides (-30%), apolipoprotein B (-26%), LDL cholesterol (-23%), and insulin (-11%), whereas HDL cholesterol was unchanged.	GW 501516	24-32	insulin	Homo sapiens	170-177
18024853-11	2008	CONCLUSIONS: The PPARdelta agonist GW501516 reverses multiple abnormalities associated with the metabolic syndrome without increasing oxidative stress.	GW 501516	35-43	peroxisome proliferator activated receptor delta	Homo sapiens	17-26
18054822-5	2008	Culturing cells in the presence of either GW0742 or GW501516 caused upregulation of the known PPARbeta/delta target gene angiopoietin-like protein 4 (ANGPTL4).	GW 501516	52-60	angiopoietin like 4	Homo sapiens	150-157
17532641-3	2007	The (S)-enantiomer of a representative compound exhibited extremely potent PPARdelta transactivation activity, comparable with or somewhat superior to that of the known PPARdelta-selective agonist, GW-501516.	GW 501516	198-207	peroxisome proliferator activated receptor delta	Homo sapiens	169-178
17803688-6	2007	The formation of these apparently aberrant complexes, as well as the ubiquitination and destabilization of PPARbeta, were strongly inhibited by GW501516.	GW 501516	144-152	peroxisome proliferator activated receptor delta	Homo sapiens	107-115
18047848-8	2007	In the first human study using a PPAR-delta agonist, experimental data obtained with GW 501516 (a highly specific PPAR-delta agonist) suggested that upregulated enzymes critical to fatty acid oxidation in human cells enhanced fatty acid and beta-oxidation in skeletal muscle.	GW 501516	85-94	peroxisome proliferator activated receptor delta	Homo sapiens	33-43
18047848-8	2007	In the first human study using a PPAR-delta agonist, experimental data obtained with GW 501516 (a highly specific PPAR-delta agonist) suggested that upregulated enzymes critical to fatty acid oxidation in human cells enhanced fatty acid and beta-oxidation in skeletal muscle.	GW 501516	85-94	peroxisome proliferator activated receptor delta	Homo sapiens	114-124
17869249-0	2007	The PPARdelta agonist, GW501516, promotes fatty acid oxidation but has no direct effect on glucose utilisation or insulin sensitivity in rat L6 skeletal muscle cells.	GW 501516	23-31	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-13
17869249-2	2007	Recently, GW501516, a selective PPARdelta agonist, was reported to increase glucose uptake in human skeletal myotubes by an AMPK-dependent mechanism that may contribute to the improved glucose tolerance.	GW 501516	10-18	peroxisome proliferator activated receptor delta	Homo sapiens	32-41
17869249-3	2007	Here, we demonstrate that whilst GW501516 increases expression of PGC-1alpha and CPT-1 and stimulates fatty-acid oxidation in L6 myotubes, it fails to enhance insulin sensitivity, AMPK activity or glucose uptake and storage.	GW 501516	33-41	PPARG coactivator 1 alpha	Rattus norvegicus	66-76
17461989-6	2007	Depletion of the PPARdelta receptor, but not of PPARalpha or gamma, attenuated the suppressive effect of GW501516 on interleukin-6-induced alpha1-antichymotrypsin mRNA expression, indicating that PPARdelta specifically mediated this effect.	GW 501516	105-113	peroxisome proliferator activated receptor delta	Homo sapiens	17-26
17543901-5	2007	Only the PPARdelta ligand GW501516, but not PPARalpha ligand Wy-14,643 or PPARgamma ligand rosiglitazone, significantly increased PPAR-dependent promoter activity and expression of the PPAR-responsive gene UCP2 ( approximately 5-fold).	GW 501516	26-34	peroxisome proliferator activated receptor delta	Homo sapiens	9-18
17543901-5	2007	Only the PPARdelta ligand GW501516, but not PPARalpha ligand Wy-14,643 or PPARgamma ligand rosiglitazone, significantly increased PPAR-dependent promoter activity and expression of the PPAR-responsive gene UCP2 ( approximately 5-fold).	GW 501516	26-34	peroxisome proliferator activated receptor alpha	Homo sapiens	9-13
17543901-5	2007	Only the PPARdelta ligand GW501516, but not PPARalpha ligand Wy-14,643 or PPARgamma ligand rosiglitazone, significantly increased PPAR-dependent promoter activity and expression of the PPAR-responsive gene UCP2 ( approximately 5-fold).	GW 501516	26-34	uncoupling protein 2	Homo sapiens	206-210
17500064-3	2007	We recently demonstrated that the PPARdelta agonist GW501516 activates AMP-activated protein kinase (AMPK) and stimulates glucose uptake in skeletal muscle.	GW 501516	52-60	peroxisome proliferator activated receptor delta	Homo sapiens	34-43
17500064-6	2007	Using small interfering RNA, we have demonstrated that PPARdelta expression is required for the effect of GW501516 on the intracellular accumulation of fatty acids.	GW 501516	106-114	peroxisome proliferator activated receptor delta	Homo sapiens	55-64
17500064-7	2007	Furthermore, we have shown that the subsequent increase in fatty acid oxidation induced by GW501516 is dependent on both PPARdelta and AMPK.	GW 501516	91-99	peroxisome proliferator activated receptor delta	Homo sapiens	121-130
17500064-8	2007	Concomitant with these metabolic changes, we provide evidence that GW501516 increases the expression of key genes involved in lipid metabolism (FABP3, CPT1, and PDK4) by a PPARdelta-dependent mechanism.	GW 501516	67-75	fatty acid binding protein 3	Homo sapiens	144-149
17500064-8	2007	Concomitant with these metabolic changes, we provide evidence that GW501516 increases the expression of key genes involved in lipid metabolism (FABP3, CPT1, and PDK4) by a PPARdelta-dependent mechanism.	GW 501516	67-75	carnitine palmitoyltransferase 1A	Homo sapiens	151-155
17500064-8	2007	Concomitant with these metabolic changes, we provide evidence that GW501516 increases the expression of key genes involved in lipid metabolism (FABP3, CPT1, and PDK4) by a PPARdelta-dependent mechanism.	GW 501516	67-75	pyruvate dehydrogenase kinase 4	Homo sapiens	161-165
17500064-8	2007	Concomitant with these metabolic changes, we provide evidence that GW501516 increases the expression of key genes involved in lipid metabolism (FABP3, CPT1, and PDK4) by a PPARdelta-dependent mechanism.	GW 501516	67-75	peroxisome proliferator activated receptor delta	Homo sapiens	172-181
17500064-10	2007	In conclusion, the PPARdelta agonist GW501516 promotes changes in lipid/glucose metabolism and gene expression in human skeletal muscle cells by PPARdelta- and AMPK-dependent and -independent mechanisms.	GW 501516	37-45	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
17500064-10	2007	In conclusion, the PPARdelta agonist GW501516 promotes changes in lipid/glucose metabolism and gene expression in human skeletal muscle cells by PPARdelta- and AMPK-dependent and -independent mechanisms.	GW 501516	37-45	peroxisome proliferator activated receptor delta	Homo sapiens	145-154
17461989-0	2007	The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.	GW 501516	22-30	peroxisome proliferator activated receptor delta	Homo sapiens	4-13
17461989-0	2007	The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.	GW 501516	22-30	interleukin 6	Homo sapiens	42-55
17461989-0	2007	The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.	GW 501516	22-30	signal transducer and activator of transcription 3	Homo sapiens	101-106
17461989-3	2007	MATERIALS AND METHODS: We examined the ability of the synthetic PPARdelta agonist GW501516 to suppress interleukin-6-induced expression of acute phase proteins in human hepatoma HepG2 cells and rat primary hepatocytes.	GW 501516	82-90	peroxisome proliferator activated receptor delta	Homo sapiens	64-73
17461989-3	2007	MATERIALS AND METHODS: We examined the ability of the synthetic PPARdelta agonist GW501516 to suppress interleukin-6-induced expression of acute phase proteins in human hepatoma HepG2 cells and rat primary hepatocytes.	GW 501516	82-90	interleukin 6	Homo sapiens	103-116
17461989-4	2007	Results GW501516 dose-dependently suppressed interleukin-6-induced mRNA expression of the acute phase protein alpha1-antichymotrypsin in HepG2 cells.	GW 501516	8-16	interleukin 6	Homo sapiens	45-58
17461989-4	2007	Results GW501516 dose-dependently suppressed interleukin-6-induced mRNA expression of the acute phase protein alpha1-antichymotrypsin in HepG2 cells.	GW 501516	8-16	serpin family A member 3	Homo sapiens	110-133
17543901-6	2007	GW501516 reduced the proliferation rate of CF (-38%) and CMF (-26%), which was associated with increased expression of the cell cycle inhibitor gene G0/G1 switch gene 2 (G0S2).	GW 501516	0-8	G0/G1 switch 2	Homo sapiens	149-168
17543901-6	2007	GW501516 reduced the proliferation rate of CF (-38%) and CMF (-26%), which was associated with increased expression of the cell cycle inhibitor gene G0/G1 switch gene 2 (G0S2).	GW 501516	0-8	G0/G1 switch 2	Homo sapiens	170-174
17461989-6	2007	Depletion of the PPARdelta receptor, but not of PPARalpha or gamma, attenuated the suppressive effect of GW501516 on interleukin-6-induced alpha1-antichymotrypsin mRNA expression, indicating that PPARdelta specifically mediated this effect.	GW 501516	105-113	interleukin 6	Homo sapiens	117-130
17461989-6	2007	Depletion of the PPARdelta receptor, but not of PPARalpha or gamma, attenuated the suppressive effect of GW501516 on interleukin-6-induced alpha1-antichymotrypsin mRNA expression, indicating that PPARdelta specifically mediated this effect.	GW 501516	105-113	serpin family A member 3	Homo sapiens	139-162
17461989-8	2007	Overexpression of PPARdelta enhanced the suppressive effect of GW501516 on STAT3-activated transcriptional activity of the alpha1-antichymotrypsin promoter, while GW501516 suppressed interleukin-6-induced binding of this transcription factor to this promoter.	GW 501516	63-71	peroxisome proliferator activated receptor delta	Homo sapiens	18-27
17461989-8	2007	Overexpression of PPARdelta enhanced the suppressive effect of GW501516 on STAT3-activated transcriptional activity of the alpha1-antichymotrypsin promoter, while GW501516 suppressed interleukin-6-induced binding of this transcription factor to this promoter.	GW 501516	63-71	signal transducer and activator of transcription 3	Homo sapiens	75-80
17461989-8	2007	Overexpression of PPARdelta enhanced the suppressive effect of GW501516 on STAT3-activated transcriptional activity of the alpha1-antichymotrypsin promoter, while GW501516 suppressed interleukin-6-induced binding of this transcription factor to this promoter.	GW 501516	63-71	serpin family A member 3	Homo sapiens	123-146
17461989-8	2007	Overexpression of PPARdelta enhanced the suppressive effect of GW501516 on STAT3-activated transcriptional activity of the alpha1-antichymotrypsin promoter, while GW501516 suppressed interleukin-6-induced binding of this transcription factor to this promoter.	GW 501516	163-171	interleukin 6	Homo sapiens	183-196
17346664-4	2007	GW501516, a selective PPARbeta/delta agonist, depressed Ang II-stimulated collagen type I expression and collagen synthesis in cardiac fibroblasts in a concentration-dependent manner.	GW 501516	0-8	peroxisome proliferator-activated receptor delta	Rattus norvegicus	22-30
17140817-8	2007	PPAR agonists inhibited the stimulating effect of TGF-beta1 by 24-44% on PGs" synthesis and over 75% on aggrecan, GAGs" content and deposition with the following rank order of potency: ROSI>GW501516> or =Wy14643.	GW 501516	193-201	peroxisome proliferator activated receptor alpha	Rattus norvegicus	0-4
17140817-8	2007	PPAR agonists inhibited the stimulating effect of TGF-beta1 by 24-44% on PGs" synthesis and over 75% on aggrecan, GAGs" content and deposition with the following rank order of potency: ROSI>GW501516> or =Wy14643.	GW 501516	193-201	transforming growth factor, beta 1	Rattus norvegicus	50-59
17140817-9	2007	TGF-beta1-induced phosphorylation of Smad2/3 and ERK1/2 was reduced by ROSI over GW501516 but not by Wy14643 whereas stimulated PGE2 production was inhibited by Wy14643 over GW501516 but not by ROSI.	GW 501516	81-89	transforming growth factor, beta 1	Rattus norvegicus	0-9
17140817-9	2007	TGF-beta1-induced phosphorylation of Smad2/3 and ERK1/2 was reduced by ROSI over GW501516 but not by Wy14643 whereas stimulated PGE2 production was inhibited by Wy14643 over GW501516 but not by ROSI.	GW 501516	174-182	transforming growth factor, beta 1	Rattus norvegicus	0-9
17346664-4	2007	GW501516, a selective PPARbeta/delta agonist, depressed Ang II-stimulated collagen type I expression and collagen synthesis in cardiac fibroblasts in a concentration-dependent manner.	GW 501516	0-8	angiotensinogen	Rattus norvegicus	56-62
17346664-5	2007	Furthermore, these inhibitory effects of GW501516 were completely reversed by the knockdown of PPARbeta/delta via RNA interference.	GW 501516	41-49	peroxisome proliferator-activated receptor delta	Rattus norvegicus	95-103
17068288-2	2007	Interestingly, the selective PPARbeta/delta ligand GW501516 is in phase II clinical trials for dyslipidemia.	GW 501516	51-59	peroxisome proliferator activated receptor delta	Homo sapiens	29-37
17167170-4	2007	In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition.	GW 501516	51-59	caspase 3	Homo sapiens	261-270
17339402-9	2007	In cellular transfection assays, ssPPARbeta1A is activated by monounsaturated fatty acids, 2-bromopalmitate, and mammalian PPARbeta-specific ligand GW501516.	GW 501516	148-156	peroxisomal proliferator-activated receptor beta1A	Salmo salar	33-45
17339402-9	2007	In cellular transfection assays, ssPPARbeta1A is activated by monounsaturated fatty acids, 2-bromopalmitate, and mammalian PPARbeta-specific ligand GW501516.	GW 501516	148-156	peroxisome proliferator activated receptor delta	Homo sapiens	35-43
17339402-11	2007	Furthermore, ssPPARbeta2A repressed both the basal reporter gene activity and the GW501516-induced activity of ssPPARbeta1A.	GW 501516	82-90	peroxisomal proliferator-activated receptor beta1A	Salmo salar	111-123
17243659-5	2007	Modification of the selective PPARdelta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARalpha agonism.	GW 501516	51-59	peroxisome proliferator activated receptor delta	Homo sapiens	30-39
17243659-5	2007	Modification of the selective PPARdelta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARalpha agonism.	GW 501516	51-59	peroxisome proliferator activated receptor alpha	Homo sapiens	194-203
17068288-6	2007	GW501516 induced vascular endothelial cell growth factor mRNA and peptide release, as well as adipose differentiation-related protein (ADRP), a PPARbeta/delta target gene.	GW 501516	0-8	perilipin 2	Homo sapiens	135-139
17068288-6	2007	GW501516 induced vascular endothelial cell growth factor mRNA and peptide release, as well as adipose differentiation-related protein (ADRP), a PPARbeta/delta target gene.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	144-158
17068288-7	2007	GW501516-induced proliferation, morphogenesis, vascular endothelial growth factor (VEGF), and ADRP were absent in endothelial cells transfected with dominant-negative PPARbeta/delta.	GW 501516	0-8	vascular endothelial growth factor A	Homo sapiens	47-81
17068288-7	2007	GW501516-induced proliferation, morphogenesis, vascular endothelial growth factor (VEGF), and ADRP were absent in endothelial cells transfected with dominant-negative PPARbeta/delta.	GW 501516	0-8	vascular endothelial growth factor A	Homo sapiens	83-87
17068288-7	2007	GW501516-induced proliferation, morphogenesis, vascular endothelial growth factor (VEGF), and ADRP were absent in endothelial cells transfected with dominant-negative PPARbeta/delta.	GW 501516	0-8	perilipin 2	Homo sapiens	94-98
17068288-7	2007	GW501516-induced proliferation, morphogenesis, vascular endothelial growth factor (VEGF), and ADRP were absent in endothelial cells transfected with dominant-negative PPARbeta/delta.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	167-175
17068288-8	2007	Furthermore, treatment of cells with cyclo-VEGFI, a VEGF receptor1/2 antagonist, abolished GW501516-induced endothelial cell proliferation and tube formation.	GW 501516	91-99	vascular endothelial growth factor A	Homo sapiens	43-47
16797985-2	2006	Furthermore, taking advantage of SAR studies done elsewhere on the most selective PPARbeta/delta ligand GW501516, the conception of new ligands showing good affinity for PPARbeta/delta is reported.	GW 501516	104-112	sarcosine dehydrogenase	Homo sapiens	33-36
17178883-3	2006	Activation of PPARdelta by its pharmacologic ligand, GW501516, enhanced the growth of three human HCC cell lines (HuH7, HepG2, and Hep3B), whereas inhibition of PPARdelta by small interfering RNA prevented growth.	GW 501516	53-61	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
16930961-7	2006	GW501516 and linoleic acid, the well-known ligands of PPARdelta, increased the binding between PPARdelta and co-activators in a ligand dose-dependent manner.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	54-63
16930961-7	2006	GW501516 and linoleic acid, the well-known ligands of PPARdelta, increased the binding between PPARdelta and co-activators in a ligand dose-dependent manner.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	95-104
16960684-1	2006	AIMS/HYPOTHESIS: GW501516, an agonist of peroxisome proliferator-activated receptor-delta (PPAR-delta), increases lipid combustion and exerts antidiabetic action in animals, effects which are attributed mainly to direct effects on skeletal muscle.	GW 501516	17-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	41-89
16960684-1	2006	AIMS/HYPOTHESIS: GW501516, an agonist of peroxisome proliferator-activated receptor-delta (PPAR-delta), increases lipid combustion and exerts antidiabetic action in animals, effects which are attributed mainly to direct effects on skeletal muscle.	GW 501516	17-25	peroxisome proliferator-activated receptor delta	Rattus norvegicus	91-101
16960684-9	2006	CONCLUSIONS/INTERPRETATION: GW501516-induced activation of PPAR-delta reduces glucose utilisation by skeletal muscle through a switch in mitochondrial substrate preference from carbohydrate to lipid.	GW 501516	28-36	peroxisome proliferator-activated receptor delta	Rattus norvegicus	59-69
17148604-4	2006	Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.	GW 501516	208-216	peroxisome proliferator activator receptor delta	Mus musculus	83-92
17148604-4	2006	Here, we present genetic and pharmacologic evidence demonstrating that deletion of PPARdelta decreases intestinal adenoma growth in Apc(Min/+) mice and inhibits tumor-promoting effects of a PPARdelta agonist GW501516.	GW 501516	208-216	peroxisome proliferator activator receptor delta	Mus musculus	190-199
16966336-3	2006	Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).	GW 501516	86-94	peroxisome proliferator activated receptor delta	Homo sapiens	18-27
16966336-3	2006	Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).	GW 501516	86-94	peroxisome proliferator activated receptor delta	Homo sapiens	45-54
16966336-3	2006	Overexpression of PPARdelta or activation of PPARdelta by its pharmacological ligand, GW501516, at low doses (0.5-50 nM) promoted the growth of three human cholangiocarcinoma cell lines (CCLP1, HuCCT1, and SG231).	GW 501516	86-94	PPFIA binding protein 2	Homo sapiens	187-192
16797985-2	2006	Furthermore, taking advantage of SAR studies done elsewhere on the most selective PPARbeta/delta ligand GW501516, the conception of new ligands showing good affinity for PPARbeta/delta is reported.	GW 501516	104-112	peroxisome proliferator activated receptor delta	Homo sapiens	82-90
16797985-2	2006	Furthermore, taking advantage of SAR studies done elsewhere on the most selective PPARbeta/delta ligand GW501516, the conception of new ligands showing good affinity for PPARbeta/delta is reported.	GW 501516	104-112	peroxisome proliferator activated receptor delta	Homo sapiens	170-178
16278250-0	2006	PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle.	GW 501516	20-29	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	GW 501516	60-68	peroxisome proliferator activator receptor delta	Mus musculus	211-220
16574099-7	2006	These results suggest that (a) bezafibrate (especially) and GW501516 might improve hepatic steatosis via an improvement in fatty acid beta-oxidation and a direct prevention of inflammation, (b) treatment with a PPARdelta agonist might improve non-alcholic steatohepatitis, (c) bezafibrate may improve non-alcholic steatohepatitis via activation not only of PPARalpha but also of PPARdelta, because bezafibrate is a PPAR pan-agonist.	GW 501516	60-68	peroxisome proliferator activated receptor alpha	Mus musculus	211-215
16278250-1	2006	It has been reported that treatment of cultured human skeletal muscle myotubes with the peroxisome proliferator-activated receptor-delta (PPARdelta) activator GW-501516 directly stimulates glucose transport and enhances insulin action.	GW 501516	159-168	peroxisome proliferator activated receptor delta	Homo sapiens	88-136
16278250-1	2006	It has been reported that treatment of cultured human skeletal muscle myotubes with the peroxisome proliferator-activated receptor-delta (PPARdelta) activator GW-501516 directly stimulates glucose transport and enhances insulin action.	GW 501516	159-168	peroxisome proliferator activated receptor delta	Homo sapiens	138-147
16278250-8	2006	Treatment of epitrochlearis muscles with GW-501516 for 24 h induced a threefold increase in uncoupling protein-3 mRNA, providing evidence that the GW-501516 compound that we used gets into and is active in skeletal muscle.	GW 501516	41-50	uncoupling protein 3	Homo sapiens	92-112
15917308-5	2005	WY14643 (PPARalpha agonist), GW501516 (PPARdelta agonist) and ciglitazone (PPARgamma agonist) were tested for their ability to modulate the behaviour of p53-immortalized liver (PIL) progenitor cell lines in vitro.	GW 501516	29-37	transformation related protein 53, pseudogene	Mus musculus	153-156
16242326-0	2006	Synthesis of the PPARbeta/delta-selective agonist GW501516 and C4-thiazole-substituted analogs.	GW 501516	50-58	peroxisome proliferator activated receptor delta	Homo sapiens	17-25
16242326-1	2006	Sequential, position-selective, Pd-catalyzed cross-coupling reactions of 2,4-dibromo-5-hydroxymethylthiazole provided the scaffold for the synthesis of GW501516, the most potent PPARbeta/delta agonist yet described, and equally selective analogs at the thiazole-C4 position.	GW 501516	152-160	peroxisome proliferator activated receptor delta	Homo sapiens	178-186
16542871-5	2006	Moreover, in the present study, we demonstrated that PPAR beta/delta agonist (GW501516) could inhibit both apoM and apoB expression in the HepG2 cells.	GW 501516	78-86	peroxisome proliferator activated receptor delta	Homo sapiens	53-62
16542871-5	2006	Moreover, in the present study, we demonstrated that PPAR beta/delta agonist (GW501516) could inhibit both apoM and apoB expression in the HepG2 cells.	GW 501516	78-86	apolipoprotein M	Homo sapiens	107-111
16542871-5	2006	Moreover, in the present study, we demonstrated that PPAR beta/delta agonist (GW501516) could inhibit both apoM and apoB expression in the HepG2 cells.	GW 501516	78-86	apolipoprotein B	Homo sapiens	116-120
16337160-5	2006	By performing cell viability assays, we also showed that the selective PPARdelta agonist GW501516 protected cells from H(2)O(2)-induced cell death.	GW 501516	89-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	71-80
16337160-6	2006	The protective effect of GW501516 was due to an inhibition of H(2)O(2)-triggered apoptosis as shown by annexin-V labeling, DNA fragmentation analysis, and caspase-3 activity measurement.	GW 501516	25-33	annexin A5	Rattus norvegicus	103-112
16337160-6	2006	The protective effect of GW501516 was due to an inhibition of H(2)O(2)-triggered apoptosis as shown by annexin-V labeling, DNA fragmentation analysis, and caspase-3 activity measurement.	GW 501516	25-33	caspase 3	Rattus norvegicus	155-164
16337160-7	2006	We demonstrated by transient transfection of a dominant negative mutant of PPARdelta that the protection induced by GW501516 was totally dependent on PPARdelta.	GW 501516	116-124	peroxisome proliferator-activated receptor delta	Rattus norvegicus	75-84
16337160-7	2006	We demonstrated by transient transfection of a dominant negative mutant of PPARdelta that the protection induced by GW501516 was totally dependent on PPARdelta.	GW 501516	116-124	peroxisome proliferator-activated receptor delta	Rattus norvegicus	150-159
16337160-8	2006	Semi-quantitative RT-PCR and Western blotting analysis demonstrated that GW501516 treatment upregulated catalase.	GW 501516	73-81	catalase	Rattus norvegicus	104-112
16061473-5	2005	GW501516 induced NSCLC cell proliferation, and this effect was prevented by PPARbeta/delta antisense or EP4 short interfering RNA (siRNA).	GW 501516	0-8	prostaglandin E receptor 4	Homo sapiens	104-107
16061473-4	2005	Our studies show that NSCLC cells express peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protein and that treatment with a selective PPARbeta/delta agonist (GW501516) increases EP4 mRNA and protein levels.	GW 501516	181-189	peroxisome proliferator activated receptor delta	Homo sapiens	42-111
16061473-4	2005	Our studies show that NSCLC cells express peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protein and that treatment with a selective PPARbeta/delta agonist (GW501516) increases EP4 mRNA and protein levels.	GW 501516	181-189	peroxisome proliferator activated receptor delta	Homo sapiens	97-105
16061473-4	2005	Our studies show that NSCLC cells express peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) protein and that treatment with a selective PPARbeta/delta agonist (GW501516) increases EP4 mRNA and protein levels.	GW 501516	181-189	prostaglandin E receptor 4	Homo sapiens	201-204
16061473-5	2005	GW501516 induced NSCLC cell proliferation, and this effect was prevented by PPARbeta/delta antisense or EP4 short interfering RNA (siRNA).	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	76-84
16061473-6	2005	GW501516 increased the phosphorylation of Akt and decreased PTEN expression.	GW 501516	0-8	AKT serine/threonine kinase 1	Homo sapiens	42-45
16061473-6	2005	GW501516 increased the phosphorylation of Akt and decreased PTEN expression.	GW 501516	0-8	phosphatase and tensin homolog	Homo sapiens	60-64
16061473-7	2005	The selective inhibitor of phosphatidylinositol 3-kinase (PI3-K), wortmannin, and PPARbeta/delta antisense, abrogated the effect of GW501516 on EP4 expression, whereas that of the inhibitor of Erk did not.	GW 501516	132-140	peroxisome proliferator activated receptor delta	Homo sapiens	82-90
16061473-7	2005	The selective inhibitor of phosphatidylinositol 3-kinase (PI3-K), wortmannin, and PPARbeta/delta antisense, abrogated the effect of GW501516 on EP4 expression, whereas that of the inhibitor of Erk did not.	GW 501516	132-140	prostaglandin E receptor 4	Homo sapiens	144-147
16061473-8	2005	GW501516 also increased EP4 promoter activity through effects on the region between -1555 and -992 bp in the EP4 promoter, and mutation of the CCAAT/enhancer-binding protein (C/EBP) site in this region abrogated the effect of GW501516.	GW 501516	0-8	prostaglandin E receptor 4	Homo sapiens	24-27
16061473-8	2005	GW501516 also increased EP4 promoter activity through effects on the region between -1555 and -992 bp in the EP4 promoter, and mutation of the CCAAT/enhancer-binding protein (C/EBP) site in this region abrogated the effect of GW501516.	GW 501516	0-8	prostaglandin E receptor 4	Homo sapiens	109-112
16061473-8	2005	GW501516 also increased EP4 promoter activity through effects on the region between -1555 and -992 bp in the EP4 promoter, and mutation of the CCAAT/enhancer-binding protein (C/EBP) site in this region abrogated the effect of GW501516.	GW 501516	226-234	CCAAT enhancer binding protein alpha	Homo sapiens	175-180
16061473-9	2005	GW501516 increased not only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by the inhibitor of PI3-K, but also increased C/EBPbeta protein in a dose- and PPARbeta/delta-dependent manner.	GW 501516	0-8	CCAAT enhancer binding protein alpha	Homo sapiens	52-57
16061473-9	2005	GW501516 increased not only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by the inhibitor of PI3-K, but also increased C/EBPbeta protein in a dose- and PPARbeta/delta-dependent manner.	GW 501516	0-8	prostaglandin E receptor 4	Homo sapiens	84-87
16061473-9	2005	GW501516 increased not only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by the inhibitor of PI3-K, but also increased C/EBPbeta protein in a dose- and PPARbeta/delta-dependent manner.	GW 501516	0-8	CCAAT enhancer binding protein beta	Homo sapiens	164-173
16061473-9	2005	GW501516 increased not only the binding activity of C/EBP to the NF-IL6 site in the EP4 promoter, which was prevented by the inhibitor of PI3-K, but also increased C/EBPbeta protein in a dose- and PPARbeta/delta-dependent manner.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	197-205
16061473-10	2005	The effect of GW501516 on EP4 protein was eliminated in the presence of C/EBPbeta siRNA.	GW 501516	14-22	prostaglandin E receptor 4	Homo sapiens	26-29
16061473-10	2005	The effect of GW501516 on EP4 protein was eliminated in the presence of C/EBPbeta siRNA.	GW 501516	14-22	CCAAT enhancer binding protein beta	Homo sapiens	72-81
16061473-11	2005	Finally, we showed that pretreatment of NSCLC with GW501516 further increased NSCLC cell proliferation in response to exogenous dimethyl-prostaglandin E2 (PGE2) that was diminished in the presence of PPARbeta/delta antisense and EP4 siRNA.	GW 501516	51-59	peroxisome proliferator activated receptor delta	Homo sapiens	200-208
16061473-11	2005	Finally, we showed that pretreatment of NSCLC with GW501516 further increased NSCLC cell proliferation in response to exogenous dimethyl-prostaglandin E2 (PGE2) that was diminished in the presence of PPARbeta/delta antisense and EP4 siRNA.	GW 501516	51-59	prostaglandin E receptor 4	Homo sapiens	229-232
15821150-9	2005	The PPAR-delta ligand GW501516 also inhibited IL-1beta-stimulated PGE(2) production but only at high concentrations (1 microM).	GW 501516	22-30	peroxisome proliferator activated receptor delta	Homo sapiens	4-14
16115476-9	2005	The considered PPARdelta activator GW501516 and the considered PPARalpha activator fenofibrate also inhibited TNF-alpha-induced VCAM-1 expression, whereas pioglitazone and rosiglitazone did not.	GW 501516	35-43	tumor necrosis factor	Homo sapiens	110-119
16115476-9	2005	The considered PPARdelta activator GW501516 and the considered PPARalpha activator fenofibrate also inhibited TNF-alpha-induced VCAM-1 expression, whereas pioglitazone and rosiglitazone did not.	GW 501516	35-43	vascular cell adhesion molecule 1	Homo sapiens	128-134
15821150-9	2005	The PPAR-delta ligand GW501516 also inhibited IL-1beta-stimulated PGE(2) production but only at high concentrations (1 microM).	GW 501516	22-30	interleukin 1 beta	Homo sapiens	46-54
15821150-10	2005	IL-1beta-induced nuclear factor-kappaB (NF-kappaB) DNA binding activity was significantly inhibited by 15d-PGJ(2) (10 microM) and GW501516 (1 microM) but increased with 10 microM rosiglitazone.	GW 501516	130-138	interleukin 1 beta	Homo sapiens	0-8
15821150-10	2005	IL-1beta-induced nuclear factor-kappaB (NF-kappaB) DNA binding activity was significantly inhibited by 15d-PGJ(2) (10 microM) and GW501516 (1 microM) but increased with 10 microM rosiglitazone.	GW 501516	130-138	nuclear factor kappa B subunit 1	Homo sapiens	40-49
15764152-5	2005	PPARs were activated by ligands for PPAR alpha (Wy-14643), PPAR delta (GW-501516) and PPAR gamma (rosiglitazone or troglitazone).	GW 501516	71-80	peroxisome proliferator activated receptor delta	Homo sapiens	59-69
15867396-5	2005	In contrast, animals treated with the PPARdelta agonist GW501516 showed accelerated tumor formation.	GW 501516	56-64	peroxisome proliferator activator receptor delta	Mus musculus	38-47
15793256-2	2005	Recently, a specific PPARdelta activator (GW501516) was reported to attenuate plasma glucose and insulin levels when administered to genetically obese ob/ob mice.	GW 501516	42-50	peroxisome proliferator activator receptor delta	Mus musculus	21-30
15793256-2	2005	Recently, a specific PPARdelta activator (GW501516) was reported to attenuate plasma glucose and insulin levels when administered to genetically obese ob/ob mice.	GW 501516	42-50	insulin	Homo sapiens	97-104
15793256-4	2005	Specific activation of PPARdelta using two pharmacological agonists (GW501516 and GW0742) increased glucose uptake independently of insulin in differentiated C2C12 myotubes.	GW 501516	69-77	peroxisome proliferator activated receptor delta	Homo sapiens	23-32
15793256-5	2005	In cultured primary human skeletal myotubes, GW501516 increased glucose uptake independently of insulin and enhanced subsequent insulin stimulation.	GW 501516	45-53	insulin	Homo sapiens	96-103
15793256-5	2005	In cultured primary human skeletal myotubes, GW501516 increased glucose uptake independently of insulin and enhanced subsequent insulin stimulation.	GW 501516	45-53	insulin	Homo sapiens	128-135
15751073-4	2005	The potency of PPARgamma agonists and the PPARbeta/delta agonist GW-501516 on IL-1Ra levels was tested in the range of 1-10 microM and at 100 pM, respectively.	GW 501516	65-74	interleukin 1 receptor antagonist	Rattus norvegicus	78-84
15126355-5	2004	Conversely, we have found that several steroid-independent cell lines, including colon lines, were unresponsive to compound F. These findings were confirmed with an additional high-affinity PPARdelta agonist, GW501516.	GW 501516	209-217	peroxisome proliferator activated receptor delta	Homo sapiens	190-199
15126355-6	2004	Conditional expression of PPARdelta in MCF7 Tet-On cells resulted in a doxycycline-enhanced response to GW501516, thus providing direct genetic evidence for the role of PPARdelta in the proliferative response to this drug.	GW 501516	104-112	peroxisome proliferator activated receptor delta	Homo sapiens	26-35
15126355-6	2004	Conditional expression of PPARdelta in MCF7 Tet-On cells resulted in a doxycycline-enhanced response to GW501516, thus providing direct genetic evidence for the role of PPARdelta in the proliferative response to this drug.	GW 501516	104-112	peroxisome proliferator activated receptor delta	Homo sapiens	169-178
15126355-8	2004	Consistent with this hypothesis, we demonstrated a pro-proliferative effect of GW501516 on human umbilical vein endothelial cell cultures and found that GW501516 also regulated the expression of VEGFalpha and FLT-1 in these cells.	GW 501516	153-161	vascular endothelial growth factor A	Homo sapiens	195-204
15126355-8	2004	Consistent with this hypothesis, we demonstrated a pro-proliferative effect of GW501516 on human umbilical vein endothelial cell cultures and found that GW501516 also regulated the expression of VEGFalpha and FLT-1 in these cells.	GW 501516	153-161	fms related receptor tyrosine kinase 1	Homo sapiens	209-214
12699745-3	2003	Optimization of these hits by structure-guided design led to 7k (GW501516) and 7l (GW0742), which shows an EC(50) of 1.1 nM against PPARdelta with 1000-fold selectivity over the other human subtypes.	GW 501516	65-73	peroxisome proliferator activated receptor delta	Homo sapiens	132-141
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	45-54
14676330-2	2003	Analysis of rat L6 myotubes treated with the PPARdelta subtype-selective agonist, GW501516, by the Affymetrix oligonucleotide microarrays revealed that PPARdelta controls fatty acid oxidation by regulating genes involved in fatty acid transport, beta-oxidation, and mitochondrial respiration.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	152-161
14676330-3	2003	Similar PPARdelta-mediated gene activation was observed in the skeletal muscle of GW501516-treated mice.	GW 501516	82-90	peroxisome proliferator activator receptor delta	Mus musculus	8-17
12901877-4	2003	In this work, we have studied the effect of PPARdelta activation on COX-2 expression using a selective agonist (GW501516) in human hepatocellular carcinoma (HepG2) cells.	GW 501516	112-120	peroxisome proliferator activated receptor delta	Homo sapiens	44-53
12901877-4	2003	In this work, we have studied the effect of PPARdelta activation on COX-2 expression using a selective agonist (GW501516) in human hepatocellular carcinoma (HepG2) cells.	GW 501516	112-120	prostaglandin-endoperoxide synthase 2	Homo sapiens	68-73
12901877-7	2003	The increased COX-2 protein expression and promoter activity induced by the GW501516 was also confirmed in the monocytic cell line THP-1.	GW 501516	76-84	prostaglandin-endoperoxide synthase 2	Homo sapiens	14-19
12901877-7	2003	The increased COX-2 protein expression and promoter activity induced by the GW501516 was also confirmed in the monocytic cell line THP-1.	GW 501516	76-84	GLI family zinc finger 2	Homo sapiens	131-136
12901877-10	2003	The levels of PCNA, used as an indicator of cell division were induced, and the cell survival promoting complex p65 (NF-kappaB) was phosphorylated under GW501516 treatment.	GW 501516	153-161	proliferating cell nuclear antigen	Homo sapiens	14-18
12901877-10	2003	The levels of PCNA, used as an indicator of cell division were induced, and the cell survival promoting complex p65 (NF-kappaB) was phosphorylated under GW501516 treatment.	GW 501516	153-161	RELA proto-oncogene, NF-kB subunit	Homo sapiens	112-115
12901877-10	2003	The levels of PCNA, used as an indicator of cell division were induced, and the cell survival promoting complex p65 (NF-kappaB) was phosphorylated under GW501516 treatment.	GW 501516	153-161	nuclear factor kappa B subunit 1	Homo sapiens	117-126
14758356-2	2004	Exposure of Apc(min) mice to the PPAR-delta ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps.	GW 501516	51-59	APC, WNT signaling pathway regulator	Mus musculus	12-15
14758356-2	2004	Exposure of Apc(min) mice to the PPAR-delta ligand GW501516 resulted in a significant increase in the number and size of intestinal polyps.	GW 501516	51-59	peroxisome proliferator activator receptor delta	Mus musculus	33-43
14525954-0	2003	The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.	GW 501516	67-75	peroxisome proliferator activated receptor delta	Homo sapiens	4-51
14525954-10	2003	Activation of PPARbeta/delta by GW501516 in skeletal muscle cells induces the expression of genes involved in preferential lipid utilization, beta-oxidation, cholesterol efflux, and energy uncoupling.	GW 501516	32-40	peroxisome proliferator activated receptor delta	Homo sapiens	14-22
14525954-11	2003	Furthermore, we show that treatment of muscle cells with GW501516 increases apolipoprotein-A1 specific efflux of intracellular cholesterol, thus identifying this tissue as an important target of PPARbeta/delta agonists.	GW 501516	57-65	apolipoprotein A1	Homo sapiens	76-93
14525954-11	2003	Furthermore, we show that treatment of muscle cells with GW501516 increases apolipoprotein-A1 specific efflux of intracellular cholesterol, thus identifying this tissue as an important target of PPARbeta/delta agonists.	GW 501516	57-65	peroxisome proliferator activated receptor delta	Homo sapiens	195-203
14604391-0	2003	A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta.	GW 501516	69-77	peroxisome proliferator activated receptor delta	Homo sapiens	86-134
14604391-1	2003	The most potent and selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (1) was synthesized in 4 steps and 78% overall yield starting from o-cresol by using a one-pot regiocontrolled dialkylation of mercaptophenol 5 as the key step.	GW 501516	99-107	peroxisome proliferator activated receptor delta	Homo sapiens	30-78
14604391-1	2003	The most potent and selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (1) was synthesized in 4 steps and 78% overall yield starting from o-cresol by using a one-pot regiocontrolled dialkylation of mercaptophenol 5 as the key step.	GW 501516	99-107	peroxisome proliferator activated receptor delta	Homo sapiens	80-89
35624674-5	2022	PPARdelta activation with GW501516, a specific PPARdelta agonist, mitigated 6-OHDA-induced neuronal damage.	GW 501516	26-34	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
34649350-3	2021	Activation of PPARdelta by the specific ligand GW501516 led to a dose-dependent decrease in ferroptotic cell death triggered by xCT deficiency, along with decreased levels of intracellular iron accumulation and lipid peroxidation.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	14-23
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	44-53
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	102-111
34649350-4	2021	These effects of GW501516 were abolished by PPARdelta-targeting small interfering RNA (siRNA) and the PPARdelta inhibitor GSK0660, indicating that PPARdelta inhibits xCT deficiency-induced ferroptosis.	GW 501516	17-25	peroxisome proliferator activator receptor delta	Mus musculus	147-156
34649350-5	2021	In addition, GW501516-activated PPARdelta time- and dose-dependently upregulated catalase expression at both the mRNA and protein levels.	GW 501516	13-21	peroxisome proliferator activator receptor delta	Mus musculus	32-41
34649350-5	2021	In addition, GW501516-activated PPARdelta time- and dose-dependently upregulated catalase expression at both the mRNA and protein levels.	GW 501516	13-21	catalase	Mus musculus	81-89
34649350-7	2021	Consistently, the effects of GW501516 on ferroptosis of xCT-deficient MEFs were counteracted in the presence of 3-amino-1,2,4-triazole, a specific inhibitor of catalase, suggesting that catalase is essential for the effect of PPARdelta on ferroptosis triggered by xCT deficiency.	GW 501516	29-37	catalase	Mus musculus	160-168
34649350-7	2021	Consistently, the effects of GW501516 on ferroptosis of xCT-deficient MEFs were counteracted in the presence of 3-amino-1,2,4-triazole, a specific inhibitor of catalase, suggesting that catalase is essential for the effect of PPARdelta on ferroptosis triggered by xCT deficiency.	GW 501516	29-37	catalase	Mus musculus	186-194
34649350-7	2021	Consistently, the effects of GW501516 on ferroptosis of xCT-deficient MEFs were counteracted in the presence of 3-amino-1,2,4-triazole, a specific inhibitor of catalase, suggesting that catalase is essential for the effect of PPARdelta on ferroptosis triggered by xCT deficiency.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	226-235
34649350-8	2021	GW501516-activated PPARdelta stabilized peroxisomes through catalase upregulation by targeting peroxisomal hydrogen peroxide-mediated lysosomal rupture, which led to ferroptosis of xCT-deficient MEFs.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	19-28
34649350-8	2021	GW501516-activated PPARdelta stabilized peroxisomes through catalase upregulation by targeting peroxisomal hydrogen peroxide-mediated lysosomal rupture, which led to ferroptosis of xCT-deficient MEFs.	GW 501516	0-8	catalase	Mus musculus	60-68
11309497-4	2001	We have used combinatorial chemistry and structure-based drug design to develop a potent and subtype-selective PPARdelta agonist, GW501516.	GW 501516	130-138	peroxisome proliferator activated receptor delta	Homo sapiens	111-120
11309497-5	2001	In macrophages, fibroblasts, and intestinal cells, GW501516 increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux.	GW 501516	51-59	apolipoprotein A1	Homo sapiens	156-173
11309497-6	2001	When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin.	GW 501516	66-74	insulin	Macaca mulatta	14-21
11309497-6	2001	When dosed to insulin-resistant middle-aged obese rhesus monkeys, GW501516 causes a dramatic dose-dependent rise in serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin.	GW 501516	66-74	insulin	Macaca mulatta	260-267
22550474-3	2012	In this paper, treatment of mice conditionally expressing human PPARdelta with GW501516 resulted in a marked loss in body weight that was not evident in nontransgenic animals or animals expressing a dominant negative derivative of PPARdelta.	GW 501516	79-87	peroxisome proliferator activated receptor delta	Homo sapiens	64-73
22550474-3	2012	In this paper, treatment of mice conditionally expressing human PPARdelta with GW501516 resulted in a marked loss in body weight that was not evident in nontransgenic animals or animals expressing a dominant negative derivative of PPARdelta.	GW 501516	79-87	peroxisome proliferator activated receptor delta	Homo sapiens	231-240
34678947-0	2021	Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- delta) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine).	GW 501516	215-221	peroxisome proliferator activated receptor delta	Homo sapiens	58-69
34678947-0	2021	Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- delta) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine).	GW 501516	223-232	peroxisome proliferator activated receptor delta	Homo sapiens	58-69
34678947-2	2021	He claimed having used for some days a combination of GW1516 (cardarine), a peroxisome proliferator-activated receptor delta agonist (PPAR- delta) and MK2866 (ostarine), a selective androgen receptor modulator (SARM) to gain skeletal muscles.	GW 501516	54-60	peroxisome proliferator activated receptor delta	Homo sapiens	76-124
34678947-2	2021	He claimed having used for some days a combination of GW1516 (cardarine), a peroxisome proliferator-activated receptor delta agonist (PPAR- delta) and MK2866 (ostarine), a selective androgen receptor modulator (SARM) to gain skeletal muscles.	GW 501516	54-60	peroxisome proliferator activated receptor delta	Homo sapiens	134-145
34420848-4	2021	RESULTS: The PPAR-delta activator GW501516 upregulated expression of catalase and this upregulation was attenuated by PPAR-delta-targeting siRNA.	GW 501516	34-42	peroxisome proliferator activated receptor delta	Homo sapiens	13-23
34420848-4	2021	RESULTS: The PPAR-delta activator GW501516 upregulated expression of catalase and this upregulation was attenuated by PPAR-delta-targeting siRNA.	GW 501516	34-42	catalase	Homo sapiens	69-77
34420848-4	2021	RESULTS: The PPAR-delta activator GW501516 upregulated expression of catalase and this upregulation was attenuated by PPAR-delta-targeting siRNA.	GW 501516	34-42	peroxisome proliferator activated receptor delta	Homo sapiens	118-128
34420848-5	2021	GW501516-activated PPAR-delta induced catalase promoter activity through a direct repeat 1 response element.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-29
34420848-5	2021	GW501516-activated PPAR-delta induced catalase promoter activity through a direct repeat 1 response element.	GW 501516	0-8	catalase	Homo sapiens	38-46
34420848-7	2021	In addition, GW501516-activated PPAR-delta counteracted the reductions in activity and expression of catalase induced by UVB irradiation.	GW 501516	13-21	peroxisome proliferator activated receptor delta	Homo sapiens	32-42
34420848-7	2021	In addition, GW501516-activated PPAR-delta counteracted the reductions in activity and expression of catalase induced by UVB irradiation.	GW 501516	13-21	catalase	Homo sapiens	101-109
34420848-9	2021	GW501516-activated PPAR-delta also protected HDFs from cellular damage triggered by UVB irradiation, and this PPAR-delta-mediated reduction of cellular damage was reversed by the catalase inhibitor or catalase-targeting siRNA.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-29
34420848-9	2021	GW501516-activated PPAR-delta also protected HDFs from cellular damage triggered by UVB irradiation, and this PPAR-delta-mediated reduction of cellular damage was reversed by the catalase inhibitor or catalase-targeting siRNA.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	110-120
34420848-9	2021	GW501516-activated PPAR-delta also protected HDFs from cellular damage triggered by UVB irradiation, and this PPAR-delta-mediated reduction of cellular damage was reversed by the catalase inhibitor or catalase-targeting siRNA.	GW 501516	0-8	catalase	Homo sapiens	179-187
34420848-9	2021	GW501516-activated PPAR-delta also protected HDFs from cellular damage triggered by UVB irradiation, and this PPAR-delta-mediated reduction of cellular damage was reversed by the catalase inhibitor or catalase-targeting siRNA.	GW 501516	0-8	catalase	Homo sapiens	201-209
34420848-11	2021	Furthermore, GW501516-activated PPAR-delta targeted peroxisomal hydrogen peroxide through catalase in UVB-irradiated HDFs.	GW 501516	13-21	peroxisome proliferator activated receptor delta	Homo sapiens	32-42
34420848-11	2021	Furthermore, GW501516-activated PPAR-delta targeted peroxisomal hydrogen peroxide through catalase in UVB-irradiated HDFs.	GW 501516	13-21	catalase	Homo sapiens	90-98
34439471-4	2021	Activation of PPARdelta by a specific ligand GW501516 significantly inhibited Ang II-induced hypertrophy and the generation of reactive oxygen species (ROS) in H9c2 cardiomyocytes.	GW 501516	45-53	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
34439471-4	2021	Activation of PPARdelta by a specific ligand GW501516 significantly inhibited Ang II-induced hypertrophy and the generation of reactive oxygen species (ROS) in H9c2 cardiomyocytes.	GW 501516	45-53	angiotensinogen	Homo sapiens	78-84
34439471-5	2021	These effects of GW501516 were almost completely abolished in cells stably expressing small hairpin (sh)RNA targeting PPARdelta, indicating that PPARdelta mediates these effects.	GW 501516	17-25	peroxisome proliferator activated receptor delta	Homo sapiens	118-127
34439471-5	2021	These effects of GW501516 were almost completely abolished in cells stably expressing small hairpin (sh)RNA targeting PPARdelta, indicating that PPARdelta mediates these effects.	GW 501516	17-25	peroxisome proliferator activated receptor delta	Homo sapiens	145-154
34439471-6	2021	Significant concentration and time-dependent increases in catalase at both mRNA and protein levels were observed in GW501516-treated H9c2 cardiomyocytes.	GW 501516	116-124	catalase	Homo sapiens	58-66
34439471-7	2021	In addition, GW501516-activated PPARdelta significantly enhanced catalase promoter activity and protein expression, even in the presence of Ang II.	GW 501516	13-21	peroxisome proliferator activated receptor delta	Homo sapiens	32-41
34439471-7	2021	In addition, GW501516-activated PPARdelta significantly enhanced catalase promoter activity and protein expression, even in the presence of Ang II.	GW 501516	13-21	catalase	Homo sapiens	65-73
34439471-8	2021	GW501516-activated PPARdelta also inhibited the expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which are both marker proteins for hypertrophy.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
34439471-8	2021	GW501516-activated PPARdelta also inhibited the expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which are both marker proteins for hypertrophy.	GW 501516	0-8	natriuretic peptide A	Homo sapiens	62-88
34439471-8	2021	GW501516-activated PPARdelta also inhibited the expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which are both marker proteins for hypertrophy.	GW 501516	0-8	natriuretic peptide A	Homo sapiens	90-93
34439471-8	2021	GW501516-activated PPARdelta also inhibited the expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which are both marker proteins for hypertrophy.	GW 501516	0-8	natriuretic peptide B	Homo sapiens	99-125
34439471-8	2021	GW501516-activated PPARdelta also inhibited the expression of atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), which are both marker proteins for hypertrophy.	GW 501516	0-8	natriuretic peptide B	Homo sapiens	127-130
34439471-9	2021	The effects of GW501516 on the expression of ANP and BNP were reversed by 3-amino-1,2,4-triazole (3-AT), a catalase inhibitor.	GW 501516	15-23	natriuretic peptide A	Homo sapiens	45-48
34439471-9	2021	The effects of GW501516 on the expression of ANP and BNP were reversed by 3-amino-1,2,4-triazole (3-AT), a catalase inhibitor.	GW 501516	15-23	natriuretic peptide B	Homo sapiens	53-56
34439471-9	2021	The effects of GW501516 on the expression of ANP and BNP were reversed by 3-amino-1,2,4-triazole (3-AT), a catalase inhibitor.	GW 501516	15-23	catalase	Homo sapiens	107-115
34439471-11	2021	Furthermore, GW501516-activated PPARdelta exerted catalase-dependent inhibitory effects on Ang II-induced hypertrophy by blocking p38 mitogen-activated protein kinase.	GW 501516	13-21	peroxisome proliferator activated receptor delta	Homo sapiens	32-41
34439471-11	2021	Furthermore, GW501516-activated PPARdelta exerted catalase-dependent inhibitory effects on Ang II-induced hypertrophy by blocking p38 mitogen-activated protein kinase.	GW 501516	13-21	catalase	Homo sapiens	50-58
34439471-11	2021	Furthermore, GW501516-activated PPARdelta exerted catalase-dependent inhibitory effects on Ang II-induced hypertrophy by blocking p38 mitogen-activated protein kinase.	GW 501516	13-21	angiotensinogen	Homo sapiens	91-97
34439471-11	2021	Furthermore, GW501516-activated PPARdelta exerted catalase-dependent inhibitory effects on Ang II-induced hypertrophy by blocking p38 mitogen-activated protein kinase.	GW 501516	13-21	mitogen-activated protein kinase 14	Homo sapiens	130-166
35562376-5	2022	Furthermore, PPARdelta ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARdelta ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC.	GW 501516	63-71	peroxisome proliferator activator receptor delta	Mus musculus	13-22
35562376-5	2022	Furthermore, PPARdelta ligand activation by a high-fat diet or GW501516 (a highly selective, synthetic PPARdelta ligand) in mutant KRASG12D (KRASmu) pancreatic epithelial cells strongly accelerates PanIN progression to PDAC.	GW 501516	63-71	peroxisome proliferator activator receptor delta	Mus musculus	103-112
35624674-5	2022	PPARdelta activation with GW501516, a specific PPARdelta agonist, mitigated 6-OHDA-induced neuronal damage.	GW 501516	26-34	peroxisome proliferator activated receptor delta	Homo sapiens	47-56
35624674-10	2022	The effects of GW501516 were abrogated by shRNA knockdown of PPARdelta, indicating that the effects of GW501516 were PPARdelta-dependent.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	61-70
35624674-10	2022	The effects of GW501516 were abrogated by shRNA knockdown of PPARdelta, indicating that the effects of GW501516 were PPARdelta-dependent.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	117-126
35624674-10	2022	The effects of GW501516 were abrogated by shRNA knockdown of PPARdelta, indicating that the effects of GW501516 were PPARdelta-dependent.	GW 501516	103-111	peroxisome proliferator activated receptor delta	Homo sapiens	61-70
35624674-10	2022	The effects of GW501516 were abrogated by shRNA knockdown of PPARdelta, indicating that the effects of GW501516 were PPARdelta-dependent.	GW 501516	103-111	peroxisome proliferator activated receptor delta	Homo sapiens	117-126
33319421-1	2021	RATIONALE: The use of GW1516, a peroxisome proliferator-activated receptor delta (PPAR delta) agonist, is strictly prohibited in both horseracing and equestrian competitions.	GW 501516	22-28	peroxisome proliferator activated receptor delta	Equus caballus	32-80
32703610-4	2021	PPARdelta ligand-activation via oleic acid and GW501516, or overexpression of PPARdelta, elicits profound antitumor actions in neuroblastoma and melanoma.	GW 501516	47-55	peroxisome proliferator activator receptor delta	Mus musculus	0-9
33470485-1	2021	RATIONALE: GW1516 is a peroxisome proliferator-activated receptor-delta (PPAR-delta) agonist and is banned in horseracing and equestrian sports.	GW 501516	11-17	peroxisome proliferator activated receptor delta	Equus caballus	23-71
33470485-1	2021	RATIONALE: GW1516 is a peroxisome proliferator-activated receptor-delta (PPAR-delta) agonist and is banned in horseracing and equestrian sports.	GW 501516	11-17	peroxisome proliferator activated receptor delta	Equus caballus	73-83
32703610-10	2021	In the rotenone PD model in rats, PPARdelta ligand GW501516 saves dopaminergic neurons during injury induced by chemical toxins and improves behavioral functioning in PD via alleviation of endoplasmic reticulum stress.	GW 501516	51-59	peroxisome proliferator activator receptor delta	Mus musculus	34-43
33319421-1	2021	RATIONALE: The use of GW1516, a peroxisome proliferator-activated receptor delta (PPAR delta) agonist, is strictly prohibited in both horseracing and equestrian competitions.	GW 501516	22-28	peroxisome proliferator activated receptor delta	Equus caballus	82-92
32776613-1	2020	RATIONALE: GW1516 is a peroxisome proliferator-activated receptor-delta (PPAR-delta) agonist in the class of hormones and metabolic modulators.	GW 501516	11-17	peroxisome proliferator activated receptor delta	Equus caballus	23-71
33339154-7	2020	The PPARbeta agonist, GW501516 is a strong inducer of pro-resolution substances, derivatives of DHA: 4-HDoHE, 11-HDoHE, 17-HDoHE.	GW 501516	22-30	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-12
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	21-29	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-12
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	21-29	interleukin 10	Rattus norvegicus	83-88
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	21-29	interleukin 10	Rattus norvegicus	132-137
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	21-29	interleukin 10	Rattus norvegicus	132-137
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	21-29	tumor necrosis factor	Rattus norvegicus	166-174
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	189-197	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-12
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	189-197	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	38-47
33339154-9	2020	The PPARbeta agonist GW501516 and the PPARgamma agonist, rosiglitazone induced the IL-10 release of the anti-inflammatory cytokine, IL-10; the cytokine index, (IL-10/TNFalpha) was more for GW501516.	GW 501516	189-197	interleukin 10	Rattus norvegicus	83-88
33339154-10	2020	The PPARbeta ligands, GW501516 and GSK0660, are also the strongest inhibitors of LPS-induced phosphorylation of p38, JNK, ERK MAPKs.	GW 501516	22-30	peroxisome proliferator activated receptor alpha	Rattus norvegicus	4-12
33339154-10	2020	The PPARbeta ligands, GW501516 and GSK0660, are also the strongest inhibitors of LPS-induced phosphorylation of p38, JNK, ERK MAPKs.	GW 501516	22-30	mitogen activated protein kinase 14	Rattus norvegicus	112-115
33339154-10	2020	The PPARbeta ligands, GW501516 and GSK0660, are also the strongest inhibitors of LPS-induced phosphorylation of p38, JNK, ERK MAPKs.	GW 501516	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	117-120
33339154-10	2020	The PPARbeta ligands, GW501516 and GSK0660, are also the strongest inhibitors of LPS-induced phosphorylation of p38, JNK, ERK MAPKs.	GW 501516	22-30	Eph receptor B1	Rattus norvegicus	122-125
32776613-1	2020	RATIONALE: GW1516 is a peroxisome proliferator-activated receptor-delta (PPAR-delta) agonist in the class of hormones and metabolic modulators.	GW 501516	11-17	peroxisome proliferator activated receptor delta	Equus caballus	73-83
32669864-0	2020	The Role of PPARdelta Agosnist GW501516 in Rats with Gestational Diabetes Mellitus.	GW 501516	31-39	peroxisome proliferator activated receptor delta	Homo sapiens	12-21
33308300-4	2020	Calpain-3-deficient mice were also treated with PPAR-delta agonist (GW501516) to assess mitochondrial function and membrane repair.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	48-58
33308300-11	2020	We used GW501516 to improve mitochondrial biogenesis in vivo in 7-month-old calpain-3-deficient mice.	GW 501516	8-16	calpain 3	Mus musculus	76-85
32697599-7	2020	Treatment of primary mouse skeletal muscle cells or C2C12 cells with PPARdelta activators GW501516 and AICAR increased Lin28a expression.	GW 501516	90-98	peroxisome proliferator activator receptor delta	Mus musculus	69-78
32697599-7	2020	Treatment of primary mouse skeletal muscle cells or C2C12 cells with PPARdelta activators GW501516 and AICAR increased Lin28a expression.	GW 501516	90-98	lin-28 homolog A	Mus musculus	119-125
32519230-0	2020	Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure.	GW 501516	121-129	cadherin 2	Homo sapiens	38-48
32519230-7	2020	For the first time, we demonstrated by RTqPCR and Western blotting analyses that the peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 significantly decreased N-cadherin expression in T24 cells.	GW 501516	164-172	peroxisome proliferator activated receptor delta	Homo sapiens	85-154
32519230-7	2020	For the first time, we demonstrated by RTqPCR and Western blotting analyses that the peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) agonist GW501516 significantly decreased N-cadherin expression in T24 cells.	GW 501516	164-172	cadherin 2	Homo sapiens	197-207
32519230-10	2020	We observed a greater decrease of N-cadherin upon GW501516 exposure with AFM than that detected with molecular biology techniques.	GW 501516	50-58	cadherin 2	Homo sapiens	34-44
32519230-12	2020	Taken together, our data suggest that GW501516 could be an interesting therapeutic strategy to avoid bladder cancer cell spreading through N-cadherin decrease.	GW 501516	38-46	cadherin 2	Homo sapiens	139-149
32722564-2	2020	After alkali injury, GW501516 (PPARbeta/delta agonist) or vehicle ophthalmic solution was topically instilled onto the rat"s cornea twice a day until day 7.	GW 501516	21-29	peroxisome proliferator activated receptor alpha	Rattus norvegicus	31-39
32722564-4	2020	GW501516 strongly suppressed infiltration of neutrophils and pan-macrophages, and reduced the mRNA expression of interleukin-6, interleukin-1beta, tumor necrosis factor alpha, and nuclear factor-kappa B.	GW 501516	0-8	interleukin 6	Rattus norvegicus	113-126
32722564-4	2020	GW501516 strongly suppressed infiltration of neutrophils and pan-macrophages, and reduced the mRNA expression of interleukin-6, interleukin-1beta, tumor necrosis factor alpha, and nuclear factor-kappa B.	GW 501516	0-8	interleukin 1 beta	Rattus norvegicus	128-145
32722564-4	2020	GW501516 strongly suppressed infiltration of neutrophils and pan-macrophages, and reduced the mRNA expression of interleukin-6, interleukin-1beta, tumor necrosis factor alpha, and nuclear factor-kappa B.	GW 501516	0-8	tumor necrosis factor	Rattus norvegicus	147-174
32722564-5	2020	On the other hand, GW501516 promoted infiltration of M2 macrophages, infiltration of vascular endothelial cells associated with neovascularization in the wounded area, and expression of vascular endothelial growth factor A mRNA.	GW 501516	19-27	vascular endothelial growth factor A	Rattus norvegicus	186-222
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	65-113
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	115-125
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	24-31	peroxisome proliferator activated receptor delta	Homo sapiens	65-113
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	24-31	peroxisome proliferator activated receptor delta	Homo sapiens	115-125
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	35-44	peroxisome proliferator activated receptor delta	Homo sapiens	65-113
32298044-1	2020	GW501516, also known as GW-1516 or cardarine and endurobol, is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist.	GW 501516	35-44	peroxisome proliferator activated receptor delta	Homo sapiens	115-125
32669864-10	2020	The biochemical kits were used to detect the expression of lipid metabolism-related factors in blood of GDM rats after the PPARdelta agonist GW501516 treatment.	GW 501516	141-149	peroxisome proliferator activated receptor delta	Homo sapiens	123-132
32669864-12	2020	Results: The PPARdelta agonist GW501516 decreased the expression of FGB, FINS and HOMA-IR in GDM rats, and we found that GW501516 decreased ISI in GDM rats.	GW 501516	31-39	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
32669864-12	2020	Results: The PPARdelta agonist GW501516 decreased the expression of FGB, FINS and HOMA-IR in GDM rats, and we found that GW501516 decreased ISI in GDM rats.	GW 501516	121-129	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
32669864-14	2020	In GDM rats, the expression of PPARdelta in islet decreased and the expression of Angptl8 increased, which was reversed by GW501516.	GW 501516	123-131	peroxisome proliferator activated receptor delta	Homo sapiens	31-40
32669864-14	2020	In GDM rats, the expression of PPARdelta in islet decreased and the expression of Angptl8 increased, which was reversed by GW501516.	GW 501516	123-131	angiopoietin-like 8	Rattus norvegicus	82-89
32669864-16	2020	Finally, we found that GW501516 inhibited the expression of SREBP-1c and promoted the expression of GLUT2 in the islet tissue.	GW 501516	23-31	sterol regulatory element binding transcription factor 1	Rattus norvegicus	60-68
32669864-16	2020	Finally, we found that GW501516 inhibited the expression of SREBP-1c and promoted the expression of GLUT2 in the islet tissue.	GW 501516	23-31	solute carrier family 2 member 2	Rattus norvegicus	100-105
32669864-17	2020	Conclusion: The PPARdelta agonist GW501516 could improve the blood glucose level, damaged islet tissue and increase the insulin content in the rats with GDM, possibly by regulating the SREBP-1c/GLUT2 pathway.	GW 501516	34-42	peroxisome proliferator activated receptor delta	Homo sapiens	16-25
32669864-17	2020	Conclusion: The PPARdelta agonist GW501516 could improve the blood glucose level, damaged islet tissue and increase the insulin content in the rats with GDM, possibly by regulating the SREBP-1c/GLUT2 pathway.	GW 501516	34-42	sterol regulatory element binding transcription factor 1	Rattus norvegicus	185-193
32669864-17	2020	Conclusion: The PPARdelta agonist GW501516 could improve the blood glucose level, damaged islet tissue and increase the insulin content in the rats with GDM, possibly by regulating the SREBP-1c/GLUT2 pathway.	GW 501516	34-42	solute carrier family 2 member 2	Rattus norvegicus	194-199
32669864-18	2020	Our study provided a new basis for clinical treatment of GDM in pregnant women with PPARdelta agonist GW501516.	GW 501516	102-110	peroxisome proliferator activated receptor delta	Homo sapiens	84-93
31364177-1	2019	GW501516-activated peroxisome proliferator-activated receptor (PPAR) beta/delta and G-protein-coupled receptor (GPR) 40 were shown to protect pancreatic beta cells against lipoapoptosis.	GW 501516	0-8	peroxisome proliferator-activated receptor delta	Rattus norvegicus	19-79
33318871-9	2021	PPARdelta agonist GW501516 offered protections similar to NaHS in PPG treated VSMCs.	GW 501516	18-26	peroxisome proliferator activator receptor delta	Mus musculus	0-9
33318871-10	2021	Aggravated active and passive contraction in PPG mice aortas, upregulated p-STAT3 and inflammatory molecules, downregulated SOCS3 and phenotype transformation in PPG treated VSMCs could be corrected by PPARdelta agonist GW501516 treatment.	GW 501516	220-228	suppressor of cytokine signaling 3	Mus musculus	124-129
33318871-10	2021	Aggravated active and passive contraction in PPG mice aortas, upregulated p-STAT3 and inflammatory molecules, downregulated SOCS3 and phenotype transformation in PPG treated VSMCs could be corrected by PPARdelta agonist GW501516 treatment.	GW 501516	220-228	peroxisome proliferator activator receptor delta	Mus musculus	202-211
33318871-11	2021	On the contrary, PPARdelta antagonist GSK0660 exhibited opposite effects on vascular contraction in aortas, expressions of p-STAT3 and SOCS3 in VSMCs compared with GW501516.	GW 501516	164-172	peroxisome proliferator activator receptor delta	Mus musculus	17-26
32143325-4	2020	Using PPARbeta/delta agonist GW501516 upregulates FoxA2, which in turn, attenuates the production of proinflammatory cytokines and reduces the infiltration of CD45+ immune cells in two mouse models of muscle inflammation, systemic LPS and intramuscular injection of carrageenan, which mimic localized exercise-induced inflammation.	GW 501516	29-37	peroxisome proliferator activated receptor alpha	Mus musculus	6-20
32143325-4	2020	Using PPARbeta/delta agonist GW501516 upregulates FoxA2, which in turn, attenuates the production of proinflammatory cytokines and reduces the infiltration of CD45+ immune cells in two mouse models of muscle inflammation, systemic LPS and intramuscular injection of carrageenan, which mimic localized exercise-induced inflammation.	GW 501516	29-37	forkhead box A2	Mus musculus	50-55
32143325-6	2020	In line with these results, a deficiency in either PPARbeta/delta or FoxA2 diminishes the action of the PPARbeta/delta agonist GW501516 to suppress an aggravated inflammatory response.	GW 501516	127-135	peroxisome proliferator activated receptor alpha	Mus musculus	51-65
32143325-6	2020	In line with these results, a deficiency in either PPARbeta/delta or FoxA2 diminishes the action of the PPARbeta/delta agonist GW501516 to suppress an aggravated inflammatory response.	GW 501516	127-135	forkhead box A2	Mus musculus	69-74
32143325-6	2020	In line with these results, a deficiency in either PPARbeta/delta or FoxA2 diminishes the action of the PPARbeta/delta agonist GW501516 to suppress an aggravated inflammatory response.	GW 501516	127-135	peroxisome proliferator activated receptor alpha	Mus musculus	51-59
31796534-2	2020	Here, we demonstrate that SOX9 was dramatically induced by stably expressing PPARdelta and by its agonist GW501516 in human GC cell lines.	GW 501516	106-114	SRY-box transcription factor 9	Homo sapiens	26-30
31364177-5	2019	HFD aggravated GK rats" poorer INSR30, lower mass, greater apoptosis of beta cells, lower mass, and lower expression of GPR40, which were similarly improved by GW501516 at 3 or 6 mg/kg day and pioglitazone.	GW 501516	160-168	free fatty acid receptor 1	Rattus norvegicus	120-125
31364177-7	2019	GW501516 protected INS-1 cells from PAM-induced apoptosis by upregulating GPR40 and activating Akt/Bcl-2/caspase-3.	GW 501516	0-8	free fatty acid receptor 1	Rattus norvegicus	74-79
31364177-7	2019	GW501516 protected INS-1 cells from PAM-induced apoptosis by upregulating GPR40 and activating Akt/Bcl-2/caspase-3.	GW 501516	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	95-98
32238697-8	2020	CBDA inhibits PPARbeta/delta-mediated transcriptional activation stimulated by the PPARbeta/delta-specific agonist, GW501516.	GW 501516	116-124	peroxisome proliferator activated receptor alpha	Homo sapiens	14-22
32238697-8	2020	CBDA inhibits PPARbeta/delta-mediated transcriptional activation stimulated by the PPARbeta/delta-specific agonist, GW501516.	GW 501516	116-124	peroxisome proliferator activated receptor alpha	Homo sapiens	14-28
32238697-9	2020	Furthermore, the disappearance of cellular actin stress fibers, a hallmark of PPARbeta/delta and COX-2 pathway activation, as evoked by the GW501516, was effectively reversed by CBDA.	GW 501516	140-148	peroxisome proliferator activated receptor alpha	Homo sapiens	78-92
32238697-9	2020	Furthermore, the disappearance of cellular actin stress fibers, a hallmark of PPARbeta/delta and COX-2 pathway activation, as evoked by the GW501516, was effectively reversed by CBDA.	GW 501516	140-148	prostaglandin-endoperoxide synthase 2	Homo sapiens	97-102
31063584-4	2019	The activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited expression of BACE1.	GW 501516	31-39	peroxisome proliferator activated receptor delta	Homo sapiens	18-27
31063584-4	2019	The activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited expression of BACE1.	GW 501516	31-39	peroxisome proliferator activated receptor delta	Homo sapiens	52-61
31063584-4	2019	The activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited expression of BACE1.	GW 501516	31-39	beta-secretase 1	Homo sapiens	95-100
31063584-5	2019	This effect was abrogated by shRNA-mediated knockdown of PPARdelta and by treatment with the PPARdelta antagonist GSK0660, indicating that PPARdelta is involved in GW501516-mediated suppression of BACE1 expression.	GW 501516	164-172	peroxisome proliferator activated receptor delta	Homo sapiens	57-66
31063584-5	2019	This effect was abrogated by shRNA-mediated knockdown of PPARdelta and by treatment with the PPARdelta antagonist GSK0660, indicating that PPARdelta is involved in GW501516-mediated suppression of BACE1 expression.	GW 501516	164-172	peroxisome proliferator activated receptor delta	Homo sapiens	93-102
31063584-5	2019	This effect was abrogated by shRNA-mediated knockdown of PPARdelta and by treatment with the PPARdelta antagonist GSK0660, indicating that PPARdelta is involved in GW501516-mediated suppression of BACE1 expression.	GW 501516	164-172	peroxisome proliferator activated receptor delta	Homo sapiens	93-102
31063584-5	2019	This effect was abrogated by shRNA-mediated knockdown of PPARdelta and by treatment with the PPARdelta antagonist GSK0660, indicating that PPARdelta is involved in GW501516-mediated suppression of BACE1 expression.	GW 501516	164-172	beta-secretase 1	Homo sapiens	197-202
31063584-6	2019	On the other hand, GW501516-activated PPARdelta induced expression of SOCS1, which is a negative regulator of cytokine signal transduction, at the transcriptional level by binding to a PPAR response element in its promoter.	GW 501516	19-27	peroxisome proliferator activated receptor delta	Homo sapiens	38-47
31063584-6	2019	On the other hand, GW501516-activated PPARdelta induced expression of SOCS1, which is a negative regulator of cytokine signal transduction, at the transcriptional level by binding to a PPAR response element in its promoter.	GW 501516	19-27	suppressor of cytokine signaling 1	Homo sapiens	70-75
31063584-6	2019	On the other hand, GW501516-activated PPARdelta induced expression of SOCS1, which is a negative regulator of cytokine signal transduction, at the transcriptional level by binding to a PPAR response element in its promoter.	GW 501516	19-27	peroxisome proliferator activated receptor alpha	Homo sapiens	38-42
31063584-7	2019	This GW501516-mediated induction of SOCS1 expression led to down-regulation of BACE1 expression via inactivation of signal transducer and activator of transcription 1.	GW 501516	5-13	suppressor of cytokine signaling 1	Homo sapiens	36-41
31063584-7	2019	This GW501516-mediated induction of SOCS1 expression led to down-regulation of BACE1 expression via inactivation of signal transducer and activator of transcription 1.	GW 501516	5-13	beta-secretase 1	Homo sapiens	79-84
31063584-7	2019	This GW501516-mediated induction of SOCS1 expression led to down-regulation of BACE1 expression via inactivation of signal transducer and activator of transcription 1.	GW 501516	5-13	signal transducer and activator of transcription 1	Homo sapiens	116-166
31063584-8	2019	GW501516-activated PPARdelta suppressed the generation of neurotoxic amyloid beta (Abeta) in accordance with the decrease in BACE1 expression.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
31063584-8	2019	GW501516-activated PPARdelta suppressed the generation of neurotoxic amyloid beta (Abeta) in accordance with the decrease in BACE1 expression.	GW 501516	0-8	amyloid beta precursor protein	Homo sapiens	69-81
31063584-8	2019	GW501516-activated PPARdelta suppressed the generation of neurotoxic amyloid beta (Abeta) in accordance with the decrease in BACE1 expression.	GW 501516	0-8	beta-secretase 1	Homo sapiens	125-130
31364177-7	2019	GW501516 protected INS-1 cells from PAM-induced apoptosis by upregulating GPR40 and activating Akt/Bcl-2/caspase-3.	GW 501516	0-8	BCL2, apoptosis regulator	Rattus norvegicus	99-104
31364177-7	2019	GW501516 protected INS-1 cells from PAM-induced apoptosis by upregulating GPR40 and activating Akt/Bcl-2/caspase-3.	GW 501516	0-8	caspase 3	Rattus norvegicus	105-114
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	peroxisome proliferator activated receptor alpha	Rattus norvegicus	30-44
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	free fatty acid receptor 1	Rattus norvegicus	146-151
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	AKT serine/threonine kinase 1	Rattus norvegicus	171-174
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	BCL2, apoptosis regulator	Rattus norvegicus	175-180
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	caspase 3	Rattus norvegicus	181-190
31364177-9	2019	These results showed that the PPARbeta/delta agonist GW501516 protected beta cells from lipoapoptosis and improved beta cell mass by upregulating GPR40 and activating the Akt/Bcl-2/caspase-3 pathway, but not the ERK-signaling pathway.	GW 501516	53-61	Eph receptor B1	Rattus norvegicus	212-215
31364177-1	2019	GW501516-activated peroxisome proliferator-activated receptor (PPAR) beta/delta and G-protein-coupled receptor (GPR) 40 were shown to protect pancreatic beta cells against lipoapoptosis.	GW 501516	0-8	free fatty acid receptor 1	Rattus norvegicus	84-119
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	solute carrier family 2 member 1	Homo sapiens	70-75
31150647-5	2019	These findings suggest that metformin inhibited PPARdelta agonist GW501516-induced cancer cell metabolism and tumor growth.	GW 501516	66-74	peroxisome proliferator activated receptor delta	Homo sapiens	48-57
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	solute carrier family 2 member 1	Homo sapiens	77-98
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	solute carrier family 1 member 5	Homo sapiens	104-110
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	solute carrier family 1 member 5	Homo sapiens	112-143
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	37-45	peroxisome proliferator activated receptor delta	Homo sapiens	325-334
31150647-2	2019	Here we found that PPARdelta agonist GW501516 significantly increased Glut1 (Glucose transporter 1) and SLC1A5 (solutecarrier family 1 member 5) gene and protein expressions in HCT-116, SW480, HeLa, and MCF-7 cancer cell lines, while metformin inhibited this event, which was associated with metformin-mediated inhibition of PPARdelta activity in response to GW501516.	GW 501516	359-367	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
31150647-3	2019	Importantly, GW501516 inhibited the binding of PPARdelta to AMPK, while metformin reversed this process.	GW 501516	13-21	peroxisome proliferator activated receptor delta	Homo sapiens	47-56
30982495-0	2019	PPARbeta/delta Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206.	GW 501516	23-31	peroxisome proliferator activated receptor delta	Homo sapiens	0-8
30982495-0	2019	PPARbeta/delta Agonist GW501516 Inhibits Tumorigenesis and Promotes Apoptosis of the Undifferentiated Nasopharyngeal Carcinoma C666-1 Cells by Regulating miR-206.	GW 501516	23-31	microRNA 206	Homo sapiens	154-161
30982495-1	2019	In previous investigations, we reported that peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) activation by GW501516 inhibits proliferation and promotes apoptosis in the undifferentiated C666-1 nasopharyngeal carcinoma (NPC) cells by modulating caspase-dependent apoptotic pathway.	GW 501516	130-138	peroxisome proliferator activated receptor delta	Homo sapiens	45-98
30982495-1	2019	In previous investigations, we reported that peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) activation by GW501516 inhibits proliferation and promotes apoptosis in the undifferentiated C666-1 nasopharyngeal carcinoma (NPC) cells by modulating caspase-dependent apoptotic pathway.	GW 501516	130-138	peroxisome proliferator activated receptor delta	Homo sapiens	100-108
30982495-3	2019	Among the assayed miRNAs that were involved in regulating the expression of antiapoptotic protein Bcl-2, miR-206 was increased significantly and specifically by GW501516 in C666-1 cells at both the in vitro level and at the in vivo xenograft samples.	GW 501516	161-169	BCL2 apoptosis regulator	Homo sapiens	98-103
30982495-3	2019	Among the assayed miRNAs that were involved in regulating the expression of antiapoptotic protein Bcl-2, miR-206 was increased significantly and specifically by GW501516 in C666-1 cells at both the in vitro level and at the in vivo xenograft samples.	GW 501516	161-169	microRNA 206	Homo sapiens	105-112
30982495-4	2019	The induction on miR-206 expression caused by GW501516 was capable of being antagonized by the PPARbeta/delta antagonist GSK3787 and AMPK antagonist dorsomorphin in C666-1 cells.	GW 501516	46-54	microRNA 206	Homo sapiens	17-24
30982495-4	2019	The induction on miR-206 expression caused by GW501516 was capable of being antagonized by the PPARbeta/delta antagonist GSK3787 and AMPK antagonist dorsomorphin in C666-1 cells.	GW 501516	46-54	peroxisome proliferator activated receptor delta	Homo sapiens	95-103
30982495-4	2019	The induction on miR-206 expression caused by GW501516 was capable of being antagonized by the PPARbeta/delta antagonist GSK3787 and AMPK antagonist dorsomorphin in C666-1 cells.	GW 501516	46-54	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	133-137
30982495-5	2019	GW501516"s suppression on the growth and apoptosis of C666-1 cells was found to be dependent on the presence of miR-206.	GW 501516	0-8	microRNA 206	Homo sapiens	112-119
30982495-9	2019	Taken together, the current data demonstrated that miR-206 plays a critical role in the direct apoptosis-promoting effect induced by GW501516 in C666-1 cells.	GW 501516	133-141	microRNA 206	Homo sapiens	51-58
30739791-7	2019	GW501516 treatment increased the expression of insulin receptor and inhibited TNFalpha-mediated repression of insulin receptor.	GW 501516	0-8	insulin receptor	Homo sapiens	110-126
31384284-5	2019	Results: Our data showed that palmitate and PPAR agonists including WY14643 (PPARalpha), GW501516 (PPARbeta/delta), rosiglitazone (PPARgamma) in vitro all induced PLIN5 expression in INS-1 cells.	GW 501516	89-97	peroxisome proliferator activated receptor alpha	Rattus norvegicus	44-48
31384284-5	2019	Results: Our data showed that palmitate and PPAR agonists including WY14643 (PPARalpha), GW501516 (PPARbeta/delta), rosiglitazone (PPARgamma) in vitro all induced PLIN5 expression in INS-1 cells.	GW 501516	89-97	peroxisome proliferator-activated receptor delta	Rattus norvegicus	99-107
31384284-5	2019	Results: Our data showed that palmitate and PPAR agonists including WY14643 (PPARalpha), GW501516 (PPARbeta/delta), rosiglitazone (PPARgamma) in vitro all induced PLIN5 expression in INS-1 cells.	GW 501516	89-97	perilipin 5	Rattus norvegicus	163-168
30739791-0	2019	PPARbeta/delta agonist GW501516 inhibits TNFalpha-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.	GW 501516	23-31	peroxisome proliferator activated receptor delta	Homo sapiens	0-8
31144304-9	2019	KEY RESULTS: The PPARdelta agonist GW501516 increased DHFR and BH4 levels in endothelial cells (ECs).	GW 501516	35-43	peroxisome proliferator activator receptor delta	Mus musculus	17-26
31144304-9	2019	KEY RESULTS: The PPARdelta agonist GW501516 increased DHFR and BH4 levels in endothelial cells (ECs).	GW 501516	35-43	dihydrofolate reductase	Mus musculus	54-58
31153636-7	2019	PPAR-delta agonist GW501516 partially rescued the insulin resistance induced by miR-29a.	GW 501516	19-27	peroxisome proliferator activator receptor delta	Mus musculus	0-10
31153636-7	2019	PPAR-delta agonist GW501516 partially rescued the insulin resistance induced by miR-29a.	GW 501516	19-27	microRNA 29a	Mus musculus	80-87
30739791-8	2019	Our results showed that GW501516 abrogated TNFalpha-induced insulin resistance.	GW 501516	24-32	tumor necrosis factor	Homo sapiens	43-51
30739791-0	2019	PPARbeta/delta agonist GW501516 inhibits TNFalpha-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.	GW 501516	23-31	tumor necrosis factor	Homo sapiens	41-49
30739791-0	2019	PPARbeta/delta agonist GW501516 inhibits TNFalpha-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.	GW 501516	23-31	adiponectin, C1Q and collagen domain containing	Homo sapiens	72-83
30739791-0	2019	PPARbeta/delta agonist GW501516 inhibits TNFalpha-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes.	GW 501516	23-31	insulin	Homo sapiens	88-95
30739791-3	2019	GW501516 induced adipocyte differentiation and the expression of adiponectin in a dose-dependent manner in differentiated adipocytes.	GW 501516	0-8	adiponectin, C1Q and collagen domain containing	Homo sapiens	65-76
30739791-5	2019	This effect was reversed by GW501516 co-treatment with TNFalpha.	GW 501516	28-36	tumor necrosis factor	Homo sapiens	55-63
30739791-8	2019	Our results showed that GW501516 abrogated TNFalpha-induced insulin resistance.	GW 501516	24-32	insulin	Homo sapiens	60-67
30739791-9	2019	In summary, our study demonstrated that the PPARbeta/delta agonist, GW501516 reversed TNFalpha-induced decreases in adipocyte differentiation and adiponectin expression, and improved insulin sensitivity by increasing the expression of insulin receptor.	GW 501516	68-76	peroxisome proliferator activated receptor delta	Homo sapiens	44-52
30739791-9	2019	In summary, our study demonstrated that the PPARbeta/delta agonist, GW501516 reversed TNFalpha-induced decreases in adipocyte differentiation and adiponectin expression, and improved insulin sensitivity by increasing the expression of insulin receptor.	GW 501516	68-76	tumor necrosis factor	Homo sapiens	86-94
30739791-9	2019	In summary, our study demonstrated that the PPARbeta/delta agonist, GW501516 reversed TNFalpha-induced decreases in adipocyte differentiation and adiponectin expression, and improved insulin sensitivity by increasing the expression of insulin receptor.	GW 501516	68-76	adiponectin, C1Q and collagen domain containing	Homo sapiens	146-157
30739791-9	2019	In summary, our study demonstrated that the PPARbeta/delta agonist, GW501516 reversed TNFalpha-induced decreases in adipocyte differentiation and adiponectin expression, and improved insulin sensitivity by increasing the expression of insulin receptor.	GW 501516	68-76	insulin	Homo sapiens	183-190
30739791-7	2019	GW501516 treatment increased the expression of insulin receptor and inhibited TNFalpha-mediated repression of insulin receptor.	GW 501516	0-8	insulin receptor	Homo sapiens	47-63
30739791-9	2019	In summary, our study demonstrated that the PPARbeta/delta agonist, GW501516 reversed TNFalpha-induced decreases in adipocyte differentiation and adiponectin expression, and improved insulin sensitivity by increasing the expression of insulin receptor.	GW 501516	68-76	insulin receptor	Homo sapiens	235-251
30739791-7	2019	GW501516 treatment increased the expression of insulin receptor and inhibited TNFalpha-mediated repression of insulin receptor.	GW 501516	0-8	tumor necrosis factor	Homo sapiens	78-86
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	peroxisome proliferator activator receptor delta	Mus musculus	13-22
30679176-7	2019	Treatment with PPARD agonist GW501516 enhanced colorectal cancer tumorigenesis in ApcDelta580 mice, whereas treatment with PPARD antagonist GSK3787 suppressed tumorigenesis.	GW 501516	29-37	peroxisome proliferator activator receptor delta	Mus musculus	15-20
30620754-2	2019	Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly inhibited Ang II-stimulated protein synthesis in a concentration-dependent manner, as determined by [3H]-leucine incorporation.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
30620754-2	2019	Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly inhibited Ang II-stimulated protein synthesis in a concentration-dependent manner, as determined by [3H]-leucine incorporation.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	58-67
30620754-2	2019	Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly inhibited Ang II-stimulated protein synthesis in a concentration-dependent manner, as determined by [3H]-leucine incorporation.	GW 501516	27-35	angiotensinogen	Homo sapiens	93-99
30620754-3	2019	GW501516-activated PPARdelta also suppressed Ang II-induced generation of reactive oxygen species (ROS) in VSMCs.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
30620754-3	2019	GW501516-activated PPARdelta also suppressed Ang II-induced generation of reactive oxygen species (ROS) in VSMCs.	GW 501516	0-8	angiotensinogen	Homo sapiens	45-51
30620754-4	2019	Transfection of small interfering RNA (siRNA) against PPARdelta significantly reversed the effects of GW501516 on [3H]-leucine incorporation and ROS generation, indicating that PPARdelta is involved in these effects.	GW 501516	102-110	peroxisome proliferator activated receptor delta	Homo sapiens	54-63
30620754-4	2019	Transfection of small interfering RNA (siRNA) against PPARdelta significantly reversed the effects of GW501516 on [3H]-leucine incorporation and ROS generation, indicating that PPARdelta is involved in these effects.	GW 501516	102-110	peroxisome proliferator activated receptor delta	Homo sapiens	177-186
30620754-5	2019	By contrast, these GW501516-mediated actions were potentiated in VSMCs transfected with siRNA against NADPH oxidase (NOX) 1 or 4, suggesting that ligand-activated PPARdelta elicits these effects by modulating NOX-mediated ROS generation.	GW 501516	19-27	peroxisome proliferator activated receptor delta	Homo sapiens	163-172
30605833-3	2019	In this study, we hybrid FFA1 agonist AM-4668 with PPARdelta agonist GW501516, leading to the identification of orally bioavailable dual agonist 32, which revealed high selectivity over other PPARs.	GW 501516	69-77	peroxisome proliferator activator receptor delta	Mus musculus	51-60
30573521-3	2019	Here we investigated the impact of the peroxisome proliferator-activated receptor (PPAR) agonist GW501516 (GW), an agent known to boost FAO in other tissues, on CD8+ T-cell metabolism, function, and efficacy in a murine ACT model.	GW 501516	97-105	peroxisome proliferator activated receptor alpha	Rattus norvegicus	83-87
30573521-3	2019	Here we investigated the impact of the peroxisome proliferator-activated receptor (PPAR) agonist GW501516 (GW), an agent known to boost FAO in other tissues, on CD8+ T-cell metabolism, function, and efficacy in a murine ACT model.	GW 501516	97-99	peroxisome proliferator activated receptor alpha	Rattus norvegicus	83-87
30573521-4	2019	Via activation of both PPARalpha and PPARdelta/beta, GW treatment increased expression of carnitine palmitoyl transferase 1a, the rate-limiting enzyme of FAO, in activated CD8+ T cells.	GW 501516	53-55	peroxisome proliferator activated receptor alpha	Rattus norvegicus	23-32
30573521-4	2019	Via activation of both PPARalpha and PPARdelta/beta, GW treatment increased expression of carnitine palmitoyl transferase 1a, the rate-limiting enzyme of FAO, in activated CD8+ T cells.	GW 501516	53-55	peroxisome proliferator activated receptor alpha	Rattus norvegicus	37-51
30573521-4	2019	Via activation of both PPARalpha and PPARdelta/beta, GW treatment increased expression of carnitine palmitoyl transferase 1a, the rate-limiting enzyme of FAO, in activated CD8+ T cells.	GW 501516	53-55	carnitine palmitoyltransferase 1A	Rattus norvegicus	90-124
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	cytochrome c oxidase II, mitochondrial	Mus musculus	84-89
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	interleukin 6	Mus musculus	91-95
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	chemokine (C-X-C motif) ligand 15	Mus musculus	97-101
30391747-3	2019	In addition, PPARdelta agonist GW501516 enhanced pro-inflammatory gene expressions (COX-2, IL-6, IL-8 and MCP-1) in inflamed colon.	GW 501516	31-39	mast cell protease 1	Mus musculus	106-111
30391747-4	2019	Further analysis showed that GW501516 increased the expressions of Glut1 and SLC1A5 in colon cancer cells as well as AOM/DSS-induced colorectal tumors.	GW 501516	29-37	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	67-72
30391747-4	2019	Further analysis showed that GW501516 increased the expressions of Glut1 and SLC1A5 in colon cancer cells as well as AOM/DSS-induced colorectal tumors.	GW 501516	29-37	solute carrier family 1 (neutral amino acid transporter), member 5	Mus musculus	77-83
30391747-5	2019	These findings revealed a new mechanism of PPARdelta agonist GW501516-mediated colitis-associated colorectal cancer.	GW 501516	61-69	peroxisome proliferator activator receptor delta	Mus musculus	43-52
29941059-7	2018	In Experiment 2, inhibition of PPARbeta/delta had no effect on glucose uptake and lactose synthesis but they were both increased by GW-501516 in PBMC.	GW 501516	132-141	peroxisome proliferator activated receptor delta	Bos taurus	31-39
29885849-11	2019	Our results show that GW501516 reduced movement impairment in PD mice; furthermore, it attenuated dopaminergic neurodegeneration in the midbrain and the depletion of dopamine in the striatum and it inhibited inflammatory reactions and NLRP3 inflammasome activation in the midbrain of PD mice.	GW 501516	22-30	NLR family, pyrin domain containing 3	Mus musculus	235-240
29885849-13	2019	Collectively, our findings demonstrate for the first time that the specific PPARss/delta agonist GW501516 alleviates NLRP3 inflammasome-mediated neuroinflammation in astrocytes in the MPTP mouse model of PD.	GW 501516	97-105	NLR family, pyrin domain containing 3	Mus musculus	117-122
30987865-3	2019	Treatment of mice fed a high-fat diet with the PPARbeta/delta agonist GW501516 increased the hepatic expression of Vldlr.	GW 501516	70-78	peroxisome proliferator activator receptor delta	Mus musculus	47-55
30987865-3	2019	Treatment of mice fed a high-fat diet with the PPARbeta/delta agonist GW501516 increased the hepatic expression of Vldlr.	GW 501516	70-78	very low density lipoprotein receptor	Mus musculus	115-120
30987865-4	2019	Similarly, exposure of human Huh-7 hepatocytes to GW501516 increased the expression of VLDLR and triglyceride accumulation, the latter being prevented by VLDLR knockdown.	GW 501516	50-58	MIR7-3 host gene	Homo sapiens	29-34
30987865-4	2019	Similarly, exposure of human Huh-7 hepatocytes to GW501516 increased the expression of VLDLR and triglyceride accumulation, the latter being prevented by VLDLR knockdown.	GW 501516	50-58	very low density lipoprotein receptor	Homo sapiens	87-92
30987865-4	2019	Similarly, exposure of human Huh-7 hepatocytes to GW501516 increased the expression of VLDLR and triglyceride accumulation, the latter being prevented by VLDLR knockdown.	GW 501516	50-58	very low density lipoprotein receptor	Homo sapiens	154-159
30204243-6	2018	Administration of the PPARdelta ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARdelta, but not those expressing dominant-negative PPARdelta, by interfering with c-Myc function through protein-protein interaction.	GW 501516	39-47	peroxisome proliferator activator receptor delta	Mus musculus	22-31
30204243-6	2018	Administration of the PPARdelta ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARdelta, but not those expressing dominant-negative PPARdelta, by interfering with c-Myc function through protein-protein interaction.	GW 501516	39-47	peroxisome proliferator activated receptor delta	Homo sapiens	148-157
30204243-6	2018	Administration of the PPARdelta ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARdelta, but not those expressing dominant-negative PPARdelta, by interfering with c-Myc function through protein-protein interaction.	GW 501516	39-47	peroxisome proliferator activated receptor delta	Homo sapiens	148-157
30204243-6	2018	Administration of the PPARdelta ligand GW501516 inhibited tumor growth in xenograft model mice bearing MDA-MB-231 cells stably expressing wild-type PPARdelta, but not those expressing dominant-negative PPARdelta, by interfering with c-Myc function through protein-protein interaction.	GW 501516	39-47	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	233-238
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	14-23
29388693-4	2018	Activation of PPARdelta by GW501516, a specific PPARdelta agonist, inhibited glutamate release in BV-2 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	48-57
29388693-8	2018	By contrast, GW501516 upregulated the expression of suppressor of cytokine signaling 1 (SOCS1), an endogenous inhibitor of JAK2.	GW 501516	13-21	suppressor of cytokine signaling 1	Mus musculus	52-86
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	81-90
29388693-8	2018	By contrast, GW501516 upregulated the expression of suppressor of cytokine signaling 1 (SOCS1), an endogenous inhibitor of JAK2.	GW 501516	13-21	suppressor of cytokine signaling 1	Mus musculus	88-93
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-8	2018	By contrast, GW501516 upregulated the expression of suppressor of cytokine signaling 1 (SOCS1), an endogenous inhibitor of JAK2.	GW 501516	13-21	Janus kinase 2	Mus musculus	123-127
29388693-5	2018	This effect of GW501516 was significantly blocked by shRNA-mediated knockdown of PPARdelta and by treatment with GSK0660, a specific PPARdelta antagonist, indicating that PPARdelta is associated with blockade of glutamate release.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	133-142
29388693-6	2018	Additionally, GW501516-activated PPARdelta suppressed generation of reactive oxygen species and expression of gp91phox, a functional subunit of NADPH oxidase 2, in BV-2 cells stimulated with LPS.	GW 501516	14-22	peroxisome proliferator activator receptor delta	Mus musculus	33-42
29388693-6	2018	Additionally, GW501516-activated PPARdelta suppressed generation of reactive oxygen species and expression of gp91phox, a functional subunit of NADPH oxidase 2, in BV-2 cells stimulated with LPS.	GW 501516	14-22	cytochrome b-245, beta polypeptide	Mus musculus	110-118
29621036-6	2018	The known PPAR-delta agonists, GW1516, L165041, and GW0742, showed potent agonist activity against human, mouse, and rat receptors (ranging from 165- to 396-fold).	GW 501516	31-37	peroxisome proliferator activated receptor delta	Homo sapiens	10-20
29388693-6	2018	Additionally, GW501516-activated PPARdelta suppressed generation of reactive oxygen species and expression of gp91phox, a functional subunit of NADPH oxidase 2, in BV-2 cells stimulated with LPS.	GW 501516	14-22	cytochrome b-245, beta polypeptide	Mus musculus	144-159
29388693-7	2018	The inhibitory effect of GW501516 on gp91phox expression and glutamate release was further potentiated in the presence of AG490, a specific inhibitor of janus kinase 2 (JAK2), leading to the inhibition of signal transducer and activator of transcription 1 (STAT1).	GW 501516	25-33	cytochrome b-245, beta polypeptide	Mus musculus	37-45
29388693-7	2018	The inhibitory effect of GW501516 on gp91phox expression and glutamate release was further potentiated in the presence of AG490, a specific inhibitor of janus kinase 2 (JAK2), leading to the inhibition of signal transducer and activator of transcription 1 (STAT1).	GW 501516	25-33	Janus kinase 2	Mus musculus	153-167
29388693-7	2018	The inhibitory effect of GW501516 on gp91phox expression and glutamate release was further potentiated in the presence of AG490, a specific inhibitor of janus kinase 2 (JAK2), leading to the inhibition of signal transducer and activator of transcription 1 (STAT1).	GW 501516	25-33	Janus kinase 2	Mus musculus	169-173
29388693-7	2018	The inhibitory effect of GW501516 on gp91phox expression and glutamate release was further potentiated in the presence of AG490, a specific inhibitor of janus kinase 2 (JAK2), leading to the inhibition of signal transducer and activator of transcription 1 (STAT1).	GW 501516	25-33	signal transducer and activator of transcription 1	Mus musculus	205-255
29388693-7	2018	The inhibitory effect of GW501516 on gp91phox expression and glutamate release was further potentiated in the presence of AG490, a specific inhibitor of janus kinase 2 (JAK2), leading to the inhibition of signal transducer and activator of transcription 1 (STAT1).	GW 501516	25-33	signal transducer and activator of transcription 1	Mus musculus	257-262
29275935-0	2018	Highly selective peroxisome proliferator-activated receptor delta (PPARdelta) modulator demonstrates improved safety profile compared to GW501516.	GW 501516	137-145	peroxisome proliferator activated receptor delta	Homo sapiens	67-76
30002625-0	2018	PPARbeta/delta Agonist GW501516 Inhibits Tumorigenicity of Undifferentiated Nasopharyngeal Carcinoma in C666-1 Cells by Promoting Apoptosis.	GW 501516	23-31	peroxisome proliferator activated receptor delta	Homo sapiens	0-8
30002625-5	2018	Ligand activation of PPARbeta/delta by GW501516, a specific PPARbeta/delta selective agonist, inhibited cell proliferation and colony formation strikingly, and induced a G2/M phase arrest in the EBV positive undifferentiated NPC C666-1 cells relative to the control cells.	GW 501516	39-47	peroxisome proliferator activated receptor delta	Homo sapiens	21-29
30002625-5	2018	Ligand activation of PPARbeta/delta by GW501516, a specific PPARbeta/delta selective agonist, inhibited cell proliferation and colony formation strikingly, and induced a G2/M phase arrest in the EBV positive undifferentiated NPC C666-1 cells relative to the control cells.	GW 501516	39-47	peroxisome proliferator activated receptor delta	Homo sapiens	60-68
29233935-6	2018	Finally, GW501516-activated PPARdelta improved insulin signaling and glucose intolerance in mice fed a high-fat diet through its interaction with TCPTP45.	GW 501516	9-17	peroxisome proliferator activator receptor delta	Mus musculus	28-37
30002625-6	2018	Moreover, GW501516 induced C666-1 cell apoptosis in a caspase and BAX dependent manner.	GW 501516	10-18	BCL2 associated X, apoptosis regulator	Homo sapiens	66-69
30002625-9	2018	Collectively, we showed that PPARbeta/delta expression is in reverse correlation with the degree of differentiation in the NPC cell lines, and revealed the anti-tumorigenic effects of GW501516 in NPC cells by activation of AMPKalpha.	GW 501516	184-192	peroxisome proliferator activated receptor delta	Homo sapiens	29-37
29275935-1	2018	Compound 1 regulates significantly fewer genes than the PPARdelta modulator, GW501516.	GW 501516	77-85	peroxisome proliferator activated receptor delta	Homo sapiens	56-65
29275935-3	2018	The restricted gene profile of 1 relative to GW501516 suggests that 1 may be pharmacoequivalent to GW501516 with fewer PPAR-related safety concerns.	GW 501516	99-107	peroxisome proliferator activated receptor alpha	Homo sapiens	119-123
29408825-7	2018	GW501516- activated PPARdelta also reduced the H2O2-induced generation of reactive oxygen species, concomitant with inhibition of VSMC migration.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	20-29
29212212-3	2017	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, led to marked inhibition in the cell migration and TSP-1 expression of breast cancer.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
29408825-4	2018	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly attenuated hydrogen peroxide (H2O2)-induced expression of TSP-1 in VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
29408825-4	2018	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly attenuated hydrogen peroxide (H2O2)-induced expression of TSP-1 in VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
29408825-4	2018	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly attenuated hydrogen peroxide (H2O2)-induced expression of TSP-1 in VSMCs.	GW 501516	27-35	thrombospondin 1	Homo sapiens	142-147
29408825-5	2018	Small interfering RNA-mediated knockdown of PPARdelta and treatment with GSK0660, a selective PPARdelta antagonist, reversed the effect of GW501516 on H2O2-induced expression of TSP-1, suggesting that PPARdelta is associated with GW501516 activity.	GW 501516	139-147	peroxisome proliferator activated receptor delta	Homo sapiens	44-53
29408825-5	2018	Small interfering RNA-mediated knockdown of PPARdelta and treatment with GSK0660, a selective PPARdelta antagonist, reversed the effect of GW501516 on H2O2-induced expression of TSP-1, suggesting that PPARdelta is associated with GW501516 activity.	GW 501516	139-147	peroxisome proliferator activated receptor delta	Homo sapiens	94-103
29408825-5	2018	Small interfering RNA-mediated knockdown of PPARdelta and treatment with GSK0660, a selective PPARdelta antagonist, reversed the effect of GW501516 on H2O2-induced expression of TSP-1, suggesting that PPARdelta is associated with GW501516 activity.	GW 501516	139-147	thrombospondin 1	Homo sapiens	178-183
29408825-5	2018	Small interfering RNA-mediated knockdown of PPARdelta and treatment with GSK0660, a selective PPARdelta antagonist, reversed the effect of GW501516 on H2O2-induced expression of TSP-1, suggesting that PPARdelta is associated with GW501516 activity.	GW 501516	139-147	peroxisome proliferator activated receptor delta	Homo sapiens	94-103
29408825-5	2018	Small interfering RNA-mediated knockdown of PPARdelta and treatment with GSK0660, a selective PPARdelta antagonist, reversed the effect of GW501516 on H2O2-induced expression of TSP-1, suggesting that PPARdelta is associated with GW501516 activity.	GW 501516	230-238	thrombospondin 1	Homo sapiens	178-183
29212212-3	2017	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, led to marked inhibition in the cell migration and TSP-1 expression of breast cancer.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
29212212-3	2017	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, led to marked inhibition in the cell migration and TSP-1 expression of breast cancer.	GW 501516	27-35	thrombospondin 1	Homo sapiens	121-126
28955982-5	2016	GW501516-activated PPARbeta/delta suppressed TNFalpha-induced Nfkb reporter activity.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-27
28124448-0	2017	PPARdelta Modulation by GW501516: An Unsuccessful Exercise Mimetic.	GW 501516	24-32	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
28224611-0	2017	Response to "PPARdelta Modulation by GW501516: An Unsuccessful Exercise Mimetic".	GW 501516	37-45	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
26661245-7	2017	In contrast, GW501516 (a selective agonist of PPARdelta) upregulated ADAM10 and increased production of sAPPalpha.	GW 501516	13-21	peroxisome proliferator activator receptor delta	Mus musculus	46-55
26661245-7	2017	In contrast, GW501516 (a selective agonist of PPARdelta) upregulated ADAM10 and increased production of sAPPalpha.	GW 501516	13-21	a disintegrin and metallopeptidase domain 10	Mus musculus	69-75
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-164	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-135
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-164	peroxisome proliferator-activated receptor delta	Rattus norvegicus	137-146
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-158	peroxisome proliferator-activated receptor delta	Rattus norvegicus	87-135
28440451-1	2017	The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist GW501516 (GW) on lipopolysaccharide (LPS)-induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms.	GW 501516	156-158	peroxisome proliferator-activated receptor delta	Rattus norvegicus	137-146
28440451-6	2017	Pretreatment with GW also increased the bcl-2/bax ratio, and decreased CC3 protein expression as well as caspase-3 activity, in LPS-stimulated H9c2 cells.	GW 501516	18-20	BCL2, apoptosis regulator	Rattus norvegicus	40-45
28440451-6	2017	Pretreatment with GW also increased the bcl-2/bax ratio, and decreased CC3 protein expression as well as caspase-3 activity, in LPS-stimulated H9c2 cells.	GW 501516	18-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	46-49
28440451-6	2017	Pretreatment with GW also increased the bcl-2/bax ratio, and decreased CC3 protein expression as well as caspase-3 activity, in LPS-stimulated H9c2 cells.	GW 501516	18-20	caspase 3	Rattus norvegicus	105-114
28440451-9	2017	ZnPP-IX, an inhibitor of HO-1, reversed the inhibitory effect of GW on LPS-induced NF-kappaB activation, leading to the attenuation of PPARdelta-mediated apoptosis resistance.	GW 501516	65-67	peroxisome proliferator-activated receptor delta	Rattus norvegicus	135-144
28404991-5	2017	Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.	GW 501516	88-96	peroxisome proliferator activator receptor delta	Mus musculus	35-44
28404991-5	2017	Furthermore, absence of intestinal PPARdelta abolished the ability of PPARdelta agonist GW501516 to increase plasma levels of HDL-cholesterol.	GW 501516	88-96	peroxisome proliferator activator receptor delta	Mus musculus	70-79
28166979-4	2017	In this study, oocytes and parthenotes were treated with a specific agonist of PPARdelta, GW501516.	GW 501516	90-98	peroxisome proliferator activated receptor delta	Homo sapiens	79-88
28955982-5	2016	GW501516-activated PPARbeta/delta suppressed TNFalpha-induced Nfkb reporter activity.	GW 501516	0-8	tumor necrosis factor	Homo sapiens	45-53
28955982-6	2016	RNAi knockdown of Pparb attenuated the GW501516 effect on Nfkb luciferase, while knockdown of Bcl6 enhanced TNFalpha-induced Nfkb activity.	GW 501516	39-47	peroxisome proliferator activated receptor delta	Homo sapiens	18-23
28955982-7	2016	PPARbeta/delta activation induced expression of several anti-inflammatory genes in a dose-dependent manner, and GW501516 inhibited Mcp1 promoter-driven luciferase in a BCL6-dependent manner.	GW 501516	112-120	C-C motif chemokine ligand 2	Homo sapiens	131-135
28955982-7	2016	PPARbeta/delta activation induced expression of several anti-inflammatory genes in a dose-dependent manner, and GW501516 inhibited Mcp1 promoter-driven luciferase in a BCL6-dependent manner.	GW 501516	112-120	BCL6 transcription repressor	Homo sapiens	168-172
28955982-9	2016	Conditioned media from GW501516-treated pancreatic cancer cells suppressed pro-inflammatory expression in THP-1 macrophages as well as reduced invasiveness across a basement membrane.	GW 501516	23-31	GLI family zinc finger 2	Homo sapiens	106-111
27638828-0	2016	Apoptotic effect of the selective PPARbeta/delta agonist GW501516 in invasive bladder cancer cells.	GW 501516	57-65	peroxisome proliferator activated receptor delta	Homo sapiens	34-42
27573670-3	2016	PPARdelta activated by GW501516 (2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid) significantly inhibited the migration and proliferation of vascular smooth muscle cells (VSMCs) triggered by oxidized low-density lipoprotein (oxLDL).	GW 501516	23-31	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
27573670-4	2016	These GW501516-mediated effects were significantly reversed by PPARdelta-targeting small-interfering RNA (siRNA), indicating that PPARdelta is involved in the action of GW501516.	GW 501516	6-14	peroxisome proliferator activated receptor delta	Homo sapiens	63-72
27573670-4	2016	These GW501516-mediated effects were significantly reversed by PPARdelta-targeting small-interfering RNA (siRNA), indicating that PPARdelta is involved in the action of GW501516.	GW 501516	6-14	peroxisome proliferator activated receptor delta	Homo sapiens	130-139
27573670-4	2016	These GW501516-mediated effects were significantly reversed by PPARdelta-targeting small-interfering RNA (siRNA), indicating that PPARdelta is involved in the action of GW501516.	GW 501516	169-177	peroxisome proliferator activated receptor delta	Homo sapiens	63-72
27573670-4	2016	These GW501516-mediated effects were significantly reversed by PPARdelta-targeting small-interfering RNA (siRNA), indicating that PPARdelta is involved in the action of GW501516.	GW 501516	169-177	peroxisome proliferator activated receptor delta	Homo sapiens	130-139
27573670-5	2016	The antiproliferative effect of GW501516 was directly linked to cell cycle arrest at the G0/G1 to S phase transition, which was followed by the down-regulation of cyclin-dependent kinase 4 along with increased levels of p21 and p53.	GW 501516	32-40	cyclin dependent kinase 4	Homo sapiens	163-188
27573670-5	2016	The antiproliferative effect of GW501516 was directly linked to cell cycle arrest at the G0/G1 to S phase transition, which was followed by the down-regulation of cyclin-dependent kinase 4 along with increased levels of p21 and p53.	GW 501516	32-40	cyclin dependent kinase inhibitor 1A	Homo sapiens	220-223
27573670-5	2016	The antiproliferative effect of GW501516 was directly linked to cell cycle arrest at the G0/G1 to S phase transition, which was followed by the down-regulation of cyclin-dependent kinase 4 along with increased levels of p21 and p53.	GW 501516	32-40	tumor protein p53	Homo sapiens	228-231
27573670-6	2016	In VSMCs treated with GW501516, the expression of sirtuin 1 (SIRT1) mRNA and protein was time-dependently increased.	GW 501516	22-30	sirtuin 1	Homo sapiens	50-59
27573670-6	2016	In VSMCs treated with GW501516, the expression of sirtuin 1 (SIRT1) mRNA and protein was time-dependently increased.	GW 501516	22-30	sirtuin 1	Homo sapiens	61-66
27573670-7	2016	This GW501516-mediated up-regulation of SIRT1 expression was also demonstrated even in the presence of oxLDL.	GW 501516	5-13	sirtuin 1	Homo sapiens	40-45
27573670-8	2016	In addition, GW501516-dependent inhibition of oxLDL-triggered migration and proliferation of VSMCs was almost completely abolished in the presence of SIRT1-targeting siRNA.	GW 501516	13-21	sirtuin 1	Homo sapiens	150-155
27573670-9	2016	These effects of GW501516 on oxLDL-triggered phenotypic changes of VSMCs were also demonstrated via activation or inhibition of SIRT1 activity by resveratrol or sirtinol, respectively.	GW 501516	17-25	sirtuin 1	Homo sapiens	128-133
27638828-1	2016	GW501516 is a selective and high-affinity synthetic agonist of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta).	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	63-116
27638828-1	2016	GW501516 is a selective and high-affinity synthetic agonist of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta).	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	118-126
27638828-6	2016	Furthermore, GW501516 triggered T24 cell apoptosis in a caspase-dependent manner including both extrinsic and intrinsic apoptotic pathways through Bid cleavage.	GW 501516	13-21	BH3 interacting domain death agonist	Homo sapiens	147-150
26403493-2	2016	In human gingival fibroblasts (HGFs), activation of PPARdelta by GW501516, a specific ligand of PPARdelta, inhibited Pg-LPS-induced activation of MMP-2 and generation of reactive oxygen species (ROS), which was associated with reduced expression of NADPH oxidase 4 (Nox4).	GW 501516	65-73	peroxisome proliferator activated receptor delta	Homo sapiens	52-61
26403493-2	2016	In human gingival fibroblasts (HGFs), activation of PPARdelta by GW501516, a specific ligand of PPARdelta, inhibited Pg-LPS-induced activation of MMP-2 and generation of reactive oxygen species (ROS), which was associated with reduced expression of NADPH oxidase 4 (Nox4).	GW 501516	65-73	peroxisome proliferator activated receptor delta	Homo sapiens	96-105
26403493-2	2016	In human gingival fibroblasts (HGFs), activation of PPARdelta by GW501516, a specific ligand of PPARdelta, inhibited Pg-LPS-induced activation of MMP-2 and generation of reactive oxygen species (ROS), which was associated with reduced expression of NADPH oxidase 4 (Nox4).	GW 501516	65-73	matrix metallopeptidase 2	Homo sapiens	146-151
26403493-2	2016	In human gingival fibroblasts (HGFs), activation of PPARdelta by GW501516, a specific ligand of PPARdelta, inhibited Pg-LPS-induced activation of MMP-2 and generation of reactive oxygen species (ROS), which was associated with reduced expression of NADPH oxidase 4 (Nox4).	GW 501516	65-73	NADPH oxidase 4	Homo sapiens	249-264
26403493-2	2016	In human gingival fibroblasts (HGFs), activation of PPARdelta by GW501516, a specific ligand of PPARdelta, inhibited Pg-LPS-induced activation of MMP-2 and generation of reactive oxygen species (ROS), which was associated with reduced expression of NADPH oxidase 4 (Nox4).	GW 501516	65-73	NADPH oxidase 4	Homo sapiens	266-270
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	GW 501516	181-189	peroxisome proliferator activator receptor delta	Mus musculus	121-170
26160761-13	2016	Moreover, GW501516 suppressed the activation of ER stress markers including inositol-requiring enzyme 1alpha (IRE1alpha) and caspase-12.	GW 501516	10-18	caspase 12	Rattus norvegicus	125-135
26160761-14	2016	Furthermore, GW501516 inhibited caspase-12-mediated neuronal apoptosis.	GW 501516	13-21	caspase 12	Rattus norvegicus	32-42
27278004-6	2016	Results indicated that the activation of PPARdelta was correlated in a positive manner with the activity of SMS2, and the content of SM was dose dependently increased by GW501516.	GW 501516	170-178	peroxisome proliferator activated receptor delta	Homo sapiens	41-50
27278004-6	2016	Results indicated that the activation of PPARdelta was correlated in a positive manner with the activity of SMS2, and the content of SM was dose dependently increased by GW501516.	GW 501516	170-178	sphingomyelin synthase 2	Homo sapiens	108-112
27266389-4	2016	METHODS AND RESULTS: Treatment with a highly selective PPAR-delta agonist (GW501516) induced proliferation of late EPCs and enhanced their vasculogenic potential.	GW 501516	75-83	peroxisome proliferator activated receptor delta	Homo sapiens	55-65
27266389-10	2016	Platelet supernatant boosted the pro-vasculogenic effects of GW501516, which was reversed by antagonist to PPAR-delta (GSK0660) or Edg (Ki16425).	GW 501516	61-69	peroxisome proliferator activated receptor delta	Homo sapiens	107-117
26992147-9	2016	Moreover, our results suggest a close distance between the N- and C-terminal regions of full-length PPAR-beta/delta in the presence of GW1516.	GW 501516	135-141	peroxisome proliferator activated receptor delta	Homo sapiens	100-109
26004782-7	2016	Several PPARdelta selective agonists had been reported in last ten years, many of them had been advanced into the late phase of clinical trials such as Endurobol (GW501516).	GW 501516	163-171	peroxisome proliferator activated receptor delta	Homo sapiens	8-17
26481780-5	2015	RESULTS: Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, specifically upregulated the myofibroblast marker alpha-smooth muscle actin (alpha-SMA) in a time- and concentration-dependent manner.	GW 501516	36-44	peroxisome proliferator activated receptor delta	Homo sapiens	23-32
26481780-5	2015	RESULTS: Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, specifically upregulated the myofibroblast marker alpha-smooth muscle actin (alpha-SMA) in a time- and concentration-dependent manner.	GW 501516	36-44	peroxisome proliferator activated receptor delta	Homo sapiens	67-76
26481780-9	2015	GW501516-activated PPARdelta also increased the migration and contractile properties of HDFs, as demonstrated by Transwell and collagen lattice contraction assays, respectively.	GW 501516	0-8	peroxisome proliferator activated receptor delta	Homo sapiens	19-28
25854303-2	2015	The aim of this study was to evaluate the effects of the short-term administration of GW501516 on pro-inflammatory markers in white adipose tissue (WAT) and hepatic stellate cells (HSCs), lipogenesis and insulin resistance in the liver upon high-fructose diet (HFru)-induced ACE/AT1r axis activation.	GW 501516	86-94	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	275-278
25854303-2	2015	The aim of this study was to evaluate the effects of the short-term administration of GW501516 on pro-inflammatory markers in white adipose tissue (WAT) and hepatic stellate cells (HSCs), lipogenesis and insulin resistance in the liver upon high-fructose diet (HFru)-induced ACE/AT1r axis activation.	GW 501516	86-94	angiotensin II, type I receptor-associated protein	Mus musculus	279-283
25854303-8	2015	Although GW501516 abolished the increased activation of the ACE/AT1r axis in the WAT, no differences were found in the liver.	GW 501516	9-17	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	60-63
25854303-8	2015	Although GW501516 abolished the increased activation of the ACE/AT1r axis in the WAT, no differences were found in the liver.	GW 501516	9-17	angiotensin II, type I receptor-associated protein	Mus musculus	64-68
25854303-11	2015	We conclude that GW501516 may serve as a therapeutic option for the treatment of a highly activated ACE/AT1r axis in WAT and liver.	GW 501516	17-25	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	100-103
25854303-11	2015	We conclude that GW501516 may serve as a therapeutic option for the treatment of a highly activated ACE/AT1r axis in WAT and liver.	GW 501516	17-25	angiotensin II, type I receptor-associated protein	Mus musculus	104-108
26133486-7	2015	In addition, treatment with GW501516 increased the levels of insulin-like growth factor-1 (IGF-1) and high-density lipoprotein (HDL) compared to the HFD group.	GW 501516	28-36	insulin-like growth factor 1	Rattus norvegicus	61-89
26133486-7	2015	In addition, treatment with GW501516 increased the levels of insulin-like growth factor-1 (IGF-1) and high-density lipoprotein (HDL) compared to the HFD group.	GW 501516	28-36	insulin-like growth factor 1	Rattus norvegicus	91-96
26133486-9	2015	RT-qPCR and immunohistochemical staining revealed that the expression levels of sterol regulatory element binding protein-1c (SREBP-1c) and glucose transporter 2 (GLUT-2) were both restored to normal control levels following treatment with GW501516.	GW 501516	240-248	sterol regulatory element binding transcription factor 1	Rattus norvegicus	80-124
26133486-9	2015	RT-qPCR and immunohistochemical staining revealed that the expression levels of sterol regulatory element binding protein-1c (SREBP-1c) and glucose transporter 2 (GLUT-2) were both restored to normal control levels following treatment with GW501516.	GW 501516	240-248	sterol regulatory element binding transcription factor 1	Rattus norvegicus	126-134
26133486-9	2015	RT-qPCR and immunohistochemical staining revealed that the expression levels of sterol regulatory element binding protein-1c (SREBP-1c) and glucose transporter 2 (GLUT-2) were both restored to normal control levels following treatment with GW501516.	GW 501516	240-248	solute carrier family 2 member 2	Rattus norvegicus	140-161
26133486-9	2015	RT-qPCR and immunohistochemical staining revealed that the expression levels of sterol regulatory element binding protein-1c (SREBP-1c) and glucose transporter 2 (GLUT-2) were both restored to normal control levels following treatment with GW501516.	GW 501516	240-248	solute carrier family 2 member 2	Rattus norvegicus	163-169
26111938-6	2015	Increasing BH4 bioavailability either exogenously by BH4 supplementation or endogenously by treatment with the selective peroxisome proliferator-activated receptor--delta activator GW501516 (2 mg/kg/day, 14 days) attenuated eNOS uncoupling and decreased superoxide anion production in cerebral microvessels of Tg2576 mice (p < 0.05).	GW 501516	181-189	nitric oxide synthase 3, endothelial cell	Mus musculus	224-228
25943561-0	2015	A metabolomic study of the PPARdelta agonist GW501516 for enhancing running endurance in Kunming mice.	GW 501516	45-53	peroxisome proliferator activator receptor delta	Mus musculus	27-36
25857370-8	2015	KEY RESULTS: PPAR-delta agonist GW501516 decreased uptake of VLDL and expression of VLDL receptor at mRNA and protein levels.	GW 501516	32-40	peroxisome proliferator activated receptor delta	Homo sapiens	13-23
25857370-8	2015	KEY RESULTS: PPAR-delta agonist GW501516 decreased uptake of VLDL and expression of VLDL receptor at mRNA and protein levels.	GW 501516	32-40	very low density lipoprotein receptor	Homo sapiens	84-97
25857370-9	2015	GW501516 inhibited the luciferase reporter activity of the 3"-UTR of VLDL receptor.	GW 501516	0-8	very low density lipoprotein receptor	Homo sapiens	69-82
25857370-11	2015	miR-100 was significantly increased by GW501516 in HUVECs.	GW 501516	39-47	microRNA 100	Homo sapiens	0-7
25943561-3	2015	This study utilized metabolomic profiling to examine the effects of GW501516, a PPARdelta agonist, on running endurance in mice.	GW 501516	68-76	peroxisome proliferator activator receptor delta	Mus musculus	80-89
25943561-4	2015	While training alone increased the exhaustive running performance, GW501516 treatment enhanced running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice.	GW 501516	67-75	aminoadipate-semialdehyde synthase	Mus musculus	135-158
25943561-4	2015	While training alone increased the exhaustive running performance, GW501516 treatment enhanced running endurance and the proportion of succinate dehydrogenase (SDH)-positive muscle fibres in both trained and untrained mice.	GW 501516	67-75	aminoadipate-semialdehyde synthase	Mus musculus	160-163
25331977-5	2015	METHODS: Mouse chondrocytes and knee explants were treated with a pharmacologic agonist of PPARdelta (GW501516) to evaluate changes in gene expression, histologic features, and matrix glycosaminoglycan breakdown.	GW 501516	102-110	peroxisome proliferator activator receptor delta	Mus musculus	91-100
25713305-14	2015	Skeletal muscle dysfunction in HF is associated with impaired PPARdelta signaling and treatment with the PPARdelta agonist GW501516 corrects oxidative capacity and FA metabolism and improves exercise capacity in mice with LV dysfunction.	GW 501516	123-131	peroxisome proliferator activator receptor delta	Mus musculus	105-114
25732738-4	2015	Activation of PPARdelta by GW501516, which is a specific ligand, significantly inhibited oxLDL-induced cell death and generation of reactive oxygen species in VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
25728706-4	2015	Cultured adipocytes exposed to fructose also exhibited increased CD36 protein levels and this increase was prevented by the PPARbeta/delta activator GW501516.	GW 501516	149-157	peroxisome proliferator activator receptor delta	Mus musculus	124-132
25728706-5	2015	Interestingly, the levels of the nuclear factor E2-related factor 2 (Nrf2), a transcription factor reported to up-regulate Cd36 expression and to impair insulin signaling, were increased in fructose-exposed adipocytes whereas co-incubation with GW501516 abolished this increase.	GW 501516	245-253	nuclear factor, erythroid derived 2, like 2	Mus musculus	69-73
25527525-6	2015	The decreased expression of Bcl-2 and the increased expression of cleaved-caspase-3 induced by Sept4_i1 could be reversed by GW501516, a PPAR-beta/delta agonist that has been reported by others to enhance Akt signaling.	GW 501516	125-133	BCL2 apoptosis regulator	Homo sapiens	28-33
25527525-6	2015	The decreased expression of Bcl-2 and the increased expression of cleaved-caspase-3 induced by Sept4_i1 could be reversed by GW501516, a PPAR-beta/delta agonist that has been reported by others to enhance Akt signaling.	GW 501516	125-133	caspase 3	Homo sapiens	74-83
25527525-6	2015	The decreased expression of Bcl-2 and the increased expression of cleaved-caspase-3 induced by Sept4_i1 could be reversed by GW501516, a PPAR-beta/delta agonist that has been reported by others to enhance Akt signaling.	GW 501516	125-133	peroxisome proliferator activated receptor delta	Homo sapiens	137-146
25527525-6	2015	The decreased expression of Bcl-2 and the increased expression of cleaved-caspase-3 induced by Sept4_i1 could be reversed by GW501516, a PPAR-beta/delta agonist that has been reported by others to enhance Akt signaling.	GW 501516	125-133	AKT serine/threonine kinase 1	Homo sapiens	205-208
25331977-8	2015	RESULTS: In vitro, PPARdelta activation by GW501516 resulted in increased expression of several proteases in chondrocytes, as well as aggrecan degradation and glycosaminoglycan release in knee joint explants.	GW 501516	43-51	peroxisome proliferator activator receptor delta	Mus musculus	19-28
25449811-0	2015	Early controlled release of peroxisome proliferator-activated receptor beta/delta agonist GW501516 improves diabetic wound healing through redox modulation of wound microenvironment.	GW 501516	90-98	peroxisome proliferator activated receptor delta	Homo sapiens	28-75
25449811-5	2015	The underlying mechanism involved an early GW-mediated activation of PPARbeta/delta that stimulated GPx1 and catalase expression in fibroblasts.	GW 501516	43-45	peroxisome proliferator activated receptor delta	Homo sapiens	69-77
25449811-5	2015	The underlying mechanism involved an early GW-mediated activation of PPARbeta/delta that stimulated GPx1 and catalase expression in fibroblasts.	GW 501516	43-45	glutathione peroxidase 1	Homo sapiens	100-104
25449811-5	2015	The underlying mechanism involved an early GW-mediated activation of PPARbeta/delta that stimulated GPx1 and catalase expression in fibroblasts.	GW 501516	43-45	catalase	Homo sapiens	109-117
25277864-10	2015	NM23-H2 siRNA activated PPARdelta luciferase promoter activity, upregulated PPARdelta RNA and protein expression and increased GW501516-stimulated CCA growth.	GW 501516	127-135	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	0-7
25277864-11	2015	Overexpression of NM23-H2 inhibited PPARdelta luciferase promoter activity, downregulated PPARdelta expression and AKT phosphorylation and reduced GW501516-stimulated CCA growth.	GW 501516	147-155	NME/NM23 nucleoside diphosphate kinase 2	Homo sapiens	18-25
25063273-4	2014	RESULTS: The PPARbeta/delta agonist GW501516 prevented lipid-induced ER stress in mouse and human myotubes and in skeletal muscle of mice fed a high-fat diet.	GW 501516	36-44	peroxisome proliferator activator receptor delta	Mus musculus	13-21
26604919-4	2015	Mice conditionally expressing human PPARdelta demonstrated pronounced weight loss and promoted hepatic steatosis when treated with GW501516 (PPARdelta-agonist) when compared to wild type mice.	GW 501516	131-139	peroxisome proliferator activated receptor delta	Homo sapiens	36-45
26604919-4	2015	Mice conditionally expressing human PPARdelta demonstrated pronounced weight loss and promoted hepatic steatosis when treated with GW501516 (PPARdelta-agonist) when compared to wild type mice.	GW 501516	131-139	peroxisome proliferator activated receptor delta	Homo sapiens	141-150
26604919-6	2015	This confirmed the absolute requirement for PPARdelta in the physiological actions of GW501516 and confirmed the potential utility against the human form of this receptor.	GW 501516	86-94	peroxisome proliferator activated receptor delta	Homo sapiens	44-53
26604919-7	2015	Surprisingly the genetic deletion of PPARalpha also abrogated the effect of GW501516 in terms of both weight loss and hepatic lipid accumulation.	GW 501516	76-84	peroxisome proliferator activated receptor alpha	Mus musculus	37-46
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activator receptor delta	Mus musculus	27-36
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activated receptor alpha	Mus musculus	41-50
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activated receptor alpha	Mus musculus	161-170
26604919-9	2015	Our results show that both PPARdelta and PPARalpha receptors are essential for GW501516-driven adipose tissue reduction and subsequently hepatic steatosis, with PPARalpha working downstream of PPARdelta.	GW 501516	79-87	peroxisome proliferator activator receptor delta	Mus musculus	193-202
25520859-4	2014	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly increased the migration and invasion of highly metastatic A375SM cells, but not that of low metastatic A375P cells.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
25520859-4	2014	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly increased the migration and invasion of highly metastatic A375SM cells, but not that of low metastatic A375P cells.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
25520859-6	2014	Furthermore, a significant concentration- and time-dependent increase in the levels of Snail mRNA and protein was observed in A375SM cells (but not A375P cells) treated with GW501516.	GW 501516	174-182	snail family transcriptional repressor 1	Homo sapiens	87-92
25520859-7	2014	The effects of GW501516 were almost completely abrogated by a small interfering RNA against PPARdelta, suggesting that PPARdelta mediates the effects of GW501516.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	92-101
25520859-7	2014	The effects of GW501516 were almost completely abrogated by a small interfering RNA against PPARdelta, suggesting that PPARdelta mediates the effects of GW501516.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	119-128
25520859-7	2014	The effects of GW501516 were almost completely abrogated by a small interfering RNA against PPARdelta, suggesting that PPARdelta mediates the effects of GW501516.	GW 501516	153-161	peroxisome proliferator activated receptor delta	Homo sapiens	92-101
25520859-7	2014	The effects of GW501516 were almost completely abrogated by a small interfering RNA against PPARdelta, suggesting that PPARdelta mediates the effects of GW501516.	GW 501516	153-161	peroxisome proliferator activated receptor delta	Homo sapiens	119-128
25149191-6	2014	Activation of PPARdelta by GW501516, a ligand specific for PPARdelta, markedly attenuated UVB-induced MMP-2 secretion with a concomitant increase in the level of elastin.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
25149191-6	2014	Activation of PPARdelta by GW501516, a ligand specific for PPARdelta, markedly attenuated UVB-induced MMP-2 secretion with a concomitant increase in the level of elastin.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
25149191-8	2014	Furthermore, GW501516 elicited a dose- and time-dependent increase in the expression of elastin.	GW 501516	13-21	elastin	Homo sapiens	88-95
25149191-6	2014	Activation of PPARdelta by GW501516, a ligand specific for PPARdelta, markedly attenuated UVB-induced MMP-2 secretion with a concomitant increase in the level of elastin.	GW 501516	27-35	matrix metallopeptidase 2	Homo sapiens	102-107
25149191-9	2014	Modulation of MMP-2 secretion and elastin levels by GW501516 was associated with a reduction in reactive oxygen species (ROS) production in HDFs exposed to UVB.	GW 501516	52-60	matrix metallopeptidase 2	Homo sapiens	14-19
25149191-9	2014	Modulation of MMP-2 secretion and elastin levels by GW501516 was associated with a reduction in reactive oxygen species (ROS) production in HDFs exposed to UVB.	GW 501516	52-60	elastin	Homo sapiens	34-41
25149191-6	2014	Activation of PPARdelta by GW501516, a ligand specific for PPARdelta, markedly attenuated UVB-induced MMP-2 secretion with a concomitant increase in the level of elastin.	GW 501516	27-35	elastin	Homo sapiens	162-169
25149191-10	2014	Finally, in HR-1 hairless mice, administration of GW501516 significantly reduced UVB-induced MMP-2 expression with a concomitant increase in elastin levels, and these effects were significantly reduced by the presence of GSK0660.	GW 501516	50-58	matrix metallopeptidase 2	Mus musculus	93-98
24920036-6	2014	Subsequent immunoblotting experiments provided evidence for positive correlation of PPARD level and AKT and ERK signaling pathways upon GW501516 treatment.	GW 501516	136-144	peroxisome proliferator activator receptor delta	Mus musculus	84-89
25149191-10	2014	Finally, in HR-1 hairless mice, administration of GW501516 significantly reduced UVB-induced MMP-2 expression with a concomitant increase in elastin levels, and these effects were significantly reduced by the presence of GSK0660.	GW 501516	50-58	elastin	Mus musculus	141-148
24920036-6	2014	Subsequent immunoblotting experiments provided evidence for positive correlation of PPARD level and AKT and ERK signaling pathways upon GW501516 treatment.	GW 501516	136-144	thymoma viral proto-oncogene 1	Mus musculus	100-103
24920036-7	2014	Furthermore, the stimulation of GW501516 increased trophoblast cell fusion gene syncytin-A (Syna), but not syncytin-B (Synb), expression, suggesting a potential role of Ppard activation in promoting cytotrophoblast differentiation.	GW 501516	32-40	syncytin a	Mus musculus	80-90
24920036-7	2014	Furthermore, the stimulation of GW501516 increased trophoblast cell fusion gene syncytin-A (Syna), but not syncytin-B (Synb), expression, suggesting a potential role of Ppard activation in promoting cytotrophoblast differentiation.	GW 501516	32-40	syncytin a	Mus musculus	92-96
24920036-7	2014	Furthermore, the stimulation of GW501516 increased trophoblast cell fusion gene syncytin-A (Syna), but not syncytin-B (Synb), expression, suggesting a potential role of Ppard activation in promoting cytotrophoblast differentiation.	GW 501516	32-40	peroxisome proliferator activator receptor delta	Mus musculus	169-174
24864274-8	2014	Similarly, PPARdelta-mediated attenuation of FA synthesis was partially due to AMPK activation, as GW1516 reduced lipogenesis in WT hepatocytes but not AMPKbeta1(-/-) hepatocytes.	GW 501516	99-105	peroxisome proliferator activator receptor delta	Mus musculus	11-20
25116592-7	2014	We first confirmed the suppression of PPARdelta both in LR and human hepatocellular carcinoma at protein level, and then demonstrated that PPARdelta agonist GW501516 reduces the proliferative potential of hepatoma cells.	GW 501516	157-165	peroxisome proliferator activated receptor delta	Homo sapiens	38-47
25116592-7	2014	We first confirmed the suppression of PPARdelta both in LR and human hepatocellular carcinoma at protein level, and then demonstrated that PPARdelta agonist GW501516 reduces the proliferative potential of hepatoma cells.	GW 501516	157-165	peroxisome proliferator activated receptor delta	Homo sapiens	139-148
25179079-0	2014	Metabolic modulators of the exercise response: doping control analysis of an agonist of the peroxisome proliferator-activated receptor delta (GW501516) and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR).	GW 501516	142-150	peroxisome proliferator activated receptor delta	Homo sapiens	92-140
24482374-9	2014	Metformin and PPARdelta agonist GW1516 reversed tunicamycin (ER stress inducer)-induced ER stress, oxidative stress, and impairment of endothelium-dependent relaxation in mouse aortae as well as NO production in mouse aortic endothelial cells.	GW 501516	32-38	peroxisome proliferator activator receptor delta	Mus musculus	14-23
24628018-8	2014	Blood-extracted CD34(+) cells cultured with IL-5 or IL-5 + IL-3 formed Eo/B CFU, which were significantly inhibited by rosiglitazone (100 nm, P &lt; 0 01) but not GW9578 or GW501516.	GW 501516	173-181	CD34 antigen	Mus musculus	16-20
24628018-8	2014	Blood-extracted CD34(+) cells cultured with IL-5 or IL-5 + IL-3 formed Eo/B CFU, which were significantly inhibited by rosiglitazone (100 nm, P &lt; 0 01) but not GW9578 or GW501516.	GW 501516	173-181	interleukin 5	Mus musculus	44-48
24628018-8	2014	Blood-extracted CD34(+) cells cultured with IL-5 or IL-5 + IL-3 formed Eo/B CFU, which were significantly inhibited by rosiglitazone (100 nm, P &lt; 0 01) but not GW9578 or GW501516.	GW 501516	173-181	interleukin 5	Mus musculus	52-56
24628018-8	2014	Blood-extracted CD34(+) cells cultured with IL-5 or IL-5 + IL-3 formed Eo/B CFU, which were significantly inhibited by rosiglitazone (100 nm, P &lt; 0 01) but not GW9578 or GW501516.	GW 501516	173-181	interleukin 3	Mus musculus	59-63
24337677-7	2014	Moreover, GW501516 was found to attenuate glucose-stimulated inflammation in cultured rat peritoneal mesothelial cells via inhibition of transforming growth factor-beta-activated kinase 1 (TAK1), and nuclear factor kappa B (NFkappaB) signaling pathway (TAK1-NFkappaB pathway), a main inflammation regulatory pathway.	GW 501516	10-18	nuclear factor kappa B subunit 1	Homo sapiens	258-266
24337677-8	2014	In conclusion, inhibition of TAK1-NFkappaB pathway with GW501516 may represent a novel therapeutic approach to ameliorate peritonitis-induced peritoneal fibrosis for patients on PD.	GW 501516	56-64	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	29-33
24337677-8	2014	In conclusion, inhibition of TAK1-NFkappaB pathway with GW501516 may represent a novel therapeutic approach to ameliorate peritonitis-induced peritoneal fibrosis for patients on PD.	GW 501516	56-64	nuclear factor kappa B subunit 1	Homo sapiens	34-42
24698256-5	2014	Co-infusion of GW501516, an activator of PPARdelta, attenuated both the incidence and the severity of Ang II-induced AAA in apoE-deficient mice.	GW 501516	15-23	peroxisome proliferator activator receptor delta	Mus musculus	41-50
24698256-5	2014	Co-infusion of GW501516, an activator of PPARdelta, attenuated both the incidence and the severity of Ang II-induced AAA in apoE-deficient mice.	GW 501516	15-23	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	102-108
24698256-5	2014	Co-infusion of GW501516, an activator of PPARdelta, attenuated both the incidence and the severity of Ang II-induced AAA in apoE-deficient mice.	GW 501516	15-23	apolipoprotein E	Mus musculus	124-128
24698256-7	2014	The anti-inflammatory effect of GW501516 was associated with the suppression of apoptotic cell death, along with the inhibition of medial smooth muscle cell loss and focal elastin destruction, which leads to a medial dissection and aortic rupture.	GW 501516	32-40	elastin	Mus musculus	172-179
24698256-8	2014	These ameliorative effects of GW501516 on Ang II-induced aneurysm were correlated with increased expression of extracellular matrix (ECM) proteins, such as types I and III collagen, fibronectin, and elastin, along with the up-regulation of transforming growth factor-beta1.	GW 501516	30-38	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	42-48
24698256-8	2014	These ameliorative effects of GW501516 on Ang II-induced aneurysm were correlated with increased expression of extracellular matrix (ECM) proteins, such as types I and III collagen, fibronectin, and elastin, along with the up-regulation of transforming growth factor-beta1.	GW 501516	30-38	fibronectin 1	Mus musculus	182-193
24698256-8	2014	These ameliorative effects of GW501516 on Ang II-induced aneurysm were correlated with increased expression of extracellular matrix (ECM) proteins, such as types I and III collagen, fibronectin, and elastin, along with the up-regulation of transforming growth factor-beta1.	GW 501516	30-38	elastin	Mus musculus	199-206
24698256-8	2014	These ameliorative effects of GW501516 on Ang II-induced aneurysm were correlated with increased expression of extracellular matrix (ECM) proteins, such as types I and III collagen, fibronectin, and elastin, along with the up-regulation of transforming growth factor-beta1.	GW 501516	30-38	transforming growth factor, beta 1	Mus musculus	240-272
24337677-0	2014	The PPARbeta/delta agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFkappaB pathway in rats.	GW 501516	27-35	peroxisome proliferator-activated receptor delta	Rattus norvegicus	4-12
24337677-0	2014	The PPARbeta/delta agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFkappaB pathway in rats.	GW 501516	27-35	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	100-104
24337677-0	2014	The PPARbeta/delta agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFkappaB pathway in rats.	GW 501516	27-35	nuclear factor kappa B subunit 1	Homo sapiens	105-113
24337677-6	2014	Compared to control group, exposure to PD fluids caused peritoneal fibrosis that was accompanied by increased mRNA levels of monocyte chemoattractant protein-1, tumor necrotic factor-alpha, and interleukin-6 in the uremic rats, and these effects were prevented by GW501516 treatment.	GW 501516	264-272	C-C motif chemokine ligand 2	Rattus norvegicus	125-188
24337677-7	2014	Moreover, GW501516 was found to attenuate glucose-stimulated inflammation in cultured rat peritoneal mesothelial cells via inhibition of transforming growth factor-beta-activated kinase 1 (TAK1), and nuclear factor kappa B (NFkappaB) signaling pathway (TAK1-NFkappaB pathway), a main inflammation regulatory pathway.	GW 501516	10-18	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	137-187
24337677-7	2014	Moreover, GW501516 was found to attenuate glucose-stimulated inflammation in cultured rat peritoneal mesothelial cells via inhibition of transforming growth factor-beta-activated kinase 1 (TAK1), and nuclear factor kappa B (NFkappaB) signaling pathway (TAK1-NFkappaB pathway), a main inflammation regulatory pathway.	GW 501516	10-18	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	189-193
24337677-7	2014	Moreover, GW501516 was found to attenuate glucose-stimulated inflammation in cultured rat peritoneal mesothelial cells via inhibition of transforming growth factor-beta-activated kinase 1 (TAK1), and nuclear factor kappa B (NFkappaB) signaling pathway (TAK1-NFkappaB pathway), a main inflammation regulatory pathway.	GW 501516	10-18	nuclear factor kappa B subunit 1	Homo sapiens	224-232
24337677-7	2014	Moreover, GW501516 was found to attenuate glucose-stimulated inflammation in cultured rat peritoneal mesothelial cells via inhibition of transforming growth factor-beta-activated kinase 1 (TAK1), and nuclear factor kappa B (NFkappaB) signaling pathway (TAK1-NFkappaB pathway), a main inflammation regulatory pathway.	GW 501516	10-18	mitogen activated protein kinase kinase kinase 7	Rattus norvegicus	253-257
24767130-6	2014	Our results demonstrate that palmitate induced ER stress in AC16 cells, a fact which was prevented after PPARbeta/delta activation with GW501516.	GW 501516	136-144	peroxisome proliferator activated receptor delta	Homo sapiens	105-113
24767130-7	2014	Interestingly, the effect of GW501516 on ER stress occurred in an AMPK-independent manner.	GW 501516	29-37	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	66-70
24767130-8	2014	The most striking result of this study is that GW501516 treatment also upregulated the protein levels of beclin 1 and LC3II, two well-known markers of autophagy.	GW 501516	47-55	beclin 1	Homo sapiens	105-113
23991827-2	2014	Only 21 genes were up-regulated and 3 genes were down-regulated after activation by the PPARdelta agonist GW501516.	GW 501516	106-114	peroxisome proliferator activated receptor delta	Homo sapiens	88-97
23779049-4	2014	METHOD: We first established a direct stimulatory effect of the PPARdelta agonist (GW 501516) on the HO-1 gene by demonstrating increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct.	GW 501516	83-92	peroxisome proliferator-activated receptor delta	Rattus norvegicus	64-73
23779049-4	2014	METHOD: We first established a direct stimulatory effect of the PPARdelta agonist (GW 501516) on the HO-1 gene by demonstrating increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct.	GW 501516	83-92	heme oxygenase 1	Rattus norvegicus	101-105
23779049-4	2014	METHOD: We first established a direct stimulatory effect of the PPARdelta agonist (GW 501516) on the HO-1 gene by demonstrating increased luciferase activity in COS-7 cells transfected with a luciferase-HO-1 promoter construct.	GW 501516	83-92	heme oxygenase 1	Rattus norvegicus	203-207
24287635-3	2014	Exposure of U937 cells to the PPARdelta agonist GW501516 resulted in a marked increase in mRNA expression of the PPARdelta target gene Angptl4 which was quantified by qRT-PCR analysis.	GW 501516	48-56	peroxisome proliferator activated receptor delta	Homo sapiens	30-39
24269940-10	2014	GW enhanced glucose-stimulated insulin secretion (GSIS) impaired by PA through stimulation of GLP-1R expression in beta cells.	GW 501516	0-2	glucagon-like peptide 1 receptor	Rattus norvegicus	94-100
24287635-3	2014	Exposure of U937 cells to the PPARdelta agonist GW501516 resulted in a marked increase in mRNA expression of the PPARdelta target gene Angptl4 which was quantified by qRT-PCR analysis.	GW 501516	48-56	peroxisome proliferator activated receptor delta	Homo sapiens	113-122
24287635-3	2014	Exposure of U937 cells to the PPARdelta agonist GW501516 resulted in a marked increase in mRNA expression of the PPARdelta target gene Angptl4 which was quantified by qRT-PCR analysis.	GW 501516	48-56	angiopoietin like 4	Homo sapiens	135-142
24287635-4	2014	Exposure of HepG2 cells transiently transfected with a PPARdelta expression plasmid and a PPAR-response element-driven luciferase reporter plasmid to PPARdelta agonists GW501516, GW610742 and L-165041 resulted in clear dose-response curves.	GW 501516	169-177	peroxisome proliferator activated receptor delta	Homo sapiens	150-159
24158519-0	2014	Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.	GW 501516	57-63	low density lipoprotein receptor	Mus musculus	152-184
24158519-8	2014	In aortae, GW1516 increased the expression of the PPARdelta-specific gene Adfp but not PPARalpha- or gamma-specific genes.	GW 501516	11-17	peroxisome proliferator activator receptor delta	Mus musculus	50-59
24158519-0	2014	Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.	GW 501516	57-63	peroxisome proliferator activator receptor delta	Mus musculus	0-48
24158519-8	2014	In aortae, GW1516 increased the expression of the PPARdelta-specific gene Adfp but not PPARalpha- or gamma-specific genes.	GW 501516	11-17	perilipin 2	Mus musculus	74-78
24158519-9	2014	GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine Arg1, and attenuated the iNos/Arg1 ratio.	GW 501516	0-6	arginase, liver	Mus musculus	147-151
24158519-9	2014	GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine Arg1, and attenuated the iNos/Arg1 ratio.	GW 501516	0-6	nitric oxide synthase 2, inducible	Mus musculus	172-176
24158519-9	2014	GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine Arg1, and attenuated the iNos/Arg1 ratio.	GW 501516	0-6	arginase, liver	Mus musculus	177-181
21920965-7	2013	In a mouse hindlimb ischaemia model, systemic treatment of GW501516 or local transplantation of GW501516-treated EPCs induced IGF-1R phosphorylation in ECs and skeletal muscle in the ischaemic limbs, leading to augmented angiogenesis and skeletal muscle regeneration.	GW 501516	59-67	insulin-like growth factor I receptor	Mus musculus	126-132
24890166-17	2014	In vitro, GW501516 and over-expression of PPARbeta/delta attenuated gene expression of TNF-alpha, IL-1beta and IL-6 in alveolar macrophages.	GW 501516	10-18	tumor necrosis factor	Rattus norvegicus	87-96
24890166-17	2014	In vitro, GW501516 and over-expression of PPARbeta/delta attenuated gene expression of TNF-alpha, IL-1beta and IL-6 in alveolar macrophages.	GW 501516	10-18	interleukin 1 beta	Rattus norvegicus	98-106
24890166-17	2014	In vitro, GW501516 and over-expression of PPARbeta/delta attenuated gene expression of TNF-alpha, IL-1beta and IL-6 in alveolar macrophages.	GW 501516	10-18	interleukin 6	Rattus norvegicus	111-115
25116733-2	2014	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, attenuated Ang II-induced activation of MMP-2 in a concentration-dependent manner.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
25116733-2	2014	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, attenuated Ang II-induced activation of MMP-2 in a concentration-dependent manner.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
25116733-2	2014	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, attenuated Ang II-induced activation of MMP-2 in a concentration-dependent manner.	GW 501516	27-35	matrix metallopeptidase 2	Homo sapiens	110-115
25116733-4	2014	A marked increase in the mRNA levels of tissue inhibitor of metalloproteinase (TIMP)-2 and -3, endogenous antagonists of MMPs, was also observed in GW501516-treated VSMCs.	GW 501516	148-156	TIMP metallopeptidase inhibitor 2	Homo sapiens	40-93
25116733-4	2014	A marked increase in the mRNA levels of tissue inhibitor of metalloproteinase (TIMP)-2 and -3, endogenous antagonists of MMPs, was also observed in GW501516-treated VSMCs.	GW 501516	148-156	matrix metallopeptidase 2	Homo sapiens	121-125
25116733-5	2014	These effects were markedly reduced in the presence of siRNAs against PPARdelta, indicating that the effects of GW501516 are PPARdelta dependent.	GW 501516	112-120	peroxisome proliferator activated receptor delta	Homo sapiens	70-79
25116733-5	2014	These effects were markedly reduced in the presence of siRNAs against PPARdelta, indicating that the effects of GW501516 are PPARdelta dependent.	GW 501516	112-120	peroxisome proliferator activated receptor delta	Homo sapiens	125-134
25116733-6	2014	Among the protein kinases inhibited by GW501516, suppression of phosphatidylinositol 3-kinase/Akt signaling was shown to have the greatest effect on activation of MMP-2 in VSMCs treated with Ang II.	GW 501516	39-47	AKT serine/threonine kinase 1	Homo sapiens	94-97
25116733-6	2014	Among the protein kinases inhibited by GW501516, suppression of phosphatidylinositol 3-kinase/Akt signaling was shown to have the greatest effect on activation of MMP-2 in VSMCs treated with Ang II.	GW 501516	39-47	matrix metallopeptidase 2	Homo sapiens	163-168
25116733-7	2014	Concomitantly, GW501516-mediated inhibition of MMP-2 activation in VSMCs treated with Ang II was associated with the suppression of cell migration to levels approaching those in cells not exposed to Ang II.	GW 501516	15-23	matrix metallopeptidase 2	Homo sapiens	47-52
23943160-4	2013	We found that when activated with the highly selective PPARbeta/delta agonists, GW0742 and GW501516, PPARbeta/delta inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines.	GW 501516	91-99	peroxisome proliferator activated receptor delta	Homo sapiens	55-63
23943160-4	2013	We found that when activated with the highly selective PPARbeta/delta agonists, GW0742 and GW501516, PPARbeta/delta inhibited the proliferation and markedly induced the apoptosis of three endometrial cancer cell lines.	GW 501516	91-99	peroxisome proliferator activated receptor delta	Homo sapiens	101-109
23639976-2	2013	In human dermal fibroblasts (HDFs), activation of PPARdelta by its specific ligand GW501516 markedly attenuated UVB-induced secretion of matrix metalloproteinase (MMP)-1, concomitant with decreased generation of reactive oxygen species.	GW 501516	83-91	peroxisome proliferator activated receptor delta	Homo sapiens	50-59
23639976-2	2013	In human dermal fibroblasts (HDFs), activation of PPARdelta by its specific ligand GW501516 markedly attenuated UVB-induced secretion of matrix metalloproteinase (MMP)-1, concomitant with decreased generation of reactive oxygen species.	GW 501516	83-91	matrix metallopeptidase 1	Homo sapiens	137-169
23639976-5	2013	PPARdelta-mediated messenger RNA stabilization of mitogen-activated protein kinase phosphatase (MKP)-7 was responsible for the GW501516-mediated inhibition of JNK signaling.	GW 501516	127-135	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
23639976-5	2013	PPARdelta-mediated messenger RNA stabilization of mitogen-activated protein kinase phosphatase (MKP)-7 was responsible for the GW501516-mediated inhibition of JNK signaling.	GW 501516	127-135	dual specificity phosphatase 16	Homo sapiens	96-102
23639976-5	2013	PPARdelta-mediated messenger RNA stabilization of mitogen-activated protein kinase phosphatase (MKP)-7 was responsible for the GW501516-mediated inhibition of JNK signaling.	GW 501516	127-135	mitogen-activated protein kinase 8	Homo sapiens	159-162
23639976-7	2013	Finally, in HR-1 hairless mice exposed to UVB, administration of GW501516 significantly reduced wrinkle formation and skin thickness, downregulated MMP-1 and JNK phosphorylation, and restored the levels of MKP-7, types I and III collagen.	GW 501516	65-73	matrix metallopeptidase 13	Mus musculus	148-153
23639976-7	2013	Finally, in HR-1 hairless mice exposed to UVB, administration of GW501516 significantly reduced wrinkle formation and skin thickness, downregulated MMP-1 and JNK phosphorylation, and restored the levels of MKP-7, types I and III collagen.	GW 501516	65-73	mitogen-activated protein kinase 8	Mus musculus	158-161
23639976-7	2013	Finally, in HR-1 hairless mice exposed to UVB, administration of GW501516 significantly reduced wrinkle formation and skin thickness, downregulated MMP-1 and JNK phosphorylation, and restored the levels of MKP-7, types I and III collagen.	GW 501516	65-73	dual specificity phosphatase 16	Mus musculus	206-211
23811944-4	2013	Multiparous mice presented with mammary carcinomas after a latency of 12 months, and administration of the PPARdelta ligand GW501516 reduced tumor latency to 5 months.	GW 501516	124-132	peroxisome proliferator activator receptor delta	Mus musculus	107-116
23811944-5	2013	Histopathologic changes occurred concurrently with an increase in an inflammatory, invasive, metabolic, and proliferative gene signature, including expression of the trophoblast gene, Plac1, beginning 1 week after GW501516 treatment, and remained elevated throughout tumorigenesis.	GW 501516	214-222	placental specific protein 1	Mus musculus	184-189
21920965-3	2013	METHODS AND RESULTS: Treatment of EPCs with GW501516, a PPAR-delta agonist, induced specifically matrix metallo-proteinase (MMP)-9 by direct transcriptional activation.	GW 501516	44-52	peroxisome proliferator activator receptor delta	Mus musculus	56-66
21920965-3	2013	METHODS AND RESULTS: Treatment of EPCs with GW501516, a PPAR-delta agonist, induced specifically matrix metallo-proteinase (MMP)-9 by direct transcriptional activation.	GW 501516	44-52	matrix metallopeptidase 9	Mus musculus	97-130
21920965-5	2013	Treatment of conditioned medium from GW501516-stimulated EPCs enhanced the number and functions of human umbilical vein ECs and C2C12 myoblasts via MMP-9-mediated IGF-1R activation.	GW 501516	37-45	matrix metallopeptidase 9	Homo sapiens	148-153
21920965-5	2013	Treatment of conditioned medium from GW501516-stimulated EPCs enhanced the number and functions of human umbilical vein ECs and C2C12 myoblasts via MMP-9-mediated IGF-1R activation.	GW 501516	37-45	insulin like growth factor 1 receptor	Homo sapiens	163-169
21920965-6	2013	Systemic administration of GW501516 in mice increased MMP-9 expression in EPCs, and augmented IGFBP-3 degradation in serum.	GW 501516	27-35	matrix metallopeptidase 9	Mus musculus	54-59
21920965-6	2013	Systemic administration of GW501516 in mice increased MMP-9 expression in EPCs, and augmented IGFBP-3 degradation in serum.	GW 501516	27-35	insulin-like growth factor binding protein 3	Mus musculus	94-101
21920965-7	2013	In a mouse hindlimb ischaemia model, systemic treatment of GW501516 or local transplantation of GW501516-treated EPCs induced IGF-1R phosphorylation in ECs and skeletal muscle in the ischaemic limbs, leading to augmented angiogenesis and skeletal muscle regeneration.	GW 501516	96-104	insulin-like growth factor I receptor	Mus musculus	126-132
23849213-9	2013	GW501516 treatment also increased Lipin1 protein levels in the nucleus, led to the amplification of the PGC-1alpha-PPARalpha pathway and increased PPARalpha DNA-binding activity, as well as the expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	lipin 1	Mus musculus	34-40
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	55-103
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-132	peroxisome proliferator-activated receptor delta	Rattus norvegicus	105-114
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	55-103
23611928-1	2013	OBJECTIVES: This study aimed to measure the effects of peroxisome proliferator-activated receptor-delta (PPARdelta) agonist GW501516 (GW) and zinc sulfate (ZS) on ovariectomized rats" vaginal histomorphology and collagen expression.	GW 501516	124-126	peroxisome proliferator-activated receptor delta	Rattus norvegicus	105-114
23525285-6	2013	Furthermore, treatment with the PPARdelta agonist, GW501516, induced the expression of PPARdelta target genes in the pro-inflammatory M1 macrophages while no change was observed in the anti-inflammatory M2 macrophages.	GW 501516	51-59	peroxisome proliferator activated receptor delta	Homo sapiens	32-41
23525285-6	2013	Furthermore, treatment with the PPARdelta agonist, GW501516, induced the expression of PPARdelta target genes in the pro-inflammatory M1 macrophages while no change was observed in the anti-inflammatory M2 macrophages.	GW 501516	51-59	peroxisome proliferator activated receptor delta	Homo sapiens	87-96
23849213-9	2013	GW501516 treatment also increased Lipin1 protein levels in the nucleus, led to the amplification of the PGC-1alpha-PPARalpha pathway and increased PPARalpha DNA-binding activity, as well as the expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	104-114
23849213-9	2013	GW501516 treatment also increased Lipin1 protein levels in the nucleus, led to the amplification of the PGC-1alpha-PPARalpha pathway and increased PPARalpha DNA-binding activity, as well as the expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	115-124
23849213-9	2013	GW501516 treatment also increased Lipin1 protein levels in the nucleus, led to the amplification of the PGC-1alpha-PPARalpha pathway and increased PPARalpha DNA-binding activity, as well as the expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	147-156
23849213-9	2013	GW501516 treatment also increased Lipin1 protein levels in the nucleus, led to the amplification of the PGC-1alpha-PPARalpha pathway and increased PPARalpha DNA-binding activity, as well as the expression of PPARalpha-target genes involved in fatty acid oxidation.	GW 501516	0-8	peroxisome proliferator activated receptor alpha	Mus musculus	147-156
23849213-11	2013	Finally, GW501516 increased the hepatic levels of the PPARalpha endogenous ligand 16:0/18:1-PC and the expression of the VLDL receptor.	GW 501516	9-17	peroxisome proliferator activated receptor alpha	Mus musculus	54-63
23849213-11	2013	Finally, GW501516 increased the hepatic levels of the PPARalpha endogenous ligand 16:0/18:1-PC and the expression of the VLDL receptor.	GW 501516	9-17	very low density lipoprotein receptor	Mus musculus	121-134
23849213-12	2013	CONCLUSION: These data indicate that the hypotriglyceridemic effect of GW501516 in mice subjected to HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-Lipin1-PPARalpha pathway.	GW 501516	71-79	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	196-206
23849213-12	2013	CONCLUSION: These data indicate that the hypotriglyceridemic effect of GW501516 in mice subjected to HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-Lipin1-PPARalpha pathway.	GW 501516	71-79	lipin 1	Mus musculus	207-213
23849213-12	2013	CONCLUSION: These data indicate that the hypotriglyceridemic effect of GW501516 in mice subjected to HFD-fed mice is accompanied by an increase in phospho-AMPK levels and the amplification of the PGC-1alpha-Lipin1-PPARalpha pathway.	GW 501516	71-79	peroxisome proliferator activated receptor alpha	Mus musculus	214-223
22933110-8	2012	PPARdelta agonist GW1516 restored EDRs in mouse aortae under high-glucose conditions or in db/db mouse aortae ex vivo.	GW 501516	18-24	peroxisome proliferator activator receptor delta	Mus musculus	0-9
23100242-0	2013	Synthesis, mass spectrometric characterization, and analysis of the PPARdelta agonist GW1516 and its major human metabolites: targets in sports drug testing.	GW 501516	86-92	peroxisome proliferator activated receptor delta	Homo sapiens	68-77
23100242-2	2013	A new drug candidate belonging to the family of the peroxisome proliferator-activated receptor-delta agonists termed GW1516 (also referred to as GW501516) has been prohibited by the World Anti-Doping Agency in 2009 due to its potential to artificially increase endurance.	GW 501516	117-123	peroxisome proliferator activated receptor delta	Homo sapiens	52-100
23100242-2	2013	A new drug candidate belonging to the family of the peroxisome proliferator-activated receptor-delta agonists termed GW1516 (also referred to as GW501516) has been prohibited by the World Anti-Doping Agency in 2009 due to its potential to artificially increase endurance.	GW 501516	145-153	peroxisome proliferator activated receptor delta	Homo sapiens	52-100
23737761-6	2013	Through the use of short hairpin RNA inhibitors of PPARbeta/delta, BCL-6, and MMP-9, it was evident that PPARbeta/delta was responsible for the ligand-dependent effects whereas BCL-6 dissociation upon GW501516 treatment was ultimately responsible for decreasing MMP-9 expression and hence invasion activity.	GW 501516	201-209	peroxisome proliferator activated receptor delta	Homo sapiens	51-59
23737761-6	2013	Through the use of short hairpin RNA inhibitors of PPARbeta/delta, BCL-6, and MMP-9, it was evident that PPARbeta/delta was responsible for the ligand-dependent effects whereas BCL-6 dissociation upon GW501516 treatment was ultimately responsible for decreasing MMP-9 expression and hence invasion activity.	GW 501516	201-209	matrix metallopeptidase 9	Homo sapiens	78-83
23737761-6	2013	Through the use of short hairpin RNA inhibitors of PPARbeta/delta, BCL-6, and MMP-9, it was evident that PPARbeta/delta was responsible for the ligand-dependent effects whereas BCL-6 dissociation upon GW501516 treatment was ultimately responsible for decreasing MMP-9 expression and hence invasion activity.	GW 501516	201-209	BCL6 transcription repressor	Homo sapiens	177-182
23000914-4	2012	Activation of PPARdelta by the specific ligand GW501516 significantly inhibited Ang II-induced premature senescence and generation of reactive oxygen species (ROS) in HCAECs.	GW 501516	47-55	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
23000914-5	2012	A marked concentration- and time-dependent increase in the mRNA levels of SIRT1 was observed in GW501516-treated HCAECs.	GW 501516	96-104	sirtuin 1	Homo sapiens	74-79
23000914-6	2012	The effects of GW501516 were almost completely abolished in the presence of small interfering (si) RNA against PPARdelta, indicating that PPARdelta mediates the effects of GW501516.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	111-120
23000914-6	2012	The effects of GW501516 were almost completely abolished in the presence of small interfering (si) RNA against PPARdelta, indicating that PPARdelta mediates the effects of GW501516.	GW 501516	15-23	peroxisome proliferator activated receptor delta	Homo sapiens	138-147
23000914-6	2012	The effects of GW501516 were almost completely abolished in the presence of small interfering (si) RNA against PPARdelta, indicating that PPARdelta mediates the effects of GW501516.	GW 501516	172-180	peroxisome proliferator activated receptor delta	Homo sapiens	111-120
23000914-6	2012	The effects of GW501516 were almost completely abolished in the presence of small interfering (si) RNA against PPARdelta, indicating that PPARdelta mediates the effects of GW501516.	GW 501516	172-180	peroxisome proliferator activated receptor delta	Homo sapiens	138-147
23607100-0	2013	PPARdelta agonist GW501516 inhibits PDGF-stimulated pulmonary arterial smooth muscle cell function related to pathological vascular remodeling.	GW 501516	18-26	peroxisome proliferator activated receptor delta	Homo sapiens	0-9
23607100-7	2013	Activation of PPAR delta by GW501516, a specific PPAR delta ligand, significantly inhibited PDGF-induced proliferation in HPASMCs.	GW 501516	28-36	peroxisome proliferator activated receptor delta	Homo sapiens	14-24
23607100-7	2013	Activation of PPAR delta by GW501516, a specific PPAR delta ligand, significantly inhibited PDGF-induced proliferation in HPASMCs.	GW 501516	28-36	peroxisome proliferator activated receptor delta	Homo sapiens	49-59
23607100-8	2013	The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27(kip1).	GW 501516	25-33	cyclin D1	Homo sapiens	89-98
23607100-8	2013	The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27(kip1).	GW 501516	25-33	cyclin D3	Homo sapiens	100-109
23607100-8	2013	The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27(kip1).	GW 501516	25-33	cyclin dependent kinase 2	Homo sapiens	111-115
23607100-8	2013	The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27(kip1).	GW 501516	25-33	cyclin dependent kinase 4	Homo sapiens	121-125
23607100-8	2013	The inhibitory effect of GW501516 on HPASMCs was associated with decreased expression of cyclin D1, cyclin D3, CDK2, and CDK4 as well as increased expression of the cell cycle inhibitory genes G0S2 and P27(kip1).	GW 501516	25-33	cyclin dependent kinase inhibitor 1B	Homo sapiens	202-210
23607100-10	2013	GW501516 also significantly attenuated TNF-mediated expression of MCP-1.	GW 501516	0-8	tumor necrosis factor	Homo sapiens	39-42
23607100-10	2013	GW501516 also significantly attenuated TNF-mediated expression of MCP-1.	GW 501516	0-8	C-C motif chemokine ligand 2	Homo sapiens	66-71
22933110-9	2012	After oral treatment with GW1516, EDRs in aortae and FMDs in mesenteric resistance arteries were improved in obese mice in a PPARdelta-specific manner.	GW 501516	26-32	peroxisome proliferator activator receptor delta	Mus musculus	125-134
22933110-10	2012	The effects of GW1516 on endothelial function were mediated through phosphatidylinositol 3-kinase (PI3K) and Akt with a subsequent increase of endothelial nitric oxide synthase (eNOS) activity and NO production.	GW 501516	15-21	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	68-97
22933110-10	2012	The effects of GW1516 on endothelial function were mediated through phosphatidylinositol 3-kinase (PI3K) and Akt with a subsequent increase of endothelial nitric oxide synthase (eNOS) activity and NO production.	GW 501516	15-21	thymoma viral proto-oncogene 1	Mus musculus	109-112
22933110-10	2012	The effects of GW1516 on endothelial function were mediated through phosphatidylinositol 3-kinase (PI3K) and Akt with a subsequent increase of endothelial nitric oxide synthase (eNOS) activity and NO production.	GW 501516	15-21	nitric oxide synthase 3, endothelial cell	Mus musculus	143-176
22933110-10	2012	The effects of GW1516 on endothelial function were mediated through phosphatidylinositol 3-kinase (PI3K) and Akt with a subsequent increase of endothelial nitric oxide synthase (eNOS) activity and NO production.	GW 501516	15-21	nitric oxide synthase 3, endothelial cell	Mus musculus	178-182
22982594-0	2012	PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.	GW 501516	18-26	peroxisome proliferator activator receptor delta	Mus musculus	0-9
22576330-7	2012	Tropoelastin production was significantly increased by 20 muM ZS and by 10 nM GW.	GW 501516	78-80	elastin	Homo sapiens	0-12
22576330-8	2012	Cell culture surface deposited elastin production was significantly increased by 20 muM ZS and by the combination of 20 muM ZS with 10 nM GW, and collagen production was significantly increased by 10 nM GW and by the combination of 20 muM ZS with 10 nM GW.	GW 501516	138-140	elastin	Homo sapiens	31-38
22576330-8	2012	Cell culture surface deposited elastin production was significantly increased by 20 muM ZS and by the combination of 20 muM ZS with 10 nM GW, and collagen production was significantly increased by 10 nM GW and by the combination of 20 muM ZS with 10 nM GW.	GW 501516	203-205	elastin	Homo sapiens	31-38
22576330-8	2012	Cell culture surface deposited elastin production was significantly increased by 20 muM ZS and by the combination of 20 muM ZS with 10 nM GW, and collagen production was significantly increased by 10 nM GW and by the combination of 20 muM ZS with 10 nM GW.	GW 501516	203-205	elastin	Homo sapiens	31-38
22886847-10	2012	Treatment with PPARdelta ligand GW501516 (2 mg/kg/day) for 14 days significantly increased BH(4) bioavailability and improved endothelium-dependent relaxations in Tg2576 mice aortas.	GW 501516	32-40	peroxisome proliferator activator receptor delta	Mus musculus	15-24
22886847-11	2012	GW501516 also normalized protein expression of gp91(phox) and SODs, thereby reducing production of superoxide anion in the aortas.	GW 501516	0-8	paired Ig-like receptor B	Mus musculus	47-51
22982594-3	2012	In the present study, the effects of PPARdelta agonist GW501516 on uncoupling of endothelial nitric oxide synthase (eNOS) were determined in cerebral microvessels of BH4-deficient hph-1 mice.	GW 501516	55-63	nitric oxide synthase 3, endothelial cell	Mus musculus	81-114
22982594-4	2012	Wild-type (B6CBA) and hph-1 mice were orally gavaged with a selective PPARdelta activator, GW501516 (2 mg/kg/day) for 14 days, and thereafter, cerebral microvessels were isolated and studied.	GW 501516	91-99	peroxisome proliferator activator receptor delta	Mus musculus	70-79
22982594-0	2012	PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.	GW 501516	18-26	nitric oxide synthase 3, endothelial cell	Mus musculus	50-83
22982594-5	2012	Treatment of hph-1 mice with GW501516 significantly reduced oxidation of BH4 and increased the ratio of BH4 to 7,8-BH2 (P&lt;0.05, n=6-9).	GW 501516	29-37	hyperphenylalaninemia 1	Mus musculus	13-18
22982594-6	2012	Attenuation of L-NAME-inhibitable superoxide anion levels by GW501516 demonstrated that activation of PPARdelta might prevent uncoupling of endothelial nitric oxide synthase (eNOS, P&lt;0.05, n=6-9).	GW 501516	61-69	peroxisome proliferator activator receptor delta	Mus musculus	102-111
22982594-0	2012	PPARdelta agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.	GW 501516	18-26	hyperphenylalaninemia 1	Mus musculus	112-117
22814748-0	2012	Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.	GW 501516	74-82	peroxisome proliferator activated receptor delta	Homo sapiens	17-65
23046570-0	2012	GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.	GW 501516	0-8	peroxisome proliferator activator receptor delta	Mus musculus	19-27
23046570-0	2012	GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.	GW 501516	0-8	mitogen-activated protein kinase 14	Mus musculus	62-65
23046570-0	2012	GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.	GW 501516	0-8	mitogen-activated protein kinase 8	Mus musculus	66-69
23046570-3	2012	This study investigated whether activation of PPARbeta/delta with the ligand GW501516 influenced the fibrotic response to injury from chronic carbon tetrachloride (CCl4) treatment in mice.	GW 501516	77-85	peroxisome proliferator activator receptor delta	Mus musculus	46-54
23046570-7	2012	Compared to the other experimental groups, CCl4/GW501516-treated wild type mice exhibited increased expression of various profibrotic and pro-inflammatory genes, such as those involved in extracellular matrix deposition and macrophage recruitment.	GW 501516	48-56	chemokine (C-C motif) ligand 4	Mus musculus	43-47
23046570-9	2012	GW501516 stimulated HSC proliferation that caused enhanced fibrotic and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway.	GW 501516	0-8	mitogen-activated protein kinase 14	Mus musculus	133-136
23046570-9	2012	GW501516 stimulated HSC proliferation that caused enhanced fibrotic and inflammatory responses, by increasing the phosphorylation of p38 and c-Jun N-terminal kinases through the phosphoinositide-3 kinase/protein kinase-C alpha/beta mixed lineage kinase-3 pathway.	GW 501516	0-8	jun proto-oncogene	Mus musculus	141-146
23046570-10	2012	CONCLUSIONS: This study clarified the mechanism underlying GW501516-dependent promotion of hepatic repair by stimulating proliferation of HSCs via the p38 and JNK MAPK pathways.	GW 501516	59-67	mitogen-activated protein kinase 14	Mus musculus	151-154
23046570-10	2012	CONCLUSIONS: This study clarified the mechanism underlying GW501516-dependent promotion of hepatic repair by stimulating proliferation of HSCs via the p38 and JNK MAPK pathways.	GW 501516	59-67	mitogen-activated protein kinase 8	Mus musculus	159-162
22977012-0	2012	Detection of PPARdelta agonists GW1516 and GW0742 and their metabolites in human urine.	GW 501516	32-38	peroxisome proliferator activated receptor delta	Homo sapiens	13-22
22683888-7	2012	Interestingly, the PPARbeta/delta ligand GW501516 prevented the expression of inflammatory markers and the reduction in the expression of PPARbeta/delta-target genes in adipocytes stimulated with TNF-alpha.	GW 501516	41-49	peroxisome proliferator activated receptor delta	Homo sapiens	19-27
22683888-7	2012	Interestingly, the PPARbeta/delta ligand GW501516 prevented the expression of inflammatory markers and the reduction in the expression of PPARbeta/delta-target genes in adipocytes stimulated with TNF-alpha.	GW 501516	41-49	peroxisome proliferator activated receptor delta	Homo sapiens	138-146
22683888-7	2012	Interestingly, the PPARbeta/delta ligand GW501516 prevented the expression of inflammatory markers and the reduction in the expression of PPARbeta/delta-target genes in adipocytes stimulated with TNF-alpha.	GW 501516	41-49	tumor necrosis factor	Homo sapiens	196-205
23078396-5	2012	This study reveals an inhibitory effect of two commonly used PPARdelta agonists, GW501516 and L-165,041, on the protein expression and enzyme activity of cathepsin B in human endothelial cells.	GW 501516	81-89	peroxisome proliferator activated receptor delta	Homo sapiens	61-70
23078396-5	2012	This study reveals an inhibitory effect of two commonly used PPARdelta agonists, GW501516 and L-165,041, on the protein expression and enzyme activity of cathepsin B in human endothelial cells.	GW 501516	81-89	cathepsin B	Homo sapiens	154-165
22814748-8	2012	CONCLUSIONS: GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB.	GW 501516	13-21	apolipoprotein A1	Homo sapiens	88-93
22814748-8	2012	CONCLUSIONS: GW501516 produced significant changes in HDL cholesterol, LDL cholesterol, apoA1, and apoB.	GW 501516	13-21	apolipoprotein B	Homo sapiens	99-103
22473775-3	2012	Activation of PPARdelta by GW501516, a specific ligand, significantly inhibited glutamate-induced cell death and reactive oxygen species (ROS) production in HT22 cells.	GW 501516	27-35	peroxisome proliferator activator receptor delta	Mus musculus	14-23
22820186-5	2012	The PPARdelta agonist GW501516 had no effect on LPL mRNA, but increased ANGPTL4 mRNA and caused a marked reduction of the heparin-releasable LPL activity concomitantly with accumulation of inactive, monomeric LPL in the medium.	GW 501516	22-30	peroxisome proliferator activated receptor delta	Homo sapiens	4-13
22820186-5	2012	The PPARdelta agonist GW501516 had no effect on LPL mRNA, but increased ANGPTL4 mRNA and caused a marked reduction of the heparin-releasable LPL activity concomitantly with accumulation of inactive, monomeric LPL in the medium.	GW 501516	22-30	angiopoietin like 4	Homo sapiens	72-79
22820186-5	2012	The PPARdelta agonist GW501516 had no effect on LPL mRNA, but increased ANGPTL4 mRNA and caused a marked reduction of the heparin-releasable LPL activity concomitantly with accumulation of inactive, monomeric LPL in the medium.	GW 501516	22-30	lipoprotein lipase	Homo sapiens	141-144
22820186-5	2012	The PPARdelta agonist GW501516 had no effect on LPL mRNA, but increased ANGPTL4 mRNA and caused a marked reduction of the heparin-releasable LPL activity concomitantly with accumulation of inactive, monomeric LPL in the medium.	GW 501516	22-30	lipoprotein lipase	Homo sapiens	141-144
22820186-7	2012	GW501516 caused an increase in the amount of ANGPTL4 oligomers on the cell surface that paralleled the decrease in LPL activity.	GW 501516	0-8	angiopoietin like 4	Homo sapiens	45-52
22820186-7	2012	GW501516 caused an increase in the amount of ANGPTL4 oligomers on the cell surface that paralleled the decrease in LPL activity.	GW 501516	0-8	lipoprotein lipase	Homo sapiens	115-118
22820186-8	2012	Actinomycin D blocked the effects of GW501516 on ANGPTL4 oligomer formation and prevented the inactivation of LPL.	GW 501516	37-45	angiopoietin like 4	Homo sapiens	49-56
22473775-4	2012	The siRNA-mediated knockdown of PPARdelta abrogated the effects of GW501516 in neuronal toxicity and ROS production induced by glutamate.	GW 501516	67-75	peroxisome proliferator activator receptor delta	Mus musculus	32-41
22234939-8	2012	We confirmed whether these antiangiogenic effects of L-165041 were PPARdelta-dependent using GW501516 and PPARdelta siRNA.	GW 501516	93-101	peroxisome proliferator activated receptor delta	Homo sapiens	67-76
22586590-7	2012	Treatment with ruboxistaurin (a PKCbeta inhibitor) or with GW501516 (a peroxisome proliferator-activated receptor delta activator) reduced atrogin-1 expression and restored BK channel-mediated coronary vasodilation in diabetic mice.	GW 501516	59-67	F-box protein 32	Homo sapiens	139-148
22519881-3	2012	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly reduced Ang II-induced ROS generation in VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
22519881-3	2012	Activation of PPARdelta by GW501516, a specific ligand for PPARdelta, significantly reduced Ang II-induced ROS generation in VSMCs.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	59-68
22519881-6	2012	Accordingly, ablation of Akt with siRNA further enhanced the inhibitory effects of GW501516 in Ang II-induced superoxide production.	GW 501516	83-91	AKT serine/threonine kinase 1	Homo sapiens	25-28
22466807-6	2012	The expression of MafA, glucose transportor-2 (GLUT2), and insulin was found to be up-regulated in cells treated with GW501516.	GW 501516	118-126	MAF bZIP transcription factor A	Rattus norvegicus	18-22
22466807-6	2012	The expression of MafA, glucose transportor-2 (GLUT2), and insulin was found to be up-regulated in cells treated with GW501516.	GW 501516	118-126	solute carrier family 2 member 2	Rattus norvegicus	24-45
22466807-6	2012	The expression of MafA, glucose transportor-2 (GLUT2), and insulin was found to be up-regulated in cells treated with GW501516.	GW 501516	118-126	solute carrier family 2 member 2	Rattus norvegicus	47-52
22179221-0	2012	The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.	GW 501516	73-81	peroxisome proliferator activated receptor delta	Homo sapiens	4-58
22335598-4	2012	Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly attenuated UVB-mediated generation of ROS (reactive oxygen species) and suppressed senescence of human keratinocytes.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	14-23
22335598-4	2012	Activation of PPARdelta by GW501516, a specific ligand of PPARdelta, significantly attenuated UVB-mediated generation of ROS (reactive oxygen species) and suppressed senescence of human keratinocytes.	GW 501516	27-35	peroxisome proliferator activated receptor delta	Homo sapiens	58-67
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	signal transducer and activator of transcription 3	Mus musculus	153-158
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	peroxisome proliferator activator receptor delta	Mus musculus	190-198
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	signal transducer and activator of transcription 3	Mus musculus	251-256
22179221-0	2012	The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.	GW 501516	73-81	interleukin 6	Homo sapiens	91-95
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	mitogen-activated protein kinase 3	Mus musculus	276-282
22179221-8	2012	In agreement with the recovery in phospho-AMPK levels observed following GW501516 treatment, this drug increased the AMP/ATP ratio and decreased the ATP/ADP ratio.	GW 501516	73-81	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	42-46
22179221-9	2012	CONCLUSIONS/INTERPRETATION: Overall, our findings show that the PPARbeta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels.	GW 501516	89-97	peroxisome proliferator activated receptor delta	Homo sapiens	64-72
22179221-0	2012	The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.	GW 501516	73-81	signal transducer and activator of transcription 3	Homo sapiens	104-154
22179221-9	2012	CONCLUSIONS/INTERPRETATION: Overall, our findings show that the PPARbeta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels.	GW 501516	89-97	interleukin 6	Homo sapiens	107-111
22179221-9	2012	CONCLUSIONS/INTERPRETATION: Overall, our findings show that the PPARbeta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels.	GW 501516	89-97	signal transducer and activator of transcription 3	Homo sapiens	120-125
22179221-0	2012	The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.	GW 501516	73-81	signal transducer and activator of transcription 3	Homo sapiens	156-161
22179221-9	2012	CONCLUSIONS/INTERPRETATION: Overall, our findings show that the PPARbeta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels.	GW 501516	89-97	mitogen-activated protein kinase 3	Homo sapiens	151-157
22179221-0	2012	The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.	GW 501516	73-81	insulin	Homo sapiens	178-185
22179221-9	2012	CONCLUSIONS/INTERPRETATION: Overall, our findings show that the PPARbeta/delta activator GW501516 prevents IL-6-induced STAT3 activation by inhibiting ERK1/2 phosphorylation and preventing the reduction in phospho-AMPK levels.	GW 501516	89-97	protein kinase AMP-activated non-catalytic subunit beta 1	Homo sapiens	214-218
22179221-10	2012	These effects of GW501516 may contribute to the prevention of cytokine-induced insulin resistance in hepatic cells.	GW 501516	17-25	insulin	Homo sapiens	79-86
22179221-2	2012	Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells.	GW 501516	97-105	peroxisome proliferator activated receptor alpha	Homo sapiens	29-71
22179221-2	2012	Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells.	GW 501516	97-105	peroxisome proliferator activated receptor alpha	Homo sapiens	73-77
22179221-2	2012	Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells.	GW 501516	97-105	suppressor of cytokine signaling 3	Homo sapiens	134-180
22179221-2	2012	Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells.	GW 501516	97-105	suppressor of cytokine signaling 3	Homo sapiens	182-187
22179221-2	2012	Here we examined whether the peroxisome proliferator-activated receptor (PPAR)beta/delta agonist GW501516 prevented activation of the IL-6-STAT3-suppressor of cytokine signalling 3 (SOCS3) pathway and insulin resistance in human hepatic HepG2 cells.	GW 501516	97-105	insulin	Homo sapiens	201-208
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	interleukin 6	Mus musculus	28-32
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	insulin	Homo sapiens	56-63
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	thymoma viral proto-oncogene 1	Mus musculus	77-80
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	thymoma viral proto-oncogene 1	Mus musculus	124-127
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	insulin receptor substrate 1	Mus musculus	152-157
22179221-4	2012	RESULTS: GW501516 prevented IL-6-dependent reduction in insulin-stimulated v-akt murine thymoma viral oncogene homologue 1 (AKT) phosphorylation and in IRS-1 and IRS-2 protein levels.	GW 501516	9-17	insulin receptor substrate 2	Mus musculus	162-167
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	interleukin 6	Mus musculus	29-33
22179221-6	2012	Moreover, GW501516 prevented IL-6-dependent induction of extracellular-related kinase 1/2 (ERK1/2), a serine-threonine protein kinase involved in serine STAT3 phosphorylation; the livers of Pparbeta/delta-null mice showed increased Tyr705- and Ser727-STAT3 as well as phospho-ERK1/2 levels.	GW 501516	10-18	mitogen-activated protein kinase 3	Mus musculus	91-97